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Abstract 
 
Noninvasive Ambient Pressure Estimation using Ultrasound Contrast Agents  
– Invoking Subharmonics for Cardiac and Hepatic Applications 
Jaydev Dave 
Flemming Forsberg, PhD and Peter Lewin, PhD 
 
Ultrasound contrast agents (UCAs) are encapsulated microbubbles that provide a 
source for acoustic impedance mismatch with the blood, due to difference in 
compressibility between the gas contained within these microbubbles and the blood.  
When insonified by an ultrasound beam, these UCAs act as nonlinear scatterers and 
enhance the echoes of the incident pulse, resulting in scattering of the incident ultrasound 
beam and emission of fundamental (f0), subharmonic (f0/2), harmonic (n*f0; n  ) and 
ultraharmonic (((2n-1)/2)*f0; n   & n > 1) components in the echo response. 
A promising approach to monitor in vivo pressures revolves around the fact that 
the ultrasound transmit and receive parameters can be selected to induce an ambient 
pressure amplitude dependent subharmonic signal.  This subharmonic signal may be used 
to estimate ambient pressure amplitude; such technique of estimating ambient pressure 
amplitude is referred to as subharmonic aided pressure estimation or SHAPE.  This 
project develops and evaluates the feasibility of SHAPE to noninvasively monitor cardiac 
and hepatic pressures (using commercially available ultrasound scanners and UCAs) 
because invasive catheter based pressure measurements are used currently for these 
applications. 
Invasive catheter based pressure measurements pose risk of introducing infection 
while the catheter is guided towards the region of interest in the body through a 
percutaneous incision, pose risk of death due to structural or mechanical failure of the 
xviii 
 
catheter (which has also triggered product recalls by the USA Food and Drug 
Administration) and may potentially modulate the pressures that are being measured.  
Also, catheterization procedures require fluoroscopic guidance to advance the catheter to 
the site of pressure measurements and such catheterization procedures are not performed 
in all clinical centers.  Thus, a noninvasive technique to obtain ambient pressure values 
without the catheterization process is clinically helpful. 
While an intravenous injection is required to inject the UCAs into the body, this 
procedure is considered noninvasive as per the definition provided by the Center for 
Medicare and Medicaid Services; invasive procedures include surgical procedures as well 
as catheterization procedures while minor procedures such as drawing blood (which 
requires a similar approach as injecting UCAs) are considered noninvasive. 
In vitro results showed that the standard error between catheter pressures and 
SHAPE results is below 10 mmHg with a correlation coefficient value of above 0.9 – this 
experimental error of 10 mmHg is less than the errors associated with other techniques 
utilizing UCAs for ambient pressure estimation.  In vivo results proved the feasibility of 
SHAPE to noninvasively estimate clinically relevant left and right ventricular (LV and 
RV) pressures.  The maximum error in estimating the LV and RV systolic and diastolic 
pressures was 3.5 mmHg.  Thus, the SHAPE technique may be useful for systolic and 
diastolic pressure estimation given that the standard recommendations require the errors 
for these pressure measurements to be within 5 mmHg.  The ability of SHAPE to identify 
induced portal hypertension (PH) was also proved.  The changes in the SHAPE data 
correlated significantly (p < 0.05) with the changes in the portal vein (PV) pressures and 
xix 
 
the absolute amplitudes of the subharmonic signal also correlated with absolute PV 
pressures. 
The SHAPE technique provides the ability to noninvasively obtain in vivo 
pressures.  This technique is applicable not only for critically ill patients, but also for 
screening symptomatic patients and potentially for other clinical pressure monitoring 
applications, as well. 
 
 
 
1 
 
1.  INTRODUCTION 
 
1.1  An Overview 
Ultrasound contrast agents (UCAs) are microbubbles that contain a gas core 
encapsulated within a shell (for stabilization) and have mean diameters less than 5 µm so 
that they can traverse the entire vasculature (1).  Subharmonic aided pressure estimation 
(SHAPE) is a technique that involves utilizing subharmonic signals (signals at half the 
transmit frequency) exclusive to UCAs for ambient pressure estimation (2, 3) in vitro and 
in vivo.  The concept of SHAPE revolves around the fact that the ultrasound-transmit 
parameters (e.g., transmit frequency, incident acoustic output (IAO), number of transmit 
cycles, etc.) can all be tailored to induce ambient pressure dependent subharmonic signals 
from the UCAs (2, 3).  Therefore, the long-term goal of this project is to develop and 
evaluate the feasibility of SHAPE to noninvasively monitor in vivo pressures.  
Specifically, in this thesis, the clinical focus will be towards assessing the feasibility of 
SHAPE for measuring cardiac and hepatic pressures – both clinical applications utilizing 
invasive catheterizations for pressure monitoring as a standard approach (4, 5). 
Invasive catheter based pressure measurements pose risk of introducing infection 
while the catheter is guided towards the region of interest in the body through a 
percutaneous incision, pose risk of death due to structural or mechanical failure of the 
catheter (which has also triggered product recalls by the USA Food and Drug 
Administration (FDA)) and may potentially modulate the pressures that are required to be 
measured (4, 6-13).  Also, catheterization procedures require fluoroscopic guidance to 
advance the catheter to the site of pressure measurements and such catheterization 
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procedures are not performed in all clinical centers (14, 15).  Thus, a noninvasive 
technique to obtain ambient pressure values without the catheterization process will be 
clinically helpful.  An intravenous injection of UCAs is considered noninvasive as per the 
definition provided by the Center for Medicare and Medicaid Services (16); invasive 
procedures include surgical procedures as well as catheterization procedures while minor 
procedures such as drawing blood (which requires a similar approach as injecting UCAs) 
are considered noninvasive. 
Previously, other in vitro techniques to utilize UCAs for pressure monitoring have 
yielded errors in the range of 10 to 50 mmHg which is clinically unacceptable (17-21), 
because the recommendations for using a technique for systolic and diastolic pressure 
assessments require the errors to be within 5 mmHg (at least for 50 % of the recordings) 
(22).  An initial proof-of-concept SHAPE study with an invasive approach yielded a 
maximum standard error of 5.4 mmHg corresponding to a root mean square error 
(RMSE) of about 27 % in the aorta of canines (23).  Thus, the work in this thesis will 
evaluate if the SHAPE technique has translational potential for noninvasive in vivo 
pressure estimation. 
If the SHAPE technique can be successfully implemented and tested, then the 
technique will reduce the number of invasive catheterizations and the associated risks as 
well as costs for cardiac and hepatic pressure monitoring.  Also, this SHAPE approach 
will have the potential to improve patient management by providing absolute pressures 
and replacing the existing auxiliary pressure estimates/indices (5, 14, 24-38) which are 
mostly applicable in specific subsets of clinical pathologies for the aforementioned 
clinical applications.  As microbubble-based UCAs are already approved in the United 
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States for Left Ventricle (LV) opacification and due to promising clinical applications 
based on UCAs to assess severity of portal hypertension (PH) (39), the SHAPE approach 
will enhance the utility of the administered contrast agent.  Finally, this innovation will 
provide the ability to noninvasively obtain in vivo pressures not only for critically ill 
patients, but also for screening symptomatic patients and potentially for other clinical 
pressure monitoring applications as well, such as interstitial fluid pressure measurements 
in tumors, pressure measurements in renal vasculature, etc. 
 
1.2  Thesis Objective(s) 
A practical and clinically feasible SHAPE approach to determine ambient 
pressures using UCAs will be developed and investigated in vitro.  Then, refinement of 
this technique will be used to assess the feasibility of noninvasive cardiac and hepatic 
pressure monitoring in canines.  For all purposes the ambient pressures around the UCAs 
both in vitro and in vivo will be monitored using a calibrated solid state pressure catheter 
as a reference standard.  The specific aims and hypotheses for this thesis are now 
presented. 
  
4 
 
Specific Aim 1:  To develop and evaluate the feasibility of SHAPE in vitro. 
All previous attempts to harness the capability of the UCAs for measuring 
ambient pressures have lacked a clear translational potential, because these investigations 
used in-built (specifically-built) hardware platforms, or specifically engineered UCAs, or 
an equipment setup that is not feasible for clinical use.  Such bench top approaches are 
required for verifying the initial hypothesis (e.g., in (3)), but the concepts and techniques 
need to be implemented on commercially available platforms for translation into clinical 
use.  Specific Aim 1 was designed, primarily, to address this goal - commercially 
available ultrasound scanners and UCAs will be selected and used.  A suite of signal 
processing techniques will be developed for SHAPE applications (based on the 
ultrasound data format made available by the manufacturers). 
Eventually, in vivo pressure monitoring using SHAPE may require obtaining 
temporal waveforms of pressure fluctuations.  Thus, the functionality and reproducibility 
of SHAPE algorithm for tracking dynamic pressures in vitro will be investigated.  
Previous attempts to utilize UCAs for in vitro ambient pressure estimation have yielded 
errors above 10 mmHg (17-21) – this specifies the upper limit on errors for Hypothesis 1. 
 
Hypothesis 1:  Standard error between catheter pressures and SHAPE results will be 
below 10 mmHg with an r
2
 > 0.75 for continuous runs of at least 4 seconds. 
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Specific Aim 2:  To develop and evaluate the feasibility of using SHAPE for tracking 
and measuring clinically relevant left ventricle (LV) and right ventricle (RV) 
pressures noninvasively in canines. 
Here, the SHAPE technique developed under Specific Aim 1 will be tested to 
monitor cardiac pressures in canines.  The approach will be noninvasive i.e., all 
ultrasound scanning for SHAPE will be performed with closed chest cavity; unlike 
previous attempts (23).  More specifically, the potential of SHAPE to track clinically 
relevant LV and RV systolic and diastolic pressures will be investigated.  For cardiac 
SHAPE, this will serve as a pilot study for noninvasive testing of SHAPE and thus, no a 
priori power analysis will be performed.  Data from five canines will be used to test this 
proof-of-concept and evaluate the following hypotheses: 
 
Hypothesis 2:  SHAPE data will correlate with catheter pressures with an r
2
 > 0.75. 
 
Hypothesis 3: SHAPE results in the LV and RV will be in agreement with catheter 
pressures and show a maximum error of less than 10 %. 
 
The criteria of 10 % maximum error was selected because the trend in pressure 
fluctuations in addition to the absolute pressure values is also desirable.  Thus, if all the 
errors associated with the SHAPE technique show either positive or negative errors then 
the trend analysis will be useful to monitor pressure fluctuations as well, which are also 
clinically useful, in addition to the absolute pressure values
1
. 
                                                          
1
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In order to test Hypothesis 3 and to obtain absolute values of LV and RV systolic 
and diastolic pressures, a calibration factor in mmHg/dB will be calculated using least 
square regression analyses based on the aortic data (utilizing both subharmonic data and 
pressure values).  This calibration factor will be applied to the subharmonic data from the 
LV of the individual canines to determine clinically relevant LV systolic and diastolic 
pressures which include the mean LV diastolic pressure (MLVDP), minimum LV 
diastolic pressure (LVDmin), LV end diastolic pressure (LVEDP) and LV peak systolic 
pressure (LVPSP) (40).  The LV pressure estimates will also be obtained with the mean 
calibration factor determined from all the canines.  This supplementary test will provide 
verification of a sub-hypothesis i.e., can a single calibration factor be used across all 
canines/clinical cases?  Next, for the RV, the calibration factor obtained from the aorta 
will be used with the right atrial (RA) pressures (that can be obtained noninvasively) and 
the subharmonic data from the RV to obtain specific RV pressures, namely, minimum 
RV diastolic pressure (RVDmin), RV systolic pressure (RVSP) and the RV relaxation rate 
i.e., peak isovolumic –dp/dt values (40).  These LV and RV pressure values obtained with 
the SHAPE technique will be compared to the reference pressures obtained using a Millar 
pressure catheter using two tailed paired t-tests.  Two tailed paired t-tests will be used 
because it is not known (a-priori) if the pressures estimated with the SHAPE technique 
will be above or below the pressures obtained using the Millar pressure catheter. 
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Specific Aim 3:  To develop and evaluate the feasibility of SHAPE to investigate 
portal hypertension (PH) in canines and the implementation of the SHAPE 
approach on a commercial scanner for future clinical evaluation. 
The normal portal vein (PV) pressures in humans range from 6 to 12 mmHg (5, 
41, 42).  Portal hypertension (PH) is defined as absolute increases in PV pressures over 
the normal range or if the pressure gradient between the PV and the hepatic vein or the 
inferior vena cava (IVC) exceeds 5 mmHg (43).  The clinical complications associated 
with PH manifest only after severe liver dysfunction or cirrhosis develop and are 
accompanied by relatively high mortality rates (20 to 70 % mortality within 2 years); thus 
identifying nascent PH is clinically beneficial. 
In Specific Aim 3, the efficacy of the SHAPE technique for monitoring PV 
pressures and distinguishing baseline and induced PH states will be investigated.  Once 
again a canine model will be used.  Twenty-two canines will be used to develop SHAPE 
processing technique and to evaluate the feasibility and application of SHAPE to identify 
PH in canines; with 3 repetitions in each canine, the data obtained will have sufficient 
power (i.e., > 0.8) to detect the relationship of decrease in the subharmonic signals with 
an increase in PV pressures if a large effect (r > 0.5) genuinely exists (44).  Portal 
hypertension will be induced under low flow and high flow conditions in the PV.  A 
different ultrasound scanner as compared to the one used in Specific Aim 2 will be used to 
establish that the SHAPE application is independent of any specific hardware platform 
and that the concept of SHAPE can readily be implemented on other ultrasound scanners 
as well by incorporating the processing techniques developed for SHAPE on the other 
scanners.  Finally, the SHAPE approach developed will be ported on to an ultrasound 
8 
 
scanner and the implementation of this approach will be verified explicitly in a group of 
canines wherein PH will be induced using either the low- or the high- flow PH model.  
The selection of a particular model to establish acute low- or high- flow conditions in the 
PV will be based on data published in literature and the observations made by a 
radiologist, an ultrasonographer, and a certified veterinary technician present during the 
experiments.  No explicit measurements to quantify flow will be performed in this work 
so as to maintain the patency and the accessibility of the PV for acquiring ultrasound data 
for SHAPE. 
 
Hypothesis 4:  SHAPE results will be able to identify induced PH (PV pressures above 10 
- 12 mmHg) under both low flow and high flow conditions. 
 
Hypothesis 5:  The changes in subharmonic signals obtained for SHAPE will correlate 
significantly with changes in PV pressures (p < 0.05; baseline vs. PH). 
 
Hypothesis 6:  SHAPE data will correlate with catheter pressures with an r
2
 > 0.75. 
 
To test Hypotheses 4-6, linear regression analysis will be conducted to establish 
the relationship between subharmonic data and the pressure catheter data and also the 
changes in the subharmonic data due to induced PH.  Two tailed paired t-test will be used 
to identify significant changes (p-values < 0.05) in the subharmonic amplitude before and 
after inducing PH.  To evaluate the robustness of the results, a cross-validation study will 
be performed to estimate the errors obtained with the SHAPE technique.  For the cross-
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validation study, data from one canine under baseline and PH will be eliminated and, a 
linear model between subharmonic amplitude and the PV pressures will be obtained 
using data from the remaining canines.  Then, based on this linear model the PV 
pressures at baseline and at PH condition will be calculated for the canine not included in 
the linear model and compared to the pressure catheter data.  Also based on the pressures 
obtained with this cross-validation approach, the sensitivity, specificity and the accuracy 
of identifying PH in these canines will be calculated. 
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Note, for Specific Aims 1-3 (Hypotheses 1-6), all statistical analyses will be 
performed using IBM SPSS Statistics (IBM Corporation, Armonk, NY) licensed by the 
Drexel University.  Also, for Specific Aims 2 and 3, all canine experiments will be 
conducted as per specific guidelines by the American Veterinary Medical Association to 
alleviate animal discomfort and ensure compliance with the Institutional Animal Care 
and Use Committee.  Before clinical evaluation of the efficacy and accuracy of the 
SHAPE technique, in vivo verification in canines (Specific Aims 2 and 3) is warranted.  
Canines have been selected for these studies, because smaller animals, such as rabbits, 
have blood vessels too small to catheterize and because some species, such as swine, may 
have marked pulmonary hypertension during contrast microbubble experiments (45).  
The initial proof-of-concept in vivo study was also performed in canines (23).  Also the 
team at Thomas Jefferson University has had extensive experience in UCA studies in 
canines. 
 
 
Chapter 2 highlights the clinical need for measuring in vivo pressures, specifically for 
cardiac and hepatic applications.  Chapter 3 then presents the materials and methods 
espoused to address Specific Aims 1-3.  Chapter 4 presents the results and the discussions 
in light of the relevant published literature.  Chapter 5 summarizes the conclusions of this 
work with some future recommendations.  Additional material is included in the 
Appendices placed towards the end of the thesis. 
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2.  BACKGROUND AND LITERATURE REVIEW 
 
This chapter explains the clinical need for monitoring central cardiac pressures 
and PV pressures noninvasively, as well as provides a current review of the techniques 
that are being used to obtain these pressures.  Then, an overview of the UCAs is provided 
along with the rationale for potential use of the UCAs as ambient hydrostatic pressure 
sensors. 
 
2.1  Cardiac Pressure Monitoring 
2.1.1  Need for Cardiac Pressure Monitoring 
Cardiovascular diseases are ranked as the top cause of mortality responsible for 
25.4 % of the total deaths in the United States (46).  A recent update from the American 
Heart Association predicts mortality of about 2,200 Americans per day attributable to 
cardiovascular diseases – equivalent to 1 death every 39 seconds (47).  Also, worldwide 
cardiovascular diseases are the dominant cause of mortality (48).  High blood pressure 
(BP; systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) is prevalent in about 
92  % of American adults suffering from cardiovascular diseases (47).  Monitoring 
peripheral BP during routine clinical assessment with a cuff sphygmomanometer at the 
brachial artery is common.  Unfortunately, this peripheral BP measurement does not 
reveal information about systolic and diastolic pressures in the cardiac chambers (49, 50), 
which tend to be more useful for screening, diagnosing and monitoring therapeutic 
outcomes in cardiac patients as is explained in this section below. 
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Pressure measurements within the chambers of the heart provide essential 
information for the assessment and management of patients in cardiogenic shock or other 
circulatory compromise.  The assessment of intra-cardiac pressures is of particular use in 
determining the contribution of heart failure in complex clinical situations such as sepsis, 
acute renal failure or acute coronary syndrome, and for the assessment of efficacy of 
treatment (51).  Direct measurement of intra-cardiac pressures plays a role in the 
evaluation of the patient with dyspnea and concomitant pulmonary and cardiac disease, 
and patients with heart failure with preserved LV systolic function also benefit from 
accurate quantification of LVEDP, for diagnosis, intervention and prognosis.  Central BP 
measurements in the LV and RV for the systolic and diastolic phases are of use to the 
clinician. 
The central cardiac BP and hemodynamics may be a better indicator than 
peripheral BP of the target organ damage due to the increased BP - specifically to the 
heart, the brain and the kidney (50).  Furthermore, a study involving 2,073 participants 
showed that different drugs affect the central BP and the peripheral BP differently (52).  
That study revealed that amlodipine and/or perindopril treated subjects showed a 
significant reduction in the central systolic BP (4.3 mmHg; 95 % CI: 3.3 to 5.4; p < 
0.0001) and the central aortic pulse pressure (3.0 mmHg; 95 % CI: 2.1-3.9; p < 0.0001), 
while their peripheral systolic BP remained relatively constant (0.7 mmHg; 95 % CI: -0.4 
to 1.7; p = 0.2) as compared to subjects treated with atenolol and/or diuretic regimen.  
Thus, monitoring drug effects may benefit from the knowledge of central cardiac 
pressures.  A meta-analysis conducted to review the effect of different antihypertensive 
treatments with heart failure as clinical end-point, showed that treatments with diuretics 
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was the best, followed by angiotensin converting enzyme inhibitors, angiotensin-II 
receptor blockers, calcium channel blockers and beta blockers (53).  The performance of 
alpha blockers was poor with respect to placebo (53).  However, with a different clinical 
end-point such as stroke, the performance of calcium channel blockers was found to be 
superior (54).  This disparity arises from the fact that control in BP arising from different 
treatment regimens, can have different impact based on the observed clinical end-point.  
On the other hand, no change in primary outcome observed in the ACCORD (Action to 
Control Cardiovascular Risk in Diabetes) trial for patients treated with intense systolic 
BP reduction strategy (< 120 mmHg) as compared to control patients (55), suggests that 
knowing ventricular diastolic filling pressures may play a crucial role in prognosis.  Thus 
knowing changes in peripheral and central BP (both systolic and diastolic) is worthwhile 
for treatment monitoring. 
Additionally, knowledge of LV filling pressure is extremely important in the 
diagnosis and treatment of severe cardiac decompensation
2
 while the “left-sided pressure 
estimation has remained an elusive goal of noninvasive cardiac imaging” (56).  Also, 
systolic and diastolic heart failure (left-sided or right-sided or both), which are 
responsible for over 1 million hospitalizations annually, frequently requires 
hemodynamic monitoring (4, 47, 57).  The hemodynamic pressures at the level of the 
heart are also required in cardiac transplantation work-up (4).  Additionally, moderate to 
severe episodes of biopsy negative rejections following heart transplantations are 
accompanied by changes in the intra-cardiac pressures, which may require cardiac 
pressure monitoring (58). 
                                                          
2 Personal communication with Joel S. Raichlen, MD, FACC (joel.raichlen@astrazeneca.com) 
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Further, the RV has limited ability to cope with abnormal hemodynamic loading 
and chronic pressure loading before severe RV dysfunction or RV failure occurs (33).  
Since various cardiac abnormalities affect RV functionality (59), obtaining and 
measuring RV pressures is clinically relevant and necessary.  The RV dysfunction is a 
presage for inferior prognosis in patients with ischemic and idiopathic dilated 
cardiomyopathy, acute myocardial infarction, myocarditis and predicts survival in 
advanced congestive heart failure cases (60).  The RV output is extremely sensitive to 
changes in the afterload (33) and the histological changes (in myocardial density) 
associated with RV pressure overload states are more pronounced compared to the 
volume overload states (61, 62).  This implies that early determination and treatment of 
RV pressure overload may circumvent structural changes which may otherwise occur due 
to overpressures.  High RVSPs (above 35 mmHg) also portend decreased survival in 
cardiac resynchronization therapy patients (63).  An impairment in RV relaxation, 
identified by monitoring RV filling pressure difference, is marked by a reduced RV 
driving force (64) – the mean peak RV filling pressure difference was 1 mmHg in 
patients with dilated cardiomyopathy as compared to 1.4 mmHg in age-matched controls 
and 2.3 mmHg in young healthy volunteers.  Thus, measuring the RV filling pressures 
may help identify RV diastolic dysfunction.  Finally if the pressure waveforms are 
obtained from the cardiac chambers then they can be used to monitor wave reflection, 
ventricular relaxation and cardiac index in patients (65, 66). 
In summary, obtaining central cardiac pressures in the LV and the RV is clinically 
beneficial and important. 
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2.1.2  Need for Noninvasive Cardiac Pressure Monitoring 
The techniques used to obtain the central BP can be broadly classified as invasive 
or noninvasive.  Invasive techniques include fluid filled catheters and micro-tip pressure 
transducers (49).  These catheterization techniques can provide accurate absolute pressure 
values (4), but they require frequent calibration with changes in the patient‟s position 
(49).  More importantly, the invasive approach is expensive and is accompanied by a risk 
of introducing infection.  Consequently the merits of invasive catheterization procedures 
are, therefore, debated vigorously, which underscores the need for alternative 
noninvasive and reliable methods to obtain the central pressure values (4, 6-12).  
Whereas one study in a cohort of 5,051 patients showed that the catheterization process 
did not result in increased mortality or days in hospital but also did not confer any clinical 
benefit (12), another study with 5,735 patients revealed that increased mortality, cost and 
length of hospital stay were all associated with the catheterization process (6).  The 
inherent distortion in the pressure introduced by the catheter cannot be neglected either.  
Also safety issues related to the mechanical, structural or functional failure of these 
catheters have triggered the USA FDA initiated recalls for the affected catheter models – 
the latest one being in March, 2011 (13); such safety issues indicate the need for accurate 
and reliable noninvasive pressure measurement techniques. 
 
2.1.3  Noninvasive Techniques for Cardiac Pressure Monitoring 
Currently used noninvasive techniques to monitor the central BP include 
applanation tonometry, plethysmography and ultrasound-based techniques (49).  Briefly, 
applanation tonometry (based on deformation force calculations) is limited due to the 
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preferred locations for this technique – the radial or the carotid artery (49).  The 
waveform from the radial artery requires calibration (dependent on individual patients) to 
indicate central pressures, while the application at the carotids may activate baroreceptors 
and inherently suffers from a lack of posterior bony structure (49).  Another limitation of 
this technique is its sensitivity to motion artifacts (49).  Plethysmography techniques (to 
measure changes in blood volume content) have been shown to be more accurate 
revealing changes in the BP and pressure derived parameters like pulse amplitude 
variations as compared to indicating the absolute pressure values (49). 
An ultrasound based technique for tracking pressure monitors the changes in the 
BP modulated distensibility of the arteries (67).  These changes may be used to indirectly 
provide a rough estimate of the underlying BP.  A more commonly used ultrasound 
technique to assess the pressure gradients in the chambers of the heart is based on 
Doppler echocardiography - measuring the blood velocity and then use a modified form 
of the Bernoulli equation (change in pressure ~ 4xV
2
; V: velocity; assuming negligible 
flow acceleration effects, negligible viscous friction losses and very low proximal flow 
velocities relative to the distal flow velocities across the orifice i.e., the heart valves) (49).  
Noninvasive pressure determinations have been made using Doppler estimates of 
transvalvular pressure gradients.  Estimates of pulmonary artery systolic pressures are 
generated by combining RV–RA pressure gradients obtained by Doppler, with estimates 
of RA pressure (56, 68).  The estimation of LV diastolic pressures can be approached 
using measurements of pressure differences in or around the left heart.  In the presence of 
aortic insufficiency, the Doppler gradient across the aortic valve can be combined with 
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the diastolic blood pressure, to provide an estimate of LV diastolic pressure
3
.  In the 
absence of aortic valvular disease, LV diastolic pressures could be estimated from 
knowledge of the difference in LV systolic and diastolic pressure, combined with the 
systolic blood pressure
4
.  But the pressures obtained using the Doppler methods have 
been documented to be unreliable and not reproducible (69, 70). 
Another study aimed to measure local pressures in “large” arteries (2.5 cm 
diameter based on in vitro phantom setup) by using ultrasound and a pulse-wave velocity 
approach showed a precision of 1.5 mmHg (71).  Unfortunately these results are 
immature, again, due to idealized in vitro conditions that do not mimic in vivo situations 
(e.g., flow tube had uniform mechanical properties, depth of scan was 2 cm, maximum 
monitoring time was limited to 3.8 seconds, only pulse wave (PW) velocities less than 
0.8 m/s would yield accurate results, perpendicular insonification requirement and errors 
that would be introduced for noncircular areas in the vessel or nonuniform tissue 
properties) and thus, future in vivo work to measure pressures in the cardiac chambers 
appears to be doubtful (71).  The inability of these noninvasive methods to accurately 
yield systolic and diastolic LV and RV pressures has paved way for the cardiovascular 
community to embrace auxiliary or indirect estimates/indices for assessing functional 
changes associated with overpressures. 
Several Doppler indices have been proposed for predicting LV filling pressures 
and function, however there is no single index that has gained widespread clinical use 
(24, 26, 28, 35, 37, 38), particularly due to proven efficacy only in certain subsets of 
                                                          
3 Personal communication with Joel S. Raichlen, MD, FACC (joel.raichlen@astrazeneca.com) 
4 Personal communication with Joel S. Raichlen, MD, FACC (joel.raichlen@astrazeneca.com) 
18 
 
clinical pathologies.  For example, the ratio of isovolumetric relaxation time to the time 
interval between the E wave (mitral inflow velocity on conventional Doppler) and the Ea 
wave (annular early diastolic velocity) can track pulmonary capillary wedge pressures 
(PCWP), however only in patients with mitral valve disease (26).  Also, LV systolic 
function evaluated using the instantaneous ejection intra-ventricular pressure difference 
correlated (r > 0.85) with the peak of dP/dT corrected for end-diastolic volume and with 
the peak elastance (37, 58).  Still, this Doppler derived index was used to characterize LV 
systolic performance and would not be expected to reflect diastolic dysfunction in 
patients with normal systolic function.  Another technique, to quantify LV pressures is 
based on tissue Doppler imaging (TDI).  Tissue Doppler imaging utilizes the high 
amplitude Doppler signals from the relatively slower moving myocardial tissue 
(compared to the blood flow within the LV) (29).  Mitral inflow velocity and mitral 
annular movement from TDI may yield accurate left atrial pressures, which could be 
combined with transmitral pressure gradients to permit estimation of LV filling pressures 
(29, 56).  The TDI techniques provide a rough assessment of whether or not LVEDP 
exceeds 15 mmHg (30), but a more specific measurement (i.e., absolute pressure values) 
would clearly be of great benefit to the clinician.  Another study compared TDI and B-
type natriuretic peptide (BNP; obtained from venous blood samples) in 50 patients to 
estimate LV filling pressures (27).  This study found that BNP detected PCWP greater 
than 15 mmHg in patients without cardiac disease whereas the TDI echocardiography 
index (E/Ea) detected this increase in patients with cardiac disease, again exemplifying 
the deterrent to a widespread application of any particular index to gauge all cardiac 
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pressures.  Given the results from the above 2 studies, currently a resolution of 15 mmHg 
may be the best capability of techniques based on TDI (27, 30). 
For the RV, calculation of ejection fraction has been a primary echocardiographic 
measurement to evaluate the systolic function.  This ejection fraction can be measured 
noninvasively and accurately only by cardiac magnetic resonance imaging (MRI), which 
is expensive and may not be available in all clinical centers let alone in the clinician‟s 
office (33).  Instead the 2D echocardiographic size measurements from the apical four-
chambered view are used; these measurements obviously do not correlate with 3D 
volumes but are still used because the 3D echocardiographic assessments await 
standardization before clinical acceptance is possible (33, 34). 
 
Thus, there is a clinical need to obtain LV and RV pressures.  There are 
shortcomings of currently available techniques and indices to delineate these pressures.  
Swan-Ganz catheter (balloon flotation catheter requiring invasive access to vasculature) 
is therefore an accepted “gold” standard to assess cardiac hemodynamics (including 
pressures) and to classify patient populations into subsets for therapy and monitoring (4). 
 
2.2  Portal Vein (PV) Pressure Monitoring 
Anatomically, the superior mesenteric vein (from the small intestine, sometimes 
also the inferior mesenteric vein)
5
 and the splenic vein (from the spleen) unite to form the 
PV that supplies 2/3
rd
 of the total hepatic blood flow (72).  Under normal conditions, the 
hepatopetal blood flow in the PV is about 700-1200 ml/min at 15-18 cm/s and it supplies 
                                                          
5 Personal communication with Daniel B. Brown, MD (Daniel.Brown@jefferson.edu) 
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about 50 % of the oxygen consumed by the liver (43, 72).  The normal PV pressures 
range from 6 to 12 mmHg (5, 41, 42).  Portal hypertension (PH) is defined as absolute 
increases in PV pressures over the normal range or if the pressure gradient between the 
PV and the hepatic vein or the IVC exceeds 5 mmHg (43). 
 
2.2.1  Need for PV Pressure Monitoring 
Hepatic cirrhosis is characterized by a prolonged pre-clinical phase (with stealthy 
disease progression) and then a short clinical phase wherein the symptoms manifest and 
are mostly fatal (73).  Clearly an early identification of cirrhotic liver may mitigate 
fatalities.  The transition from pre-clinical to clinical phase for the cirrhotic liver is 
marked by PH i.e., elevated pressures in the PV (73). 
Chronic liver diseases also lead to PH, but nonetheless cirrhosis (mostly alcohol 
induced) accounts for over 90 % of the PH cases in the developed world (43).  
Pathophysiologically, an increase in intrahepatic vascular resistance due to architectural 
distortion of the liver (by fibrosis and increased sinusoidal tone) followed by an 
hyperdynamic circulatory state with increased plasma volume causing an increase in PV 
inflow contribute to PH states (73, 74).  These factors contribute to an increase in the 
pressure gradient between the PV and the IVC as per the modified form of Ohm‟s law for 
fluid flow (75),  
  Equation 2.1 
where, „ΔP‟ represents change in pressure, „Q‟ and „R‟ represent flow and resistance. 
Etiologically, the origin of PH may be pre-, intra- or post- hepatic (43). 
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Common complications associated with PH are ascites, encephalopathy and 
variceal bleeding, but still the natural history of PH and its complications remain to be 
understood (15).  For example, the formation and the rate of development of esophageal 
varices followed by fatal bleeding episodes vary based on the nature of liver dysfunction, 
cause of cirrhosis (alcoholic or viral induced); the development rate exceeds the 
formation of a new varix and the rupture ultimately occurs after the pressures in dilated 
mucosal veins exceed an unknown threshold dependent on hemodynamics and vessel 
wall properties (73, 76-78).  The mortality associated with these common complications 
is also high e.g., patients with ascites have 50 % two year mortality, which deteriorates to 
70 % one year mortality for infections with ascites and variceal bleeding episodes carry 
up to 20 % risk of death even after endoscopic evaluation/intervention (42, 74, 79).  
Altogether, clinical manifestations of PH occur only after severe liver dysfunction or 
cirrhosis have developed and, thus, early identification of PH is crucial for decreasing the 
associated morbidity and mortality (41, 80). 
 
2.2.2  Need for Noninvasive PV Pressure Monitoring 
For directly accessing the PV to measure PV pressures, one of the following 
approaches is required:  percutaneous transhepatic catheterization, needle puncture of 
umbilical vein, laparotomy, needle puncture of intra-hepatic portal branch or endoscopic-
ultrasound guided PV catheterization.  All of these processes are very invasive and are no 
longer performed.  Instead, an indirect measure of PH, the hepatic venous pressure 
gradient (HVPG), is the clinical standard (5).  HVPG is calculated as the difference 
between the wedged/occluded and free hepatic venous pressure (5).  HVPG measurement 
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involves introducing a pressure catheter in the hepatic vein for free and occluded pressure 
measurements mostly performed along with a transjugular liver biopsy (15).  PH is 
considered „moderate‟ for HVPG ranging from 5 - 10 mmHg, „clinically significant‟ for 
HVPG ranging from 10 - 12 mmHg and then „severe‟ for HVPG above 12 mmHg.  The 
complications associated with PH develop when HVPG is in the range of 10-12 mmHg 
and the mortality associated with severe PH is very high (> 20 %), whereas risks 
associated with moderate PH are low.  Thus, identifying nascent PH is clinically 
imperative.  Moreover, the value of HVPG measurements in the management of 
hepatocellular cancer (HCC), which is a common and deadly complication of cirrhosis, 
has been demonstrated (81).  For example, the HVPG predicts hepatic decompensation 
following hepatic resection of HCC (82).  The value of the HVPG has been demonstrated 
beyond the scenario of variceal bleeding and its prevention.  The sinusoidal pressure has 
been found to correlate with the degree of injury in cirrhosis seen on liver biopsy (83), 
and with progressive fibrosis due to recurrent hepatitis C after liver transplantation (84).  
In non-transplant patients, hemodynamic assessments have been performed and a 
correlation between HVPG and sustained virological response has been shown (85). 
Noninvasive technique(s) to measure the HVPG or the PV pressures directly may 
be of clinical value, as the clinically accepted HVPG measurements are still fairly 
invasive, are relatively expensive, require radiographic/fluoroscopic guidance to guide 
the pressure catheter and are not performed in all centers (14).  A noninvasive technique 
may also promote screening patients suspected of having compensated liver diseases to 
gauge PV pressures or progression of cirrhosis. 
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2.2.3  Noninvasive Techniques for PV Pressure Monitoring 
Some noninvasive techniques are being developed to detect PH (moderate or 
clinically significant or severe) or to indicate HVPG or to detect cirrhosis.  A technique to 
measure liver tissue stiffness using the Fibroscan apparatus (Echosens, Paris, France) 
(86) was evaluated as a predictor for severe PH (36).  This technique relies on the 
principle that the induced shear wave velocity is proportional to the liver stiffness 
measurements (LSMs) and that liver stiffness increases with cirrhosis and/or fibrosis.  
The study revealed that the correlation coefficient (r
2
) between LSMs and HVPG dropped 
from 0.61 for all patients to 0.17 for patients only with severe hypertension (36).  This 
implies patient monitoring post severe PH is compromised with LSMs (or LSM is 
independent of fibrotic or cirrhotic liver stiffness after severe PH).  This may be a major 
limitation of the LSM technique for monitoring improvement in clinical management of 
PH patients given that monitoring reduction in HVPG by greater than 20 % for severe 
PH, significantly reduces bleeding risks and mortality (87).  Also, patient recruitment was 
biased based on body-mass-index (BMI) – only patients with BMI less than 35 were 
included as above this range the LSM reproducibility is sub-optimal (36).  Similarly, the 
applicability of this technique in patients with nonalcoholic fatty liver disease may be 
questionable due to over- or under-estimation of stiffness because of high BMI.  While 
LSMs may be used to select patients with large esophageal varices and subsequent 
endoscopic follow-up (36), LSMs are prohibited for patients with ascites (because fluid 
buildup will restrict shear wave propagation and consequently, shear wave velocity 
measurements). 
24 
 
Another study attempted to quantify splenic stiffness in assessment of PH using 
MRI (14).  The hypothesis driving that study was that esophageal varices developed due 
to PH may result in splenomegaly ultimately resulting in a modification of spleen 
stiffness.  The group observed a strong correlation (r
2
 = 0.75) between liver and spleen 
stiffness, however no correlation was performed between spleen stiffness and HVPG 
(which was the original objective of the study i.e., to assess PH and its severity) (14).  
Even if that goal is met and high correlation values are observed in subsequent studies, 
the use of MRI restricts a number of patient types (e.g., with metallic implants, 
defibrillators, etc.).  Other noninvasive tests such as measurement of cardiac output, 
circulation hemodynamics, baroreflector sensitivity may provide information about PH, 
due to the associated hyperdynamic circulatory state (or hyperkinetic syndrome, (15)).  In 
this regard a recent study showed that the heart rate, cardiac index and baroreceptor 
sensitivity weakly correlated with HVPG measurements (r
2
 ranging from 0.28 to 0.48); 
also the optimal cut-offs need to be defined for predicting clinically significant PH (87).  
Some other biomarkers that may potentially be useful for assessing cirrhotic PH include 
serum endothelin levels or endothelial cell count (88, 89), but these need to be validated 
before they can be used widely along with HVPG.  Child–Pugh scores and/or MELD 
(model for end-stage liver disease) scores were initially used to predict mortality 
associated with liver diseases and are based on biochemical markers including serum 
bilirubin, creatinine and albumin, prothrombin time and international normalized ratio, 
and presence of ascites or hepatic encephalopathy (90).  However the Child-Pugh scores 
have relied on empirical evidence and give equal weight to all sub-components (thus 
correlated components can amplify the score), whereas the MELD scores lack clearly 
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defined values for categorizing cirrhotic patients (90).  Also, these scores are not useful in 
quantifying PV pressures. 
The use of ultrasound to assess several indirect measures predicting PH like PV 
diameter and flow, hepatic artery and vein flow, subjective evaluation of liver 
morphology, splenic size, portosystemic collateral and ascites has also been studied (43).  
Unfortunately PV diameter and flow patterns vary even in PH states, due to differential 
development of portosystemic shunts and collateral circulation in patients (43, 91).  
Similarly, other ultrasound based estimators also provide an indirect assessment of 
HVPG, which in turn is an indirect measure of PV pressures or PH.  Another study, 
analyzed Doppler ultrasound waveforms of the hepatic vein to monitor PV pressures 
indirectly (25).  It was concluded that monophasic or biphasic Doppler waveforms were 
observed with patients suffering from PH.  A triphasic Doppler ultrasound waveform was 
observed for normal PV pressures.  It was also shown that the biphasic waveforms 
transformed to triphasic (6/8 patients) and the monophasic waveforms transformed to 
biphasic (7/11 patients) and triphasic (4/11 patients), indicating reduction in the PV 
pressure, following administration of Terlipressin (a vasoconstrictor for the mesentric 
artery).  A major limitation of this study is the lack of quantitative assessment of 
reduction in the PV pressures.  Further the inter-observer variability was tested with n = 
2.  Also, the role of treatment agents may have different effects on the Doppler 
waveforms of the hepatic vein, thereby restricting the usefulness of this technique (25).  
In a subsequent study, a quantitative parameter called the damping index (ratio of 
minimum to maximum hepatofugal flow velocities) was compared with HVPG and also 
evaluated to track changes in HVPG after propranolol administration (used for decreasing 
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hypertension) (31).  This damping index showed a weak correlation with HVPG (r
2
 = 
0.42) and changes in HVPG after drug administration also weakly correlated with 
changes in damping index (r
2
 = 0.47).  However, an increase in HVPG (in 2 patients) 
after drug administration showed a corresponding increase in the damping index in only 1 
patient, while no changes in HVPG were also marked by changes in damping index (31).  
This reveals that tracking changes in damping index for analyzing changes in HVPG (and 
hence in severity of PH) after treatment may be limited.  Also Doppler measurements are 
known to be operator dependent and all patients in this study were scanned by a single 
individual, thus repeatability of these measurements with respect to inter-operator 
dependency needs to be established.  Another study added the damping index ratio 
(calculated at expiration and inspiration) and also the corresponding damping index 
difference to assess severity of PH (32).  These parameters may be indicative of 
decompensated liver cirrhosis (in patients with higher damping index and damping index 
ratio, and lower damping index difference) but the efficacy of these parameters for 
tracking temporal progression of nascent PH to clinically significant and severe levels 
needs to be validated (32).  The safety of an approach combining endoscopy and PV 
pressure measurements was proved in a live porcine model, however no simultaneous 
pressure measurements were obtained from other techniques to validate this method (92). 
 
The current requirement by the interventional community for screening, 
diagnosis, monitoring and prognosis of chronic liver diseases or cirrhosis is a 
noninvasive, accurate and reliable method to estimate HVPG or PV pressures (15).  Such 
a method will permit repeated PV pressure measurements and thereby, limit the number 
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of endoscopies performed (especially for screening populations or for patients without 
clinical signs of PH) (15). 
 
Overall, there is a need to obtain in vivo pressures noninvasively, at least for 
cardiac and hepatic applications as the standard clinical approaches rely on invasive 
catheter based measurements. 
 
2.3  Ultrasound and Ultrasound Contrast Agents (UCAs) 
An overview of some of the basic ultrasound concepts is provided specifically in 
sub-section 2.3.1 for review.  An overview of UCAs with the intent of elucidating the 
mechanism for subharmonic signal generation in the echo response of the UCAs is also 
provided because the subharmonic signals are used for SHAPE. 
 
2.3.1  Ultrasound 
Ultrasound refers to sound waves of frequencies exceeding the range of human 
hearing (93, 94).  Medical ultrasound imaging refers to transmission of sound waves 
(longitudinal waves comprising of compressions and rarefactions) through a body and 
production of “echo” images based on the reflected components of these sound waves 
(93, 94).  As sound waves travel through the body, they undergo either reflection, 
refraction or absorption.  Reflection is dependent upon the acoustic impedance (in Rayls) 
defined by equation 2.2 and the angle of incidence (93, 94), 
  Equation 2.2 
28 
 
where, „Z‟ is the acoustic impedance in Rayls, „ ‟ is the density of the medium „g/cm3‟ 
and „v’ is the velocity of sound in the medium in „cm/s‟.  More specifically, for 
perpendicular incidence of sound waves on a smooth boundary separating two media 
with different acoustic impedances, the amount of reflected intensity component „R‟ of 
the beam may be calculated as,  
  Equation 2.3 
where, Z1 and Z2 are the acoustic impedances of the two media (94). 
Consequently, the transmitted intensity component (T) can be calculated as (94), 
  Equation 2.4 
An ultrasound transducer converts electrical energy into mechanical energy based on 
piezoelectricity, thereby creating sound waves that are propagated through the body and 
the received echoes i.e., mechanical energy is reconverted to electrical energy, which is 
then used for image formation (95).  The ultrasound beam can be broadly classified into a 
Fresnel zone or the divergent Fraunhofer zone extending beyond the Fresnel zone; the 
length of the Fresnel zone being dependent on the diameter of the ultrasound transducer 
and the wavelength of the ultrasound, as given by, 
  Equation 2.5 
where, „D‟ is the diameter of the transducer and „λ‟ is the ultrasound wavelength (94).  
Thus by decreasing the ultrasound wavelength, the length of Fresnel zone (non-divergent 
beam) may be increased; however, a decrease in wavelength is associated with a 
corresponding increase in the frequency because the speed of sound in a given medium is 
essentially constant, given by, 
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   Equation 2.6 
where, „λ‟ is the ultrasound wavelength and „f‟ is the frequency. 
The attenuation offered to the ultrasound beam is directly proportional to frequency, 
     Equation 2.7 
where, „f‟ represents the frequency and „n‟ is about 1.1 for soft tissue. 
The axial resolution for an ultrasound beam is, 
   Equation 2.8 
where, „nλ‟ represents the spatial pulse length. 
Thus, from equations 2.7 and 2.8, it can be seen that a relatively better axial resolution 
requires a decrease in the ultrasound wavelength (or an increase in ultrasound frequency), 
but an increase in ultrasound frequency leads to increased attenuation of the ultrasound 
beam.  This necessitates a compromise between the axial resolution of the given 
ultrasound beam and the depth of penetration.  For diagnostic ultrasound imaging, the 
frequency spans a range from 1 MHz to 18 MHz depending on the clinical applications, 
whereas specific transducers permitting even higher frequency operations for certain 
clinical applications utilizing catheter based ultrasound transducers (e.g., intravascular 
ultrasound) are available (96).  For the frequency range of 1 MHz to 18 MHz, the 
wavelength varies from about 1.5 mm to 0.09 mm, assuming the speed of sound in soft 
tissue to be 1540 m/s and based on equation 2.6; thus the corresponding axial resolution 
also varies depending on the number of transmit cycles constituting a given transmit 
pulse as per equation 2.8.  A detailed overview of ultrasound transducers and basic 
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ultrasound scanning modes is not provided in this section because it has been 
summarized elsewhere
6
 (93-95). 
The field of diagnostic ultrasound has graduated progressively through single 
element transducers used in mid-1970s to transducer array based systems, and currently 
research is being focused on hand held ultrasound systems and real-time 3D/4D imaging 
(96).  This rapid growth of diagnostic ultrasound is also evident from the annual 
instruments sales cumulating to greater than $4 billion
7
.  Also, based on Medicare data it 
was shown that from 1993 to 2001, the utilization rate of ultrasound examinations 
increased by about 25 % amongst radiologists, 87 % amongst cardiologists and 43 % 
amongst other physicians (97).  Amongst the cardiologists, a vast majority of the 
ultrasound examinations were echocardiograms (97).  The number of non-cardiac 
ultrasound examinations has also increased by about 21 % from 2004 through 2009 for 
the Medicare population (98).  Likewise, the total number of emergency department 
ultrasound examinations in the Medicare population has increased by as much as 164.5 % 
over the time frame from 1993 through 2001 (99).  Although these data (97-99) are based 
on a specific subset of the American population, a general growth trend in the utilization 
of ultrasound examinations may be surmised, especially because of the advantages 
offered by ultrasound over other imaging modalities.  The chief advantages include 
portability, low-cost and real-time imaging.  The premier advantage of ultrasound over x-
                                                          
6 Masters Thesis:  Novel automated motion compenasation algorithm for producing cumulative maximum 
intensity images from subharmonic ultrasound imaging of breast lesions (pages: 4-10) – May be accessed 
from the Drexel University Archives at: 
http://idea.library.drexel.edu/bitstream/1860/2918/1/Dave_Jaydev.pdf (last verified: May 20, 2012; 22:00) 
7 Ultrasonic Imaging Systems: From Principles to Implementation – A Short Course at the 2011 IEEE 
Ultrasonics Symposium presented by Kai E. Thomenius, PhD. 
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ray based modalities is the non-ionizing nature of ultrasound unlike x-rays where 
ionization events may pose stochastic risks (e.g., cancer) or deterministic risks (e.g., skin 
injury) to the patient.  The other imaging modalities like fluoroscopy, computed 
tomography, MRI, etc., have benefitted from utilizing contrast agents for diagnosis, 
prognosis and therapy especially for vascular anomalies.  A similar development in 
utilizing contrast agents with ultrasound has also occurred (1, 96). 
The next section introduces UCAs and their basic properties with specific focus 
on the ambient pressure sensitivity of UCAs, providing a connecting link between the 
clinical need to obtain in vivo pressures and the potential of the UCAs to act as ambient 
pressure sensors. 
 
2.3.2  Ultrasound Contrast Agents (UCAs) 
The field of ultrasound contrast imaging began with a personal communication 
between Joyner C. Jr. and Gramiak R. in 1968; agitated saline was used with 
echocardiography and the origin of enhanced echoes in the received signal was attributed 
to microbubbles in the agitated saline (100, 101).  Considering microbubbles with air, the 
acoustic reflection or scattering from these bubbles for a perpendicular incident beam 
may be calculated using equation 2.3, and Zair = 0.0004 Rayls and Zblood = 1.61 Rayls 
(94), as, 
 
 
Thus, in presence of microbubbles (air/blood or air/tissue interface) more than 99 % of 
the incident ultrasound beam is reflected or scattered. 
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In the sub-sections that follow, details about modeling the behavior of 
microbubbles (both, free or un-encapsulated and encapsulated microbubbles) when 
subjected to time varying acoustic pressure excitation and the properties of the 
microbubbles-based UCA are presented before providing a current update on the use of 
available UCAs and a motivation for using these UCAs as ambient pressure sensors - this 
forms the background for the work presented in this thesis. 
 
2.3.2.1  Modeling of Un-Encapsulated and Encapsulated Microbubbles 
Modern UCAs are encapsulated microbubbles that vary in the chemical 
composition of the gas contained within the shell and, the encapsulating shell developed 
to prevent bubble coalescence and breakup under normal conditions.  Before studying the 
behavior of the encapsulated microbubbles, a brief overview of the dynamics of un-
encapsulated microbubbles is provided here.  Note, that several publications (1, 102, 103) 
have provided substantial information on the modeling of the microbubbles and in this 
section the excerpts based on the review of these publications and of other models to 
predict behavior of microbubbles are given. 
In an attempt to study the high pressures developed during the collapse of 
bubbles, specifically when the collapse is against a rigid obstacle
8
, Lord Rayleigh 
presented the mathematical approach for investigating bubble collapse in an 
                                                          
8 A study, probably undertaken to present an alternate theoretical approach explaining the erosion/surface 
damage for the propeller blades of the ships used by the Royal Navy, around World War I (Wilson M, 
Physics Today, September-2010 issue, Pg. 17) and because it was earlier demonstrated by S. Cook that the 
associated pressures may be greater than 1 GPa (Rayleigh L. Philosophical Magazine Series 6. 
1917;34(200):94-8) 
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incompressible liquid, which led to one of the basic equation describing bubble dynamics 
(104), 
     Equation 2.9 
where, „ ‟ represents the liquid density, „R, ‟, represents the 
instantaneous bubble radius and the velocity and acceleration associated with the bubble 
boundary motion, „P(R)‟ is the pressure in the liquid at the bubble boundary and „P∞(t)‟ 
represents the pressure in the liquid at very large distance from the bubble. 
The equation 2.9 was not explicitly mentioned in the study (104) - but using the 
equations of kinetic energy imparted to the liquid due to the bubble boundary motion and 
the corresponding work done this equation is realized.  Also, the effects of surface 
tension and liquid viscosity were not considered.  Therefore, a modified form of equation 
2.9, including these effects was presented (105), 
      Equation 2.10 
where, „σ‟ represents the surface tension and „µ‟ represents the coefficient of 
liquid viscosity.  This equation is termed as a generalized Rayleigh-Plesset (RP) equation 
for bubble dynamics.  The significance of the RP equation lies in its solution, which 
yields the instantaneous bubble wall motion „R(t)‟; this motion results in an “emitted” (or 
scattered or reflected) acoustic wave which is a function of the distance from the bubble 
„r‟ and time „t‟, given by, 
     Equation 2.11 
Thus, in simulations, after providing an excitation signal to the bubble, the resulting 
acoustic wave due to the bubble oscillations may be obtained and may be used to predict 
the frequency components in the received signal; this information may be then used for 
designing transmit sequences or specific scanning modes on an ultrasound scanner.  
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Strasberg showed that the volume pulsations associated with gas bubbles in a liquid could 
generate pressure waves (106, 107).  These volume pulsations i.e., small changes in the 
radius (R(t) << Ro; R(t) instantaneous radius; Ro equilibrium radius) of the gas bubbles, 
occur due to the changes in the pressure on the bubbles, irrespective of their shape (106, 
107).  Strasberg also showed that the sound pressure radiated by the gas bubbles could 
deviate from linearity and exhibit nonlinear oscillations i.e., higher harmonics of the 
pulsation frequency, when the bubbles are insonated by an external sinusoidally varying 
pressure (107).  Apart from the nonlinear oscillations of higher harmonic frequencies, 
Neppiras confirmed experimentally the presence of the subharmonic signals from the 
insonated bubbles in liquids (108).  Further, Eller and Flynn calculated the threshold 
acoustic pressure for subharmonic generation and showed that the minimum pressure 
value for subharmonic generation occurs when the driving frequency of the external 
pressure is twice the linear resonance frequency of the bubble (109).  Thus, after 
excitation the response of a microbubble may contain components above and below the 
frequency of the excitation, and may span a range from the subharmonics to higher 
harmonics. 
Empirically the presence of subharmonics and higher harmonics generated by 
modern UCAs have also been confirmed (1, 103).  These UCAs differ from free bubbles 
because of an encapsulating shell preserving the gas core as the UCAs traverse the 
vasculature.  Consequently, to better understand the dynamics of encapsulated 
microbubbles several equations that represent modifications of the RP equation, 
specifically to include the effect of the encapsulating shell, have been presented in the 
literature (102, 103).  In the following paragraph the models using different approaches 
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for modelling the shell encapsulation have been reviewed with the motivation of 
providing an accurate encapsulation model that can explain the subharmonic emissions. 
The shell encapsulation has been modeled as a viscoelastic solid (110), as an 
incompressible solid elastic material (111), and as a material with viscous and elastic 
properties (112) – and RP-type equations were derived for each model.  However, the 
above models required assumptions of isotropy and homoegeneity for the shell (assumed 
to have finite thickness).  Because these assumptions may not be accurate, a different 
approach to model the shell with an infinitesimal thickness and express the interactions at 
the boundary with Newtonian interface rheology has been developed (113).  The model 
was validated in the linear regime using experimental data and by comparison with 
another model (112); the model also predicted the nonlinear behavior specifically the 
subharmonic response.  However, the value for interfacial tension was an order of 
magnitude higher as compared to the air-water interface tension value of about 0.07 N/m.  
This cannot be a correct result as the interfactial tension should have been lower relative 
to the air-water interface because of the surfactants.  Susequently, another approach was 
adopted to model the encapsulation using a non-Newtonian interface rheology including 
an elasticity component (114) absent in the Newtonian interface rheology model (113).  
The calculated interfacial tension values were, as expected, about 70 % below the air-
water interfacial tension values.  However, this model did not predict the subharmonic 
emissions as well as the Newtonian interface rheology model (113) and (112) – the 
problem was ascribed to the use of a constant elasticity parameter value.  Another model 
for shell encapsulation was presented based on a „buckling‟ shell radius, shell 
compressibilty and maximum interfacial tension value corresponding to the rupture of the 
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UCAs (115).  This model predicted the compression only behavior of the bubbles at 
acoustic pressures below 150 kPa (115).  Two different approaches were adopted to 
model the encapsulation similar to the non-Newtonian interface rheology model (114), 
but with either a quadratic elasticity model or a exponential elasticity model (contrary to 
the linear elasticity model with thresholds based on change in bubble area as used in 
(115)).  Both these models were capable of predicting the subharmonic response from the 
UCAs, specifically the appearance of a threshold value for IAOs, below which no 
subharmonic response was present and above which the subharmonic response from the 
UCA matched the experimental values – note, that this nature of threshold dependent 
subharmonic emissions was demonstrated by Eller and Flynn for un-encapsulated 
bubbles (109). 
 
2.3.2.2  Properties of Microbubbles based UCAs 
Resonance Frequency:  The resonance frequency of an air bubble in water may be 
roughly estimated using (116), 
       Equation 2.12 
where, „fo‟ and „Ro‟ are the resonance frequency in MHz and the bubble radius in µm, 
respectively.  Another common approximation used to identify the resonance frequency 
of a bubble neglecting the surface tension and assuming adiabatic conditions is (116), 
      Equation 2.13 
where, „Po‟ and „ ‟ represent the fluid pressure and density, „R‟ represents the bubble 
radius and „κ‟ is the polytropic gas exponent. 
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For specific models of encapsulation, the equation for the resonance frequency of 
the bubble will vary according to the model parameters, but, in general, the resonance 
frequency of the encapsulated bubble will be greater than the un-encapsulated bubble of 
the same size (110), mainly due to the damping provided by the encapsulation. 
 
Scattering Cross-section:  The scattering cross-section for a small scatterer (small: 
product of wavenumber „k‟ and the radius „r‟ of the scatterer is less than 1) is given by 
(1), 
         
        Equation 2.14 
where, „K‟ and „ ‟ represent compressibility and the density of the fluid/medium and „Ks‟ 
and „ s‟ represent similar quantities for the scatterer.  This equation indicates that the 
scattering cross section depends on the differences in compressibility and the density 
between the scatterer and the surrounding medium, and is sensitive to the frequency 
(dependency of the fourth power) and to the radius of the scatterer (dependency of the 
sixth power).  The microbubbles act as good scatterers and enhance the backscattered 
signals compared to the surrounding fluid i.e., blood (in vivo) because of the difference 
between the compressibility and the density of the gas contained within these 
microbubbles and the blood; the effect of difference in compressibility is greater because 
of the squared term in the bracket in equation 2.14.  Thus, UCAs are encapsulated 
microbubbles that provide a source for an acoustic impedance mismatch with the blood, 
due to difference in compressibility between the gas contained within these microbubbles 
and the blood (1). 
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Stability:  Modern UCAs consist of a gas core encapsulated in a shell because free 
bubbles will dissolve within milliseconds after introduction in the vasculature.  Also,  
      Equation 2.15 
Thus, changing the gas core to contain gases with high molecular weight and low 
solubility like SF6 and C4F10 is valuable so that the UCAs are stable for relatively longer 
durations permitting diagnostic imaging. 
 
Size:  The UCAs should have size small enough to pass through the capillaries.  The 
capillaries on average have about a diameter of 7 µm (117) and this represents an upper 
limit on the size of the UCAs for clinical use.  Most commercially available UCAs have 
mean diameters below 5 µm. 
 
2.3.2.3  UCAs – Status Update & Safety 
A summary of currently available UCAs is presented in Table 2.1. 
 
Table 2.1:  Currently available UCAs 
UCA Manufacturer Gas 
Core 
Shell Approval for 
clinical use in 
Definity® Lantheus Medical Imaging C3F8 Phospholipids Canada, USA
*
 
Optison™ GE Healthcare C3F8 Human Albumin EU, USA
*
 
Sonazoid™ GE Healthcare C4F10 Lipids Japan, S. Korea 
SonoVue® Bracco Diagnostics SF6 Phospholipids EU, China, 
South America 
*
:  Approved for LV opacification studies 
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As seen in Table 2.1, in the USA, the FDA approved clinical use of UCAs is 
restricted to the study of the LV.  Optison and Definity received approval for clinical use 
in the USA in 1997 and in 2001, respectively.  The safety concerns over the clinical use 
of UCAs in the USA arose after 4 deaths following Definity administration which led the 
FDA to announce a „black-box‟ warning for the use of UCAs (118).  However as 
reviewed in (118), these 4 deaths occurred in patients with severe cardiac anomalies and 
the deaths may presumably be due to “pseudocomplications” i.e, death attributable to 
either the procedure (Definity administration) or due to the progression of underlying 
disease states.  Main et al further state that even if the deaths were directly due to 
Definity administration, then, given over 2 million Definity administrations worldwide, 
the risk of death due to Definity administration will be 1:500,000 – considerably less than 
the risk of death or myocardial infraction following exercise treadmill testing (1:2500; 
commonly referred to as stress testing) (118).
9
  Further description of events between the 
FDA and the physicians citing the safety and clinical use and benefits of UCAs is 
summarized elsewhere (119), finally leading to downgrading of the „black-box‟ warning.  
An in-depth review of the usage and safety profile of UCAs, with prime focus on 
Definity, has also been provided (120).  The limitation of the use of UCAs in the USA is 
in stark contrast with the recently published update on the guidelines of the European 
Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) for contrast 
enhanced ultrasound (CEUS) in pediatric and adult populations (121).  Sonazoid is 
currently approved for diagnosis in patients with liver lesions in Japan and South Korea 
                                                          
9  In the USA, the average probability of being struck by lightning is 1-in-280,000 
(http://www.lightningsafety.com/nlsi_pls/probability.html) or of death due to lightning strike is 1-in-83930 
(http://www.livescience.com/3780-odds-dying.html) – these represent far greater risk as compared to 
deaths due to Definity administration. 
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(122).  The safety of the use of Sonazoid for clinical applications has also been 
established (123); Sonazoid is not yet approved for clinical use in the USA.  [The work 
presented in this thesis is based on the use of Sonazoid, but may be extended to the other 
UCAs as well – this is discussed in Chapter 4]. 
 
2.3.2.4  Contrast Specific Ultrasound Imaging Modes and Applications 
Due to the recent advancements in the field of ultrasound imaging and UCAs 
(such as the production of stable encapsulated microbubbles and their capability to 
traverse the entire vasculature) several contrast specific non-linear imaging modes have 
been developed to increase the sensitivity and specificity of CEUS, e.g., (1, 124-129).  
Acting as nonlinear scatterers the microbubbles enhance the echoes of the incident pulse, 
resulting in scattering of the incident ultrasound beam and emission of fundamental (f0), 
subharmonic (f0/2), harmonic (n*f0; n  ) and ultraharmonic (((2n-1)/2)*f0; n   & n > 
1) components in the scattered beam profile (1).  A brief overview of the principles and 
modes for CEUS imaging is provided here (1): 
 
Fundamental B-Mode Imaging:  In this mode, the fundamental signal, at the insonation 
frequency, is used from the received beam profile.  The backscattered signals from the 
microbubbles are relatively stronger than the surrounding tissues and this enables 
localization and visualization of the vasculature in the imaging plane. 
 
Harmonic B-Mode Imaging:  In this mode, the higher harmonics specifically the second 
harmonic signals are used for image formation.  Since the backscattered energy at the 
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harmonic components of the insonation frequency is relatively greater for the 
microbubbles compared to the tissue, an improved contrast ratio is obtained relative to 
the fundamental B-mode imaging. 
 
Harmonic Power Doppler Imaging:  As in harmonic B-mode imaging, the signals 
received at twice the insonation frequency are used.  However, compared to conventional 
power Doppler imaging, the susceptibility of motion-induced artifacts is reduced because 
contrast agent signals are utilized to display the blood flow. 
 
Subharmonic Imaging:  In this imaging mode, the signals at half the transmit frequency 
are used for image formation.  An advantage of this mode is that the subharmonic signals 
are exclusive to microbubbles and thus, provide an exclusive view of the vasculature, 
much like digital subtraction angiography.  A limitation is the lack of tissue landmarks, 
but this can be addressed with a split screen setup as recently published (130). 
 
Pulse Inversion Imaging:  In this mode, two pulses with 180° phase difference are 
transmitted and the received echoes are summed.  The linear echoes from tissues cancel 
out, while the even nonlinear echoes mostly from the microbubbles increase the contrast 
seen in the ultrasound images. 
 
Power Modulation Imaging:  Another mode exploiting the nonlinear response of 
microbubbles to different types of pulses is the power modulation imaging mode.  In this 
mode two pulses with different amplitudes (power) are transmitted and the received 
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signals are weighted appropriately before being subtracted to isolate and enhance the 
depiction of nonlinear signals mostly arising from the microbubbles. 
 
Destruction Replenishment Imaging:  In this mode a transmit pulse with high mechanical 
index (MI; but less than the maximum permissible limit of 1.9) is used to destroy the 
microbubbles in the imaging plane, and then the slow replenishment of the vasculature 
(anatomy) in the scanned plane is captured by the inflow of microbubbles using low MI 
pulses.  This assists in defining the vasculature (tortuous, etc.), estimating the blood flow 
(in ml/min), perfusion (in ml/min/g), etc. and may aid in diagnosis. 
 
The above list is not totally exhaustive of the techniques used by different 
manufacturers.  Here, an insight into the use of nonlinear components of the 
backscattered signals from the microbubbles to create contrast specific imaging modes is 
provided. 
 
2.4  UCAs as Ambient Pressure Sensors 
The nonlinear signals from UCAs have been used in clinical imaging applications, 
both in harmonic and subharmonic scanning modes with specifically tailored pulse 
sequences varying amongst ultrasound manufacturers.  In addition to the imaging 
applications, various techniques to estimate ambient pressures using UCAs have been 
proposed (2, 3, 17-21).  Broadly, these may be classified into two types, techniques 
proposed based on experiments conducted with un-encapsulated (or free) microbubbles 
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(18-21) and those based on experiments conducted with encapsulated microbubbles (2, 3, 
17). 
Fairbank and Scully proposed measuring the ambient pressure based on the shift 
in resonance frequency of small bubbles (diameter 20 μm to 40 μm).  They proposed that 
ambient pressure changes would manifest as changes in bubble volume ultimately 
leading to a change in resonant frequency (18).  Their technique suffered from non-
uniformity in bubble sizes.  This resulted in broad-band scattered spectrum at the receive 
transducer, which did not show the predicted resonance shift with an increase in ambient 
pressure and prevented accurate tracking of ambient pressure changes (18).  To 
circumvent the problem of non-uniform bubble sizes, Hök proposed to utilize single 
bubble echo amplitude as a measure of ambient pressure (19).  However the technique is 
limited in application to areas containing non-flowing clear fluid (not applicable in heart 
and blood vessels).  Also the localization of a single air bubble in vivo would require 
precisely controlled ultrasound scanning parameters. More importantly Hök‟s experiment 
conducted under “ideal” conditions resulted in an error of approximately 30 % (75 
mmHg true pressure; 99 mmHg derived pressure); clearly not clinically acceptable.  
Based on a principle similar to Fairbank and Scully for measuring the ambient pressure 
based on changes in the size of the bubbles, Shankar et al. utilized a dual frequency 
technique for calculating these size changes more accurately and thereby obtain the 
ambient pressure profile (21).  However their technique achieved a resolution of only 10-
15 mmHg at best (measured vs. observed; (21)).  Miwa patented a technique to mark the 
onset of cavitation as a function of ambient pressure (20), but no in vivo experiments 
were reported.  Bouakaz et al proposed a technique to measure the dissolution time of 
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free microbubbles following the rupture of encapsulated microbubbles (17).  However, 
the technique proposed by Bouakaz et al could only detect pressure changes of about 50 
mmHg (17).  A simulation study utilizing the disappearance time of the gas bubbles 
along with the appearance of the subharmonic signal and its gradual decay (as the bubble 
shrinks) for ambient pressure estimation showed that using this technique ambient 
overpressures in the range of 11 mmHg may be measureable (131).  However, these 
simulations revealed that such low errors would require gas bubbles with diameters of the 
order of 14 µm (131), considerably greater than the average diameters of the capillaries 
(7 µm) (117).  Also no follow-up experimental evaluations using this approach have been 
documented.  Overall these techniques yield errors ranging from 10-50 mmHg, which is 
clinically unacceptable because the recommendations for using a technique for systolic 
and diastolic pressure assessments require the errors to be within 5 mmHg (at least for 50 
% of the recordings) (22). 
A different technique to determine changes in the ambient pressure based on 
subharmonic emissions from microbubbles called subharmonic aided pressure estimation 
or SHAPE has also been proposed (2, 3).  The subharmonic signal generation as a 
function of IAO, may be characterized into 3 stages – occurrence, growth and saturation; 
this observation has also been characterized in the models published in the literature (2, 3, 
113, 114, 132, 133).  In the occurrence stage, the subharmonic signal amplitude is 
probably too low to be detected above the noise level.  In the saturation stage, the 
subharmonic signal is the highest (amongst the 3 stages of the subharmonic signals) 
mostly due to strong subharmonic emissions by the collapsing bubbles.  The concept of 
SHAPE revolves around the subharmonic signal emissions in the intermediate stage i.e., 
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the growth stage.  In this stage, the subharmonic amplitude decreases linearly (in dB; r
2
 ≥ 
0.96) with an increase in ambient pressure over a range of 0 to 186 mmHg (3); note that 
this range covers blood pressures encountered clinically in most situations.  Thus, 
subharmonic emissions from microbubbles in the growth stage can be calibrated to 
provide the ambient overpressures. 
Recently other groups have also explored SHAPE applications in vitro, but either 
with the use of in-house ultrasound transducers/systems, single element transducers or 
custom-made contrast bubbles (131, 134-141).  An inherent limitation in these studies is 
the lack of consideration of the flow dynamics encountered in vivo, and also the use of 
such “in-house platforms,” which delays the clinical evaluation and, ultimately, 
acceptance (due to prerequisite safety studies and lack of availability).  Another recently 
proposed technique showed (theoretically) that the shift in subharmonic optimal driving 
frequency may be attributable to changes in ambient pressure, and thus this shift may be 
useful to indicate ambient pressures (142).  In this technique, simulations with single 
bubble model and with bubbles having a size distribution typically encountered in a UCA 
vial were used, with the characteristics of SonoVue microbubbles.  The subharmonic 
optimal driving frequency was defined as the driving (insonation) frequency that elicited 
a maximum subharmonic signal amplitude (142).  Consequently such an approach 
requires the transducer to sweep through a range of the transmit frequencies in order to 
determine the optimal driving frequency.  Since this would require transmitting a number 
of interrogating pulses at different transmit frequencies, a real time in vivo application 
may be challenging, given that the ambient pressures in vivo i.e., blood pressure varies 
considerably within a cardiac cycle that lasts about 0.83 s (assuming 72 beats per 
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minute).  The authors suggest using calibrations with in vitro experiments to relate the 
shift measured in vivo to the ambient pressures (142) – and these interesting results shall 
be awaited.  The two simulations of LV pressures provided in the results by the authors 
were for a SonoVue microbubble with diameter 1.6 µm and a group of SonoVue 
microbubbles with mean diameter of 0.8 µm and a standard deviation of 0.2 µm 
following a Gaussian distribution, and the errors in reporting maximum LV pressure were 
within 3 mmHg (142).  Again the implications of these results may require scrutiny 
especially when in vitro and in vivo experiments are conducted, given that 80 % of the 
echogenicity from SonoVue microbubbles is provided by bubbles ranging from 3 to 9 µm 
in diameter (143). 
Thus, in the next section, the concept of SHAPE is revisited with the specific 
purpose of providing motivation for the work presented in this thesis. 
 
2.5  Subharmonic Aided Pressure Estimation (SHAPE) with UCAs 
It was demonstrated that subharmonic signal amplitude shows a sigmoidal 
relationship with IAO and in the growth phase the subharmonic signal amplitude 
becomes dependent on the ambient pressures (2, 3).  Thus, growth phase subharmonic 
emissions may be used to estimate ambient pressures i.e., SHAPE may be feasible with 
growth phase subharmonics.  After the initial in vitro results (3), the first in vivo 
application of SHAPE was investigated (23).  The experimental setup used for that study 
is shown in Figs. 2.1 and 2.2
10
. 
                                                          
10 Courtesy Dr. Forsberg. 
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Figure 2.1:  Experimental setup for first in vivo SHAPE experiments 
 
 
Figure 2.2:  Data acquisition for first in vivo SHAPE experiments 
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The experiments were conducted with an invasive approach to access the aorta.  A 
mid-line abdominal incision was created and 2 single element transducers (one for 
transmit and the other for receive) were used.  The results from the study were promising 
because a maximum standard error of 5.4 mmHg was obtained with SHAPE relative to 
simultaneous pressures recorded by a Millar pressure catheter (23).  Since single element 
transducers were used there was no simultaneous imaging performed, which is a severe 
limitation given that in human measurements need to be conducted noninvasively.  This 
experimental setup was plagued by other acquisition problems (employing 2 single 
element transducers held together with duct tape – see Fig. 2.2), which is also not 
clinically acceptable. 
 
Hence, while several methods have been proposed over the last 4 decades to track 
in vivo pressures using microbubbles, none of these techniques have been translated into 
clinical use, either due to high errors (greater than 10 mmHg) in vitro and/or due to 
experimental setups lacking clinical feasibility.  The objective of the work presented in 
this thesis was to develop and evaluate the feasibility of SHAPE to noninvasively 
monitor cardiac and PV pressures using a commercially available ultrasound scanner and 
an existing UCA, mitigating problems associated with previous experimental techniques. 
 
 
The next chapter (Chapter 3) presents the materials and the methods espoused for 
the in vitro studies and, cardiac and hepatic in vivo studies and the results with 
discussions are presented in Chapter 4.  
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3.  MATERIALS AND METHODS 
 
3.1  Materials 
3.1.1  Selection of UCA for Dynamic In Vitro Studies and In Vivo Studies 
Preliminary studies for SHAPE applications were undertaken with different 
UCAs.  The UCAs investigated for SHAPE are listed with their key properties in Table 
3.1. 
 
 
Table 3.1:  UCAs investigated for SHAPE in vitro 
UCA Manufacturer 
Gas 
Core 
Shell 
Mean 
Diameter 
(μm) 
fo
*
 
(MHz) 
†
Definity® 
Lantheus Medical 
Imaging 
C3F8 Phospholipids 1.1-3.3 2.7 
Levovist® Schering, AG Air 
Galactose / 
Palmitic Acid 
2.0-4.0 2 
†Optison™ GE Healthcare C3F8 Human Albumin 2.0-4.5 2 
Sonazoid™ GE Healthcare C4F10 Lipids 2.4-3.5
‡
 4.4 
ZFX 
Zhifuxian, Xinqiao 
Hospital 
C4F10 Lipids 2.0-4.0 3 
*
:  resonance frequency;  
†
:  Approved for LV opacification studies in the USA;  
‡
:  median diameter 
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Note, that these UCAs were investigated, because other experimental agents like 
the one used in Ref. (137) were not accessible.  The results showed that over a static 
pressure increase from 0 to 186 mmHg (almost the clinical BP range), the maximum 
linear decrease in subharmonic signal occurred for Sonazoid (3, 144) – see Table 3.2 
below (sorted in descending order based on subharmonic reduction).  Note, that the 
highest sensitivity of Sonazoid was also confirmed by a parameter study in which the 
subharmonic reduction of Levovist and Sonazoid were compared (135) – Sonazoid 
showed relatively higher ambient pressure sensitivity.  Thus, Sonazoid was selected as 
the UCA for developing and evaluating the SHAPE algorithm in a dynamic in vitro setup 
(pressures continually varying with time) and for subsequent in vivo studies. 
 
 
Table 3.2:  Behavior of different UCAs when ambient pressure was varied in the 
range from 0 to 186 mmHg 
 
 Subharmonic reduction 
(dB)  
(n= 3) 
Linear Regression 
(r
2
) 
Sonazoid 13.3 ± 0.19 0.99 
ZFX 12.2 ± 0.17 0.97 
Definity 11.0 ± 0.26 0.98 
Optison 10.1 ± 0.18 0.97 
Levovist 9.6 ± 0.23 0.98 
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Sonazoid microbubbles consist of perfluorobutane gas encapsulated in a 
membrane of hydrogenated egg phosphatidyl serine and have the capability of 
withstanding ambient pressure as high as 300 mmHg (145).  The clinical safety profile 
for Sonazoid has been established (123) and it has already been approved for diagnosis in 
patients with liver lesions outside the USA (122).  Sonazoid is provided as a powder for 
reconstitution before injection.  After addition of 2 ml of sterile water and gentle shaking 
by hand, the product is easily reconstituted and produces a homogenous dispersion of 
microbubbles with a concentration of 10 l of microbubbles/ml (in this form the agent is 
stable for four hours at room temperature). 
 
3.1.2  Selection of Ultrasound Scanner for SHAPE 
Two ultrasound scanners were selected, the Sonix RP (Ultrasonix, Richmond, 
BC, Canada) and the GE Logiq 9 (GE Healthcare, Milwaukee, WI).  The Sonix RP 
scanner was selected because it provided full access and control of the imaging data.  The 
Sonix RP platform permitted access to the radiofrequency (RF) data and enabled new 
imaging modes like pulse inversion to be configured (146).  The RF data refers to the 
data after conversion of mechanical energy (backscattered signals) back to the electrical 
signals by the transducer – this RF data may be pre-beamformed, post-beamformed, 
filtered or unfiltered.  Thus, for the dynamic in vitro studies and the cardiac studies in 
canines the Sonix RP scanner was used.  To prove that the concept of SHAPE may be 
implemented on multiple hardware platforms, in the next phase of study - to identify PH 
for hepatic applications, a GE Logiq 9 scanner was selected.  A research contract with 
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GE Global Research permitted access to the RF data after modification of the operating 
software. 
An additional consideration after the selection of the ultrasound scanner was the 
choice of transmit frequency, which governs the selection of the ultrasound transducers 
(probes) for the respective ultrasound scanners.  In preliminary studies in static tank 
experiments (144), the subharmonic reduction of Sonazoid over an ambient pressure 
variation of 0 to 186 mmHg was investigated as a function of transmit frequency.  The 
optimum transmit frequency for SHAPE with Sonazoid was 2.5 MHz which implies that 
the theoretical subharmonic receive frequency would be 1.25 MHz.  Based on this 
selected transmit frequency (2.5 MHz), on the in vivo application to be investigated 
(cardiac and hepatic) and on the available transducers with the respective ultrasound 
scanners, a PA4-2 phased array was selected for the Sonix RP scanner for in vitro and in 
vivo cardiac studies and a curvi-linear array 4C probe was selected for the Logiq 9 
scanner for in vivo hepatic studies.  The modifications of the Sonix RP scanner and the 
Logiq 9 scanner were performed and tested in conjunction with the respective 
manufacturer‟s research support team personnel ensuring adequate representations of 
transmit and receive signals at 2.5 MHz and 1.25 MHz, respectively. 
 
Additionally a detailed list of equipment including the auxiliary equipment with 
model and serial numbers (where applicable) is provided in Appendix 1.  
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3.2  Methods 
This section is divided into three sub-sections, namely, dynamic in vitro studies, 
cardiac in vivo studies and then hepatic in vivo studies.  For each sub-section the 
experimental setup, data processing and statistical tests used are explained.  The data 
processing were performed offline in Matlab (The Mathworks, Inc., Natick, MA), unless 
explicitly stated.  An explicit mention of the „Use of Vertebrate Animals in Experiments‟ 
is provided in Appendix 2. 
 
3.2.1  Dynamic In Vitro Studies 
3.2.1.1  Incident Acoustic Output (IAO) Measurements for Sonix RP Scanner with the 
PA4-2 Array 
The subharmonic emissions from the UCAs may be in the occurrence stage, the 
growth stage, or the saturation stage (3) – this depends on the IAO; about 100-200 kPa 
for the occurrence stage, 300-600 kPa for the growth stage and higher IAO levels for the 
saturation (or bubble destruction) stage.  The growth phase subharmonic emissions are 
sensitive to ambient pressures (3).  Thus, it is necessary to select the IAO levels that elicit 
growth phase subharmonic emissions.  For dynamic in vitro studies and in vivo studies it 
is not feasible to obtain the accurate IAO levels at the site of the microbubbles, because 
this would require inserting a hydrophone in the lumen of the vessel (in the Doppler flow 
phantom) or in the heart or the liver for the in vivo studies.  However, it is important to 
have an estimate of the IAO levels given the need for growth phase subharmonic 
emissions to measure ambient pressures.  At the same time, most manufacturers encode 
the acoustic output of the scanner – for the Sonix RP, the acoustic output is encoded as -2 
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dB levels with 0 dB representing the maximum acoustic output.  The acoustic output 
spans a range from -32 dB to 0 dB.  Consequently, the IAO levels corresponding to these 
encoded dB levels were measured using a standard water bath approach. 
The incident acoustic pressures at the focus of the transducer were measured 
using a calibrated 0.2 mm needle hydrophone (Precision Acoustics, Dorchester, Dorset, 
UK; sensitivity of 57.1 mV/MPa at 2.5 MHz).  The focal point was determined by finding 
the point of maximum acoustic pressure using a semi-automated electronic x-y-z- 
positioning system.  The measurements at each encoded dB level were performed in 
triplicate. 
 
3.2.1.2  Experimental Setup 
A schematic of the experimental setup is shown in Fig. 3.1. 
 
 
 
Figure 3.1:  In vitro experimental setup for dynamic SHAPE studies  
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Closed-Loop Flow System:  A closed-loop flow system was implemented using an acrylic 
water bath (4071.5 cm
3
), a Sarns S10K II Blood Pump (Sarns Inc., Ann Arbor, MI; 
operated at 650 ml/min), a Doppler flow phantom (ATS Laboratories, Inc., Bridgeport, 
CT) and flexible PVC tubes (8 mm inner diameter).  The ambient pressures in the flow 
system were controlled using the blood pump and the revolutions per minute on the blood 
pump was set to achieve ambient pressures varying from 0 to 120 mmHg.  A dose of 0.2 
ml reconstituted Sonazoid microbubbles (approximately equivalent to 1.6 μl 
microspheres with volume median diameter of about 2.6 μm (145)) was mixed with 750 
ml of isotonic diluent (Val Tech Diagnostics Inc., Pittsburgh, PA) in the acrylic water 
bath (temperature 25 °C).  A magnetic stirrer was used to ensure uniform mixing.  A 
tissue-mimicking phantom (L ×W × H: 15 × 9.5 × 8 cm
3
; ATS Laboratories Inc.) was 
coupled to the Doppler flow phantom with acoustic gel.  This tissue mimicking phantom 
was used, because the depth of the vessel within the Doppler flow phantom was only 1.5 
to 2 cm, and thus, would not simulate the depth encountered in vivo in cardiac and 
hepatic applications.  A 5 French solid-state curved tip pressure catheter (SPR 350, Millar 
Instruments Inc., Houston, TX) was inserted into the flow phantom through the acrylic 
water bath.  The pressure catheter was connected to a control unit (TCB 500, Millar 
Instruments) and the output of the control unit was connected to an oscilloscope (9350 
AM, LeCroy, Chestnut Ridge, NY) providing the reference standard for these 
experiments i.e., the ambient pressure values in the flow phantom.  The pressure catheter 
was calibrated to have an error band of ± 1.5 mmHg at zero pressure and adjusted using 
the manufacturer's specification to indicate the absolute pressure values. 
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Ultrasound Scanner Configuration:  A Sonix RP scanner with a PA4–2 phased array 
transducer (Ultrasonix Medical Corp., Richmond, BC, Canada) was operated in the 
Research mode.  The Sonix RP scanner was configured to perform in pulse-inversion 
imaging mode, transmitting 2-cycle pulses at a 2.5 MHz center frequency (-6 dB 
bandwidth: 1.3 MHz).  In pulse-inversion mode, 2 pulses with a 180° phase difference 
are transmitted and the received echoes are summed, enhancing the even nonlinear 
signals while canceling out the linear signals and odd harmonics.  In this study, the pulse-
inversion technique was selected to enhance the nonlinear signals from the Sonazoid 
microbubbles, specifically the nonlinear subharmonic signal.  The pulse inversion 
imaging mode caused the frame rate (for simultaneous imaging; on the Sonix RP 
scanner) to be reduced to nearly half in the B/PW mode compared to grayscale B-mode 
imaging alone.  However, the temporal resolution of the signal acquired for tracking 
ambient pressure depends on the pulse repetition frequency (PRF) corresponding to the 
PW mode and is, therefore, not markedly affected.  A pulsed Doppler gate size of 1.5 mm 
placed within the lumen of the vessel was used to acquire unprocessed accumulated pulse 
data.  The unprocessed RF data was post-beamformed and accessed before envelope 
modulation of the RF signal. 
 
Synchronization Setup:  A synchronization pulse, obtained from the „Print‟ output on the 
Sonix RP scanner, was used to trigger the oscilloscope during active data capture.  The 
oscilloscope was configured to acquire the pressure catheter data on a lab computer via a 
GPIB interface (driver version 2.7.0.49152) through LabVIEW (version 8.0, National 
Instruments Corp., Austin, TX).  The PRF was set to the maximum possible value of 3.3 
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kHz (limited by the depth of penetration i.e., 9.5 cm in this setup) to achieve maximum 
temporal resolution. 
A summary of data acquisition parameters for the in vitro experiment setup is 
provided in Table 3.3.  The IAO levels were varied across the range as indicated in Table 
3.3 to identify the IAO level that would elicit subharmonic emissions from Sonazoid in 
the growth phase i.e., the ambient pressure sensitive phase.  Additionally, specific details 
including configuration and operating procedures are given in Appendix 3. 
 
Table 3.3:  Data acquisition parameters for the in vitro SHAPE studies 
Scanner; probe: Sonix RP; PA4-2 
Scanning mode: Pulse inversion imaging; 2 transmit cycles 
ftransmit; freceive: 2.5 MHz; 1.25 MHz 
Contrast agent; Administration: Sonazoid; 0.2 ml reconstituted microbubbles with 
750 ml isotonic diluent 
Synchronous pressure monitoring: 5F solid state catheter tip manometer  
IAO: -8 dB to 0 dB (0 dB maximum output; 76 kPa to 
897.04 kPapk-pk; mechanical index < 0.38) 
Pulse repetition frequency:                   3.3 kHz 
Vessel depth(s) in flow phantom: 9.5 cm with external tissue mimicking phantom 
and 1.5 cm without the tissue mimicking phantom 
Scanned region: Vessel lumen (4 mm diameter) 
Gate size (PW Doppler): 1.5 mm  
Acquisitions: 5 second runs (n = 3 to 5 per IAO level) 
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3.2.1.3  Data Acquisition, Processing and Statistical Analyses 
 
Part-I Goal:  To identify most sensitive IAO level for SHAPE 
 
Data Acquisition-I:  Five IAO levels corresponding to -8 dB, -6 dB, -4 dB, -2 dB and 0 
dB were selected because the range of these IAO levels varied from 76 to 897 kPapk-pk 
i.e., these encoded levels spanned a range of IAO levels that are most likely to elicit 
growth phase subharmonic emissions.  For each IAO level, the data from the ultrasound 
PW gate were acquired over 5 s in synchrony with the pressure catheter – these 
measurements were repeated in triplicate.  Based on the PRF of 3.3 kHz, data from about 
16500 pulses (from each experimental run) were obtained. 
 
Data Processing-I:  The data from each pulse were converted to the Fourier domain.  The 
subharmonic signal was extracted as the mean signal in a 0.2 MHz (16 %) bandwidth 
around the subharmonic frequency (1.25 MHz) i.e., signals from 1.15 to 1.35 MHz for 
each pulse data.  Then the resulting subharmonic amplitude time variation signal was 
noise filtered using a median filter of order 500.  This technique was selected because it 
was analogous to our previous approach (147).  The median filter was selected, because it 
eliminates transient high-frequency noise (probably due to multiple scattering, etc.) and 
extracts the underlying slow-frequency amplitude variations; in this case, the underlying 
subharmonic signal that may be used for ambient pressure estimation.  This process is 
illustrated in Fig. 3.2 and was repeated for all data sets acquired at the selected IAO 
levels.  Since the data acquisition was performed at varying IAO levels, there is a 
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possibility of more than one IAO level eliciting growth phase subharmonics.  
Consequently there is a need to identify the IAO level that elicits the growth phase 
subharmonic emissions that are most sensitive to ambient pressures.  Thus, the range of 
subharmonic signals for each pulse contour (i.e., maximum – minimum subharmonic 
amplitude) were extracted, averaged over all pulse contours at a given IAO level and 
compared. 
 
Statistical Analyses-I:  To determine the most sensitive IAO level for ambient pressure 
tracking in this experimental setup, the changes (i.e., the range) of subharmonic 
amplitude were compared using a one-way analysis of variance (ANOVA) with 
Bonferroni corrections for multiple comparisons (148).  P-values less than 0.05 were 
considered significant.  The ANOVA tests and the Bonferroni corrections for multiple 
comparisons were used because subharmonic amplitude ranges obtained at five IAO 
levels were to be compared and for comparing these different mean values the ANOVA 
technique in conjunction with the Bonferroni corrections will maintain the probability of 
making type I error to 5 % (i.e., a p-value of 0.05). 
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Figure 3.2:  Process of extracting the time-variant subharmonic signal for ambient 
pressure tracking. The signal obtained from the pulse Doppler gate (A) is shown along 
with the Fourier Domain representation (B) and the short-time Fourier transformation 
(C). The subharmonic signal obtained from all the pulses acquired during the acquisition 
(D) was processed using a median filter of order 500 to remove high frequency noise (E). 
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Part-II Goal:  To investigate the ability of SHAPE to estimate ambient pressures 
 
Data Acquisition, Processing and Statistical Analyses-II:  In the next phase of 
experiments, the data were acquired at the IAO level that elicited subharmonic emissions 
most sensitive to ambient pressure variations.  The data sets (synchronous pressure 
catheter data and the PW data) were acquired as 5 s runs and also as a long 20 s run 
consisting of at least 20 cycles of pressure changes.  The processing approach was as 
adopted in Data Processing-I.  Least squares linear regression analysis was used to assess 
the ability of the processed subharmonic data (in dB) to predict the ambient pressure 
values (in mmHg).  Also in order to verify that the variations in the subharmonic signal 
were not solely due to the variations in the concentration of Sonazoid microbubbles (due 
to the pulsatile flow), the fundamental and the second harmonic signals were also 
extracted and studied.  If the fundamental and/or the second harmonic signals also 
showed a similar variation as compared to the subharmonic signals, then the efficacy of 
SHAPE would be questionable. 
 
Part-III Goal:  To confirm the variation of subharmonic signals as a function of ambient 
pressures 
 
Data Acquisition, Processing and Statistical Analyses-III:  This part of the 
experimentation was developed for cross-validation of the subharmonic emissions.  The 
tissue mimicking phantom from Fig. 3.1 was removed and it was hypothesized that the 
IAO level used in Part-II should induce collapse of the microbubbles (due to the removal 
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of 8 cm of attenuation; the tissue mimicking material attenuation was 0.5 dB/cm/MHz).  
Due to the collapse of the microbubbles, the resulting subharmonic signals may not be 
able to predict the subharmonic emissions, and the resulting pressure waveforms obtained 
from the subharmonic data may be distorted.  The processing approach and statistical 
analyses were as adopted in Part-II. 
 
Part-IV Goal:  To develop “best” processing technique for in vivo SHAPE studies 
 
Data Acquisition-IV:  The experimental setup was as shown in Fig. 3.1 and, pressure 
catheter data and RF data were acquired at the most sensitive IAO level used for Part-II.  
The data were acquired as 5 s runs and the acquisitions were repeated 5 times. 
 
Data Processing-IV:  When the accumulated data from the PW gate after pulse inversion 
was inspected in the Fourier domain, shifts in peak subharmonic amplitudes from the 
expected subharmonic frequency of 1.25 MHz were noted (Fig. 3.3A).  These shifts may 
occur due to transient variations in the concentration and the size of microbubbles 
probably due to the variable/pulsatile flow and the problem may be aggravated in vivo 
due to processes like phagocytosis (149) affecting microbubbles‟ concentration or due to 
the combined frequency response of the ultrasound transducer and system.  Overall there 
was a need to compensate for such shifts in the subharmonic peak frequency before the 
subharmonic data were used for ambient pressure estimation. 
Four different techniques were used to extract the subharmonic signal amplitude 
from each accumulated pulse data (after pulse inversion) – average subharmonic 
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amplitude in a 0.5 MHz bandwidth about the theoretical subharmonic frequency (Fig. 
3.3B) representing a relatively wide bandwidth (40 %) signal, average subharmonic 
amplitude in a 0.2 MHz bandwidth about the theoretical subharmonic frequency (Fig. 
3.3C) representing a relatively narrow bandwidth (16 %) signal, parabolic fit to capture 
the subharmonic peak in a 0.5 MHz bandwidth about the theoretical subharmonic 
frequency (Fig. 3.3D) and the exact signal amplitude at the theoretical subharmonic 
frequency (Fig 3.3A).  A parabolic fitting technique was used to locate the expected 
subharmonic peak within this range.  In Part-I, an extraction bandwidth of 0.2 MHz was 
used.  The extracted subharmonic amplitudes were filtered using two techniques to 
eliminate the high frequency noise.  A median filter with varying order from 50 to 500 
(specifically, 50, 100, 250, 325 and 500; representing a time integral of 15 ms to 151 ms) 
was implemented.  Note, that in Part-I, a median filter with order 500 was used.  Another 
filtering approach was based on wavelets.  An 8-stage subband decomposition using 
Daubechies second-order low-pass and high-pass filter coefficients was employed to 
isolate the time-varying subharmonic signal within a frequency band of 0 to 6.5 Hz 
corresponding to 0 to 360 beats per minute (i.e., encompassing a wide range of cardiac 
arrhythmias from bradycardia to tachycardia that may be encountered clinically).  The 
frequency response of the Daubechies filter coefficients is shown in Fig. 3.4.  Daubechies 
second-order low-pass and high-pass filter coefficients were chosen because they are 
compactly supported orthonormal wavelets useful for data analysis (150, 151).  
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Figure 3.3:  Extraction techniques for subharmonic amplitudes.  (A) A frequency shift in 
the received spectrum between the theoretical (bars) subharmonic (1.25 MHz), 
fundamental (2.5 MHz) and second harmonic (5 MHz) peaks and the actual signal peaks 
(arrows).  Average subharmonic amplitude extraction (bars) in 0.5 MHz (B) and in 0.2 
MHz (C) bandwidth about the subharmonic frequency.  (D) Extraction of the peak value 
in a 0.5 MHz bandwidth around the theoretical subharmonic frequency after performing a 
parabolic fit (solid). 
 
 
Figure 3.4:  Frequency response for Daubechies second-order low-pass (A) and high-
pass filter coefficients (B).  
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Statistical Analyses-IV:  A least-squares linear regression analysis was initially conducted 
to determine the slope (mmHg/dB), the correlation coefficient and the RMSE generated 
from predicting the pressure values (in mmHg) using the filtered subharmonic signal (in 
dB) relative to the reference standard (the pressure catheter).  A repeated measures 
ANOVA was used to compare the four extraction techniques and the median filtering 
approach with five filter orders, and the combination of four extraction techniques with 
the wavelet based approach to identify the combined technique with the smallest RMSE – 
thereby providing the best representation of the ambient pressure fluctuations.  The post-
hoc comparisons were performed using t-tests with Bonferroni corrections for multiple 
comparisons (148).  P-values less than 0.05 were considered significant. 
 
The Matlab functions and subroutines created for processing the data are 
presented in Appendix 4. 
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3.2.2  In Vivo Cardiac SHAPE Studies 
The study was approved by the Institutional Animal Care and Use Committee of 
Thomas Jefferson University and conducted in accordance with the recommendations of 
the Panel on Euthanasia of the American Veterinary Medical Association.  The cardiac 
SHAPE studies were divided into three separate studies:  in 2 canines the efficacy of 
obtaining subharmonic signals for SHAPE was evaluated, then in 4 canines a technique 
to obtain clinically relevant LV pressures was investigated and lastly, in 5 canines a 
technique to obtain clinically relevant RV pressures was investigated.  The animal 
preparation for these studies were similar and thus, the next section summarizes the 
common steps in the three studies.  Following the „Animal Preparation‟ section, the 
specific motivation for each study and data acquisition, processing and statistical analyses 
steps are presented. 
 
3.2.2.1  Animal Preparation 
Initially, an intravenous injection of Propofol (Abbott Laboratories, Chicago, IL; 
dose of 7 ml/kg) was used as the anesthetic.  The canines were placed in supine position 
on the operating table.  During the course of the experiments, the animals were intubated 
and anesthesia maintained with 0.5 to 2 % Isoflurane (Iso-thesia; Abbott Laboratories, 
Chicago, IL) via an endotracheal tube.  Also a warming blanket was used to maintain 
normal body temperature.  An 18-gauge catheter was placed in a forelimb vein for 
infusion of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) at a concentration of 
0.015 μl/kg/min.  This concentration was selected based on previous study (23).  A 5F 
solid state micromanometer tipped catheter (SPR 350, Millar Instruments, Inc., Houston, 
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TX) was used as the reference standard and was introduced at the site for pressure 
measurements under ultrasound guidance.  The pressures signals were recorded on an 
oscilloscope and digitized and captured on the computer using LabVIEW.  A 
synchronization signal between the Sonix RP scanner and the oscilloscope enabled 
simultaneous acquisition of the pressure catheter data and the RF data on the Sonix RP.  
The Sonix RP scanner was operated with the PA4-2 probe and configured for pulse 
inversion imaging with 2 transmit pulses.  At the end of the experiments the canines were 
sacrificed by an intravenous injection of Beuthanasia (0.25 mg/kg). 
 
3.2.2.2  Evaluating Feasibility of Noninvasive In Vivo SHAPE 
The motivation for this study was to evaluate the feasibility of obtaining 
subharmonic signals that would be sensitive to pressures in the LV, noninvasively.  To 
the best of our knowledge, this documents the first-ever study of noninvasive SHAPE and 
thus, 2 canines were studied for the feasibility of the approach. 
 
Data Acquisition:  The ultrasound guided pressure catheter was positioned in the LV.  
After confirmation of the pressure catheter in the LV (Fig. 3.5A), the infusion of 
Sonazoid microbubbles was started.  After confirmation of the presence of Sonazoid 
microbubbles in the LV the data acquisition began (Fig. 3.5B).  The PW gate was 
positioned in the LV close to the location of the pressure catheter.  The IAO levels on the 
Sonix RP scanner were varied from -8 dB to 0 dB (to compensate for attenuation 
differences between canines) and the data were acquired in triplicate as 5 s runs.  A 
representative of snapshot of equipment setup is shown in Fig. 3.6.  
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Figure 3.5:  Grayscale ultrasound images of the LV before Sonazoid infusion (A) and 
after Sonazoid infusion (B).  The pressure catheter and the PW Doppler gate to acquire 
RF data are indicated. 
 
 
 
Figure 3.6:  Snapshot of the data acquisition during in vivo cardiac SHAPE studies.  
Note, that the ultrasound scanning is done noninvasively (solid green arrow) – in stark 
contrast with an earlier approach (cf., Fig. 2.2).  The dotted green arrows indicate the 
pressure in the LV as viewed on the oscilloscope and simultaneously being captured on a 
lab computer via LabVIEW.  
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Data Processing:  The subharmonic data were extracted as the mean signal in a 0.2 MHz 
bandwidth around the theoretical subharmonic frequency of 1.25 MHz (Fig. 3.7). 
 
 
 
Figure 3.7:  Sample data acquired from a PW Doppler gate.  Data acquired from a single 
pulse (A) using the PW Doppler gate and the corresponding frequency domain 
representation (B).  The shaded region in (B) indicates the bandwidth used for 
subharmonic amplitude extraction. 
 
 
The resulting subharmonic signals were median filtered.  This process was performed for 
all the runs acquired at every IAO level. 
 
Statistical Analyses:  The IAO levels eliciting most LV pressure sensitive subharmonic 
emissions were identified in each canine after performing one way ANOVA and post-hoc 
comparisons using Bonferroni corrections (148).  In order to evaluate the feasibility of 
SHAPE, a linear regression analyses was performed using the pressure catheter values 
and the subharmonic data acquired at the most sensitive IAO level.  
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3.2.2.3  Developing a Technique to Obtain Clinically Relevant Left Ventricle (LV) 
Pressures using SHAPE 
This study with 4 canines was undertaken because in the previous study (Section 
3.2.2.2), the LV pressure values were used in conjunction with the subharmonic data 
obtained from the LV for regression analyses.  While the results there would elucidate the 
relationship between the subharmonic data and the ambient pressure values, the approach 
is not suitable to obtain unknown in vivo pressures.  Thus an approach needed to be 
developed for utilizing the subharmonic data from the LV to indicate LV pressures 
without using the LV pressure values obtained using the pressure catheter.  Thus, in 
contrast to the previous study (Section 3.2.2.2), in this section the study was geared 
towards obtaining the “blind” LV pressures from the subharmonic data and then 
comparing the values to the reference LV pressures obtained with the pressure catheter. 
 
Data Acquisition:  The data acquisition involved two steps.  First, the ultrasound guided 
pressure catheter was introduced into the aorta.  The PW gate for RF data acquisition 
(accumulated or post pulse inversion) was placed in the aorta.  After confirmation of the 
pressure catheter in the aorta based on grayscale ultrasound images, Sonazoid infusion 
was initiated.  Once the presence of Sonazoid microbubbles in the aorta was confirmed 
data were acquired.  The IAO levels on the Sonix RP scanner were varied from -8 dB to 0 
dB, and the synchronous RF data and pressure catheter data were acquired; in triplicate at 
each IAO level. 
For the second part, the Sonazoid infusion was stopped.  The pressure catheter 
was advanced into the LV.  The confirmation of the pressure catheter in the LV was 
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obtained from grayscale ultrasound images and by studying the shape of the pressure 
profile measured.  The PW gate for RF data acquisition (accumulated or post pulse 
inversion) was placed in the LV.  Sonazoid infusion was resumed and the presence of 
Sonazoid microbubbles in the LV was again confirmed with ultrasound.  Then, the IAO 
levels on the Sonix RP scanner were varied from -8 dB to 0 dB, and the synchronous RF 
data and pressure catheter data were acquired; in triplicate at each IAO level. 
 
Data Processing:  The following steps were repeated for data acquired from the aorta and 
the LV.  The RF data for each accumulated pulse were transformed to the Fourier 
domain, and the subharmonic signal amplitude in dB was extracted as the average signal 
in a bandwidth ranging from 1 to 1.5 MHz (40 %).  These data were processed using a 
median filter to eliminate noise spikes.  The range of the subharmonic signal (i.e., 
maximum minus minimum subharmonic amplitude) was compared from each pulse 
contour (after eliminating noisy pulses) for each IAO level.  The IAO level with 
maximum stable subharmonic signal range (at each location – aorta and LV) was selected 
for pressure estimation in each canine.  Note, that a stable range was required because at 
higher IAO levels, the subharmonic range may be maximum due to the collapse of the 
microbubbles (saturation stage) but may not be stable; growth stage subharmonic 
emissions were shown to be ambient pressure sensitive (3). 
Based on the subharmonic data and the pressure catheter data from the aorta, a 
calibration factor was calculated in (mmHg/dB) by dividing the systemic pulse pressure 
values and the selected subharmonic range.  This calibration factor with the peak 
systemic pulse pressures, was applied to the subharmonic data from the LV to obtain LV 
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pressure contours.  From the resulting LV pressure contours the MLVDP, LVDmin, 
LVEDP and LVPSP were obtained and compared with the pressure catheter values. 
In two canines (canines 1 and 2), the data were acquired from the aorta and the 
LV, while in two other canines (canines 3 and 4) the data were only acquired from the 
LV.  This experimental design was used to evaluate a sub-hypothesis that a single 
calibration factor could be used across all canines or clinical cases – if this hypothesis is 
true, then, in future, only the data from the LV would be required.  Also, such an 
approach would simulate a real clinical scenario, wherein a patient whose LV pressures 
were to be determined, is not a part of the patient-group that led to the formation of the 
calibration factor (statistically equivalent to a cross-validation study which involves using 
a data set (canines 3 and 4) independent of the data set (canines 1 and 2) used to obtain 
the model (i.e., calibration factor in this case).  Thus, in 2 canines (canines 1 and 2) the 
LV pressure estimates were obtained using the calibration factors from the respective 
aorta data.  In 2 other canines (canines 3 and 4) the LV pressure estimates were obtained 
with the mean calibration factor from canines 1 and 2. 
 
Statistical Analyses:  To determine the most sensitive IAO level for pressure estimation, 
the range of subharmonic amplitudes were compared using a one-way analysis of 
variance (ANOVA) with Bonferroni corrections for multiple comparisons (148).  For 
each LV pressure estimate, two-tailed paired t-tests were conducted to evaluate if there 
were statistically significant differences between the estimates obtained using the 
subharmonic data and the pressure catheter.  P-values less than 0.05 were considered 
significant.  
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3.2.2.4  Developing a Technique to Obtain Clinically Relevant Right Ventricle (RV) 
Pressures using SHAPE 
This study with 5 canines was undertaken to develop an approach for utilizing the 
subharmonic data acquired from the RV to indicate RV pressures i.e., the motivation was 
similar to the study in Section 3.2.2.3, except that the focus of measuring pressures was in 
the RV. 
 
Data Acquisition:  The data acquisition involved three steps.  First, the ultrasound guided 
pressure catheter was introduced into the aorta.  The PW gate for RF data acquisition 
(accumulated or post pulse inversion) was placed in the aorta.  After confirmation of the 
pressure catheter in the aorta based on grayscale ultrasound images, Sonazoid infusion 
was initiated.  Once the presence of Sonazoid microbubbles in the aorta was confirmed 
based on grayscale ultrasound images, the data were acquired.  The IAO levels on the 
Sonix RP scanner were varied from -8 dB to 0 dB, and the synchronous RF data and 
pressure catheter data were acquired; in triplicate at each IAO level. 
For the second part, the Sonazoid infusion was stopped.  The pressure catheter 
was removed and re-inserted through the jugular/brachiocephalic vein and advanced into 
the RV.  The confirmation of the pressure catheter in the RV was obtained from grayscale 
ultrasound images.  The PW gate for RF data acquisition (accumulated or post pulse 
inversion) was placed in the RV.  Sonazoid infusion was resumed and the presence of 
Sonazoid microbubbles in the RV was again confirmed on ultrasound.  Then, the IAO 
levels on the Sonix RP scanner were varied from -8 dB to 0 dB, and the synchronous RF 
data and pressure catheter data were acquired; in triplicate at each IAO level. 
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In the third part, the Sonazoid infusion was stopped and the pressure catheter was 
advanced in the RA.  The RA pressures were recorded after confirming the presence of 
the pressure catheter in the RA on ultrasound images and by studying the shape of the 
pressure profile measured. 
 
Data Processing:  The RF data for each accumulated pulse (Figs. 3.8A and 3.8B) were 
transformed to the Fourier domain (Figs. 3.8C and 3.8D) and the subharmonic signal 
amplitude (in dB) was extracted as the average signal in a bandwidth ranging from 1 to 
1.5 MHz (40 %).  The process was repeated for all the pulses for each acquisition.  The 
extracted data were noise filtered in a similar way as compared to the LV data, for data 
acquired from the aorta and the RV in these canines, and the IAO levels eliciting 
maximum growth stage stable subharmonic emissions were selected for pressure 
estimation (from each site i.e., aorta and RV) for each canine. 
Based on the subharmonic data and the pressure catheter data from the aorta, a 
calibration factor was again calculated in (mmHg/dB) by dividing the systemic pulse 
pressure values and the selected subharmonic range.  This calibration factor and the RA 
pressure values were used with the subharmonic data from the RV to obtain RV pressure 
contours.  This process was repeated for data from each canine. 
From the RV pressure contours obtained using the subharmonic data, the RVDmin, 
RVSP and RV peak –dp/dt values were determined.  These estimates were also obtained 
from the pressure catheter data and comparisons were performed. 
 
75 
 
Statistical Analyses:  To determine the most sensitive IAO level for pressure estimation, 
the range of subharmonic amplitude were compared using a one-way analysis of variance 
(ANOVA) with Bonferroni corrections for multiple comparisons (147).  For each RV 
pressure estimate, two-tailed paired t-tests were conducted to evaluate if there were 
statistically significant differences between the estimates obtained using the subharmonic 
data and the pressure catheter.  P-values less than 0.05 were considered significant. 
 
 
 
Figure 3.8:  Ultrasound RF data acquired from the PW Doppler gate from the RV.  The 
pulses correspond to time points of minimum diastolic (A) and peak systolic (B) RV 
pressure phases.  The Fourier domain representation of the pulses in (A) and (B) are 
shown in (C) and (D) with the bandwidth selected for extracting the subharmonic 
amplitude shaded in gray.  Note, that the subharmonic signal amplitude decreases from 
about 56 dB (C) to about 51 dB (D) as the pressure increases during systole, consistent 
with an inverse relationship between subharmonic signals and ambient pressure values (3, 
23, 135, 138, 144).  During this systolic pressure rise there is no change in the 
fundamental amplitude.  
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Overall experimental approach summarizing in vivo cardiac SHAPE studies is 
shown in Fig. 3.9.  The list of canines used for cardiac SHAPE studies is given in 
Appendix 5. 
 
 
 
Figure 3.9:  Summary of experimental approach for in vivo cardiac SHAPE studies 
 
 
A summary of data acquisition parameters for the cardiac SHAPE studies is 
provided in Table 3.4 
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Table 3.4:  Data acquisition parameters for cardiac SHAPE studies 
 
Scanner; Probe: Sonix RP; PA4-2 
Scanning mode: Pulse inversion imaging; 2 transmit cycles 
ftransmit; freceive: 2.5 MHz; 1.25 MHz 
Contrast agent; Administration: Sonazoid; Continuous infusion (0.15 μl/kg/min) 
with 0.9% NaCl (saline) via forelimb vein 
Synchronous pressure monitoring: 5F solid state catheter tip manometer  
IAO: -8 dB to 0 dB (0 dB maximum output; 76 kPa to 
897.04 kPapk-pk; mechanical index < 0.38) 
Pulse repetition frequency: 4 kHz to 6.7 kHz 
Scanning depth: 2 cm to 7 cm 
Scanned anatomy: Aorta, LV, RV and right atrium (11 canines total) 
Gate size (PW Doppler): 2 mm 
Acquisitions: 5 second runs (n = 3 per IAO level) 
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3.2.3  In Vivo Portal Hypertension (PH) SHAPE Studies 
The study was approved by the Institutional Animal Care and Use Committee of 
Thomas Jefferson University and conducted in accordance with the recommendations of 
the Panel on Euthanasia of the American Veterinary Medical Association.  The PH 
SHAPE studies were divided into two separate studies: in 17 canines the efficacy of 
SHAPE to track PV pressures under both, low- and high- flow conditions was 
investigated (also the efficacy of the SHAPE processing technique was tested); then 
before conducting PH SHAPE studies in 5 other canines, an automated IAO optimization 
algorithm was implemented on Logiq 9 scanner and the efficacy of the algorithm was 
tested in 5 canines (with PH). 
 
3.2.3.1  IAO Measurements for Logiq 9 Scanner with the 4C Array 
The subharmonic emissions from the UCAs may be in the occurrence stage, the 
growth stage, or the saturation stage (3) – this depends on the IAO; about 100-200 kPa 
for the occurrence stage, 300-600 kPa for the growth stage and higher IAO levels for the 
saturation (or bubble destruction) stage.  The growth phase subharmonic emissions are 
sensitive to ambient pressures (3).  Thus, it is necessary to select the IAO levels that elicit 
growth phase subharmonic emissions.  Consequently, it is important to have an estimate 
of the IAO levels given the need for growth phase subharmonic emissions to measure 
ambient pressures.  For the Logiq 9 scanner, the acoustic output is encoded as 28 discreet 
percent levels ranging from 0 % to 100 % (maximum).  The IAO levels corresponding to 
these encoded percent levels were measured using a standard water bath approach. 
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The IAO at the focus of the transducer were measured using calibrated 0.2 mm 
needle hydrophone (Precision Acoustics, Dorchester, Dorset, UK; sensitivity of 57.1 
mV/MPa at 2.5 MHz).  The focal point was determined by finding the point of maximum 
acoustic pressure using a semi-automated electronic x-y-z- positioning system.  The 
measurements at each encoded percent level were performed in triplicate. 
 
3.2.3.3  Selection of PH Models 
These in vivo PH studies involved inducing PH in canines; thus a review of PH 
models published in the literature was conducted. 
Model Selection:  Various PH models for mice, rats, pigs, rabbits and canines have been 
described (75, 152-160).  The guidelines for selection of a particular animal PH model (or 
for other hepatic abnormalities) have also been published (161).  Note, that canines more 
closely approximate human physiology – at least for PH studies (156) and thus, allow 
transducers and settings for human studies to be investigated.  Based on the animal 
models and clinical studies, it is known that pathophysiologically an increase in 
intrahepatic vascular resistance ultimately leads to PH (73, 74), while etiologically the 
origin of PH may be pre-, intra- or post- sinusoidal (43).  Overall, a modified form of 
Ohm‟s law for fluid flow (equation 2.1) explains increases in PV pressures (75), either by 
an increase in PV flow or an increase in resistance to PV flow or a combination of these 
two.  Thus, two acute PH models were considered, one based on an increase in resistance 
to PV flow representing a low-flow model of PH and another one with an increase in PV 
flow representing a high-flow volume PH model. 
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For the acute low-flow model of PH, increasing intra-sinusoidal resistance in the 
liver parenchyma by using Gelfoam (Ethicon, Somerville, NJ) injections via the PV was 
considered.  Gelfoam has been used in canines before (162) and has shown no foreign 
body reactions or inflammatory developments (163).  Here the hypotheses were that PV 
pressures would increase and the pulsatility of PV flow would decrease (due to low-flow) 
after Gelfoam administration.  For the acute high-flow PH model, the use of an arterial-
venous (A-V) shunt by connecting the splenic or femoral artery to the PV was 
considered.  In this case, the hypotheses were that PV pressures would increase and the 
pulsatility of PV flow would also increase (due to the superimposition of arterial flow) 
after initiating the high-flow conditions in the PV. 
 
3.2.3.3  Animal Preparation 
For both PH studies, the animal preparation part of the study was similar and thus, 
has been summarized together. 
The canines were fasted for a period of 24 hours prior to the experiments, to 
reduce post-prandial effects on PV pressures (164).  Initially, an intravenous injection of 
Propofol (Abbott Laboratories, Chicago, IL; dose of 7 ml/kg) was used as the anesthetic.  
The canines were placed in supine position on the operating table.  During the course of 
the experiments, the animals were intubated and anesthesia maintained with 0.5 to 2 % 
Isoflurane (Iso-thesia; Abbott Laboratories, Chicago, IL) via an endotracheal tube.  Also 
a warming blanket was used to maintain normal body temperature.  An 18-gauge catheter 
was placed in the cephalic vein for infusion of Sonazoid microbubbles (GE Healthcare, 
Oslo, Norway) at a concentration of 0.015 μl/kg/min. 
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For obtaining data from the IVC, a calibrated 5F pressure catheter (SPR 350S or 
SPR 350, Millar Instruments, Inc., Houston, TX) was introduced in the canines‟ IVC 
through the femoral vein.  The catheter was advanced from the femoral vein to the IVC 
under ultrasound guidance.  The presence and localization of the pressure catheter in the 
IVC was confirmed using color Doppler ultrasound (Fig. 3.10). 
 
 
 
Figure 3.10:  A color Doppler image depicting flow (blue) in the IVC.  Solid arrows 
indicate the pressure catheter in the IVC whereas the dotted arrow indicates the diameter 
of the IVC. 
 
 
For obtaining data from the PV, a midline abdominal incision was created to 
provide access to the main PV or one of its branches using a sterile technique (Fig. 
3.11A).  A PV branch 15 cm distal to the main PV was identified and a calibrated 5 
French pressure catheter (SPR 350S or SPR 350) was introduced into the PV branch (Fig. 
3.11A), and then advanced into the main PV trunk under ultrasound guidance (Fig. 
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3.11B).  The pressure catheter was fixed with a 2-0 silk suture at the entry point of the PV 
branch (Fig. 3.11A) to maintain the catheter position during baseline and PH data 
acquisition.  The pressure values were observed on the oscilloscope. 
At the end of the experiments the canines were sacrificed by an intravenous 
injection of Beuthanasia (0.25 mg/kg). 
 
 
 
Figure 3.11:  Animal preparation for PH studies.  (A) Surgical intervention to introduce 
pressure catheter (green arrows) into the main PV; the blue arrow indicates the direction 
towards the liver.  (B) Grayscale ultrasound image while scanning PV of the canine; the 
solid arrow points to the pressure catheter while the dotted arrow indicates the diameter 
of the PV.  
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3.2.3.4  Implementation of PH Models 
A 5 French catheter was inserted into another branch of PV to access the main PV 
for Gelfoam injection or A-V shunt connection when needed.  The patency of the PV was 
confirmed by ultrasound imaging after these surgical procedures. 
 
Gelfoam Model or Low-Flow Model:  The acute low-flow model of PH was induced by 
embolization of the liver circulation using Gelfoam (Ethicon, Somerville, NJ) injection.  
The sterile sheet(s) of Gelfoam (100 cm
2
) was (were) cut into small pieces 
(approximately less than 5 mm in each dimension) and immersed into sterile saline 
solution.  The resulting mixed solution was introduced into the PV through the 5 French 
catheter. 
 
A-V Shunt Model or High-Flow Model:  The acute high-flow PH model was surgically 
induced by connecting the femoral artery to the PV using a 3-way stopcock with 
extension tube thereby creating an A-V shunt (Fig. 3.12).  A high pressure saline infusion 
generated by an inflatable pressure cuff was used to supplement the flow volume when 
needed. 
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Figure 3.12:  Implementation of the A-V shunt model.  The numbers indicate the ports of 
the 3-way stopcock with the arrows indicating the direction of flow used in this 
experimental setup.  Port 1 serves as the outlet through which blood (and extra saline, if 
required) is diverted to the PV, port 2 serves as the inlet for blood through the femoral 
vein whereas port 3 is used for high pressure saline infusion, if required. 
 
 
Model Endpoints:  For both PH models, the PV pressures were continuously monitored 
with the pressure catheter and the patency of the main PV was re-verified with 
ultrasound.  The normal PV pressures in canines vary from 7 to 11 mmHg, whereas the 
mean IVC pressures vary from 5.6 to 6.6 mmHg (152, 156, 158-160, 165).  Thus, the PH 
endpoint for this study was defined as a stabilized elevation (tracked for > 2 minutes) in 
PV pressures of 5 mmHg above the baseline value.  The IVC pressures obtained from the 
canines were used for cross-verification of induced PH because PH is also present if the 
gradient between IVC and PV pressures exceeds 5 mmHg (15). 
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Model Validation:  Baseline pressures were monitored for 15 to 45 minutes and pressure 
signals were recorded on the computer for 27 – 36 acquisitions with each acquisition 
containing 5 s of data.  The PV diameters were obtained from the ultrasound images.  
Then PH was induced in canines, using either the Gelfoam model or the A-V shunt 
model.  Pressures after inducing PH were again measured for 15 to 45 minutes and PV 
pressure and diameter data were acquired as before.  The IVC and PV pressure data were 
analyzed using Matlab.  The mean pressure signals from each acquisition were averaged 
to obtain IVC and PV pressures for the canines.  The pulsatility index was calculated as 
the ratio of the difference between maximum and minimum pressures to the mean 
pressure value for each canine (similar to its initial use for characterizing velocities (166); 
but here this index was modified to characterize pressures). 
 
Statistical Analyses:  The pressures, pulsatility index and diameter of the PV before and 
after inducing PH were compared using two-tailed paired t-tests.  P-values below 0.05 
were considered significant. 
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3.2.3.5  Efficacy of SHAPE to Investigate PH (PH Study 1) 
The motivation for this study was to evaluate the efficacy of SHAPE to track PV 
pressures under both, low- and high- flow conditions.  Another goal was to investigate 
the efficacy of the SHAPE processing technique and to determine the effect of number of 
transmit cycles on the performance of SHAPE. 
Fourteen canines were used in this study, the animal preparation for the 
experiments and the PH models were already explained (sections 3.2.3.3 and 3.2.3.4).  
The Gelfoam model was used to induce PH in 8 canines and in the remaining 6 canines 
A-V shunt model was used to induce PH. 
 
Data Acquisition:  The experimental setup for data acquisition is illustrated in Fig. 3.13. 
 
 
 
Figure 3.13:  Experimental setup for PH study 1  
87 
 
A Logiq 9 scanner with a curvi-linear array 4C probe was modified to operate 
either in the standard imaging mode or in pulse inversion subharmonic imaging mode 
(ftransmit = 2.5 MHz, freceive = 1.25 MHz).  The 4C transducer was positioned directly over 
the PV and placed in the abdominal cavity with a support stand as illustrated in Fig. 3.14 
to provide a constant scanning plane during the experiment.  A sonographer and a 
physician confirmed the presence of the pressure catheter in the PV and the patency of 
the PV using standard grayscale and/or color Doppler imaging (Fig. 3.15).  The pressures 
signals from the pressure catheter were recorded on an oscilloscope and digitized and 
captured on the computer using LabVIEW.  A synchronization signal between the Logiq 
9 scanner and the oscilloscope enabled simultaneous acquisition of the pressure catheter 
data and the RF data on the Logiq 9 scanner (Fig. 3.13).  Note, the sonographer and the 
physician monitored the ultrasound scanning plane and data acquisition with the clamped 
probe throughout the experiment. 
Using the ultrasound image as a guide, a region of interest (ROI) including the PV 
near the site of the pressure catheter was selected (Fig. 3.16A).  The Logiq 9 scanner was 
then switched to RF data acquisition mode to acquire beamformed unfiltered RF data 
from the ROI (Fig. 3.16B). 
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Figure 3.14:  Snapshot showing the setup to acquire the data.  The green solid arrow 
indicates the 4C transducer; note, the sterile cover over the 4C transducer used to 
maintain the sterile environment during data acquisition.  The green dotted arrow 
indicates the clamp to hold the transducer.  The red arrows show the pressure catheter 
whose tip is present in the PV. 
 
 
 
Figure 3.15:  Images confirming the presence of the pressure catheter in the PV and 
showing the surgical inlet for inducing PH.  (A) The surgical inlet for introducing PH is 
shown as dotted red ring and the pressure catheter is shown as solid red ring.  (B). A 
color Doppler image showing flow in the PV and in the IVC, with the pressure catheter in 
the PV (solid red ring). 
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Figure 3.16:  RF data acquisition mode on Logiq 9 scanner.  (A) Conventional color 
Doppler image to identify the region including the PV (yellow outlined area).  (B) Logiq 
9 scanner operated in RF data acquisition mode.  Note, that the data corresponding to the 
yellow outlined area in (A) is shown in (B).  Only the RF data only corresponding to the 
depth outlined in (A) is acquired. 
 
 
The performance of the SHAPE technique is dependent on the growth-stage 
subharmonic emissions, which in turn are dependent on the IAOs.  The range of peak 
negative IAOs spanned 0 to 0.58 MPa as the IAO output on the scanner was stepped from 
0 to 100 % (section 3.2.3.1).  Based on this data and previous in vitro and in vivo studies 
showing “optimum” performance of SHAPE with Sonazoid to be in the range of 0.2 to 
0.6 MPa (3, 144, 167), three IAO levels corresponding to 10 % (0.14 MPa; peak 
negative), 20 % (0.23 MPa; peak negative) and 40 % (0.36 MPa; peak negative) were 
selected.  Minimal attenuation was expected in vivo due to intra-abdominal scanning.  
Higher IAOs (> 40 %) were avoided to prevent the destruction of microbubbles.  The 
confirmation that destruction of microbubbles did not occur below 40 % IAO was 
obtained using an in vitro flow phantom setup similar to the experimental setup used in 
previous studies (167).  Lower IAOs (< 10 %) that elicit relatively low energy in the 
scattered beam profile at the subharmonic frequency were not used.  Additionally, 
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because the performance of SHAPE will vary with the number of transmit cycles used, 2, 
3 and 4 transmit cycle pulses were considered, each at 10 %, 20 % and 40 % IAO levels. 
Under baseline conditions (i.e., with normal PV pressures) after Sonazoid infusion and 
visual confirmation of Sonazoid microbubbles in the PV, the RF data and the pressure 
catheter data were acquired synchronously with each combination of transmit cycles and 
IAO levels cumulating in 27 acquisitions (three acquisitions for every combination).  
Since the visibility of the ROI was compromised in the RF data acquisition mode (Fig. 
3.16B), after every 3 acquisitions visual verification of the scanning plane and ROI were 
performed by the sonographer and the physician after switching the unit into imaging 
mode (Fig. 3.16A) and the ROI was relocated if required.  After baseline conditions, the 
Sonazoid infusion was stopped and PH states were established using either Gelfoam or 
A-V shunt for the respective group of canines.  Data acquisition in the PH states were 
again performed after initiating Sonazoid infusion for all transmit cycles and IAOs as 
described above.  Note, that again 27 acquisitions were made (three acquisitions for each 
combination).  The data were transferred to a computer for offline analyses in Matlab. 
 
Data Processing:  The data from each acquisition were saved as a DICOM (Digital 
Imaging and Communications in Medicine) file and the RF data extracted using a 
proprietary software „GE Raw RF data extraction facility‟ (GE Global Research, 
Niskayuna NY).  This RF data were DC filtered and then a filter centered at 1.25 MHz 
with 0.25 MHz bandwidth was applied to extract the subharmonic data (these filter 
parameters were selected based on previous in vitro results (167)).  The subharmonic data 
were log-compressed to generate maximum intensity image (MIP) (Fig. 3.17).  
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Figure 3.17:  MIP subharmonic image.  Here the vectors span a region of about 2.5 cm in 
the lateral dimension as observed with the curvi-linear 4C probe. 
 
 
An ROIPV (to distinguish it from the ROI used to acquire the complete RF data) 
was used to select the region within the PV.  The PV exhibited maximum subharmonic 
signal intensity from the presence of Sonazoid microbubbles, whereas there was 
suppression of tissue signals (because of no subharmonic generation in tissue) and 
cancellation of other linear signals in the field of view that result from the use of pulse 
inversion technique (as depicted in Fig. 3.17).  These ROIPV selections were made in 
consultation with the sonographer present during data acquisition stage.  Based on the 
selected ROIPV, the subharmonic signals were extracted as the mean subharmonic 
amplitude value obtained from the data corresponding to the MIP image (SHMIP) as well 
as the mean subharmonic signal obtained from the ROIPV data from all frames 
(SHAll_Frames).  The data corresponding to the MIP images was included in the analyses, 
because the MIP images are useful in providing a snapshot of vasculature and thus, 
whether the data corresponding to the MIP images alone, could be directly used for 
pressure estimation (or not), would also be verified. 
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Statistical Analyses:  The subharmonic signal amplitudes were used to determine if there 
was a statistically significant difference between the number of transmit cycles and the 
subharmonic signal amplitude using a factorial repeated measures ANOVA.  Post-hoc 
comparisons were performed after correcting for multiple comparisons based on the 
Bonferroni method (148).  Linear correlation analyses were performed to identify the 
relationship between change in the mean PV pressures and change in the subharmonic 
signal amplitude, and between absolute mean PV pressures and absolute subharmonic 
signal amplitudes.  The correlation coefficients were compared based on calculated t-
statistics (168).  Paired t-tests were used to analyze the difference between baseline and 
PH conditions for subharmonic signal amplitudes. 
A cross-validation study was also performed to estimate the errors obtained with 
the SHAPE technique.  For the cross-validation study, data from one canine under 
baseline and PH was eliminated and, a linear model between subharmonic amplitude and 
the PV pressures was obtained using data from the remaining canines.  Then, based on 
this linear model the PV pressures at baseline and at PH condition were calculated for the 
canine not included in the linear model and compared to the pressure catheter data.  Also 
based on the pressures obtained with this cross-validation approach, the sensitivity, 
specificity and the accuracy of identifying PH in these canines was calculated choosing a 
threshold value of 16 mmHg, because this represents the clinical scenario of HVPG 
values corresponding to moderate through severe PH cases.  For canines, this value of 16 
mmHg was selected based on data presented in the literature (152, 156, 158-160, 165, 
169). 
P-values below 0.05 were considered significant.  
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A summary of data acquisition parameters for the PH study (study 1) is provided 
in Table 3.5. 
 
 
Table 3.5:  Data acquisition parameters for PH study (study 1) 
Scanner; Probe: Logiq 9; 4C 
Scanning mode: Standard / Pulse inversion subharmonic 
ftransmit; freceive: 2.5 MHz; 1.25 MHz 
Contrast agent; Administration: Sonazoid; 0.015 μl/kg/min with saline via forelimb 
vein catheter (18 Gauge) 
Synchronous pressure monitoring: 5F solid state catheter tip manometer  
IAO:  10 % (0.13 to 0.15 MPapk -ve) 
20 % (0.21 to 0.24 MPapk -ve) 
40 % (0.35 to 0.37 MPapk –ve; mechanical index < 
0.24) 
Induced PH: 8 canines: Increased resistance: Gelfoam 
6 canines: Increased flow: Arterial-Venous (A-V) 
shunt (femoral artery to PV) 
Transmit cycles:  2, 3 and 4 
Acquisitions: 5 second runs (n = 3 per combination of IAO levels 
and transmit cycles) 
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3.2.3.6  Validation of Automated IAO Optimization Algorithm (Implemented on Logiq 
9 Scanner; PH Study 2) 
A major limitation in the above studies (cardiac and PH study 1) impeding real-
time clinical applications is the lack of knowledge about the in situ IAO levels 
experienced by the Sonazoid microbubbles in vivo.  The IAO levels may be known at the 
transducer focal point based on in vitro measurements using a hydrophone, but these IAO 
levels will differ in vivo based on the scanned anatomy and patient body habitus.  The 
IAO levels determine the stage of the subharmonic signals and in the growth stage these 
are sensitive to ambient pressures.  Hence, a failure to elicit subharmonic emissions in the 
growth phase may result in erroneous pressure tracking when using SHAPE. 
Therefore, the goal of this study was to develop, implement and validate an 
algorithm to automatically determine the optimum IAO for SHAPE applications in a 
given patient.  A secondary goal of this study was to also compare SHAPE‟s performance 
with 8 and 16 transmit cycles (note that 2, 3 and 4 transmit cycles were compared in the 
previous sections).  If successful, this approach may help eliminate the problems of 
acquiring and analyzing the data at all IAO levels as discussed in the previous sections 
and, thus, pave the way for real-time clinical applications. 
Five canines were used in this study, the animal preparation for the experiments 
and the PH models utilized were already explained (sections 3.2.3.3 and 3.2.3.4).  The 
Gelfoam model was used to induce PH in these 5 canines. 
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Equipment Setup:  The experimental setup is shown in Fig. 3.18.  A Logiq 9 scanner (GE 
Healthcare, Milwaukee, WI) with a curvi-linear array 4C probe was modified to operate 
in a dual imaging mode i.e., grayscale and pulse inversion subharmonic imaging modes 
(130).  The transmit and receive frequencies were 2.5 MHz and 1.25 MHz, respectively.  
The RF data were acquired with all the available configurations of the transmit cycles.  
All scanning were performed by a sonographer and/or by a radiologist, and data were 
collected after Sonazoid infusion and visual verification of Sonazoid microbubbles in the 
PV.  A crossover cable was connected for real-time data transfer between the Logiq 9 
scanner and a lab computer running Matlab. 
 
 
 
Figure 3.18:  Experimental setup for PH study 2.  Note the difference between this 
experimental setup and the setup used for PH study 1 (Fig. 3.13) – an additional lab 
computer is used to interface with the Logiq 9 scanner to enable real time transfer with 
the Logiq 9 scanner.  The automated IAO optimization algorithm was implemented on 
this lab computer. and it controlled the IAO levels of the Logiq 9 and processed the data 
captured on Logiq 9 simultaneously.  Note, that this algorithm may be ported on the 
Logiq 9 itself.  However to avoid loading the Logiq 9‟s capability during scanning 
(especially with the physical available memory size) and to test the capability of the 
algorithm (first), this configuration was used.  
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Automatic IAO Optimization:  In order to determine the optimum IAO for SHAPE a ROI 
was placed inside the PV as shown in Fig. 3.19.  Note that the left side of Fig. 3.19 
depicts the grayscale imaging mode, whereas the right side is configured to show 
subharmonic data (at 1.25 MHz with 1 MHz bandwidth) in the selected ROI.  The 
automatic IAO control program was initiated based on the flowchart presented in Fig. 
3.20.  First, the scanner was set to 0 % (0 MPa) IAO level (Fig. 3.19: green arrow) and 
the corresponding data from the subharmonic ROI over 3 frames were collected.  A 50 % 
threshold mask was applied to the subharmonic data to remove portions of the ROI with 
relatively low subharmonic signal (i.e., low microbubbles concentration e.g., in the 
surrounding tissue in Fig. 3.19) and the mean subharmonic amplitude was stored on the 
PC.  This process was repeated for 28 discrete IAO levels up to 100 % IAO 
corresponding to 3.34 MPa (based on section 3.2.3.1).  The resulting subharmonic data 
were plotted as a function of IAO on the PC.  A polynomial fitting function was applied 
to this data set and the slope at each IAO level was calculated using the point-slope 
equation.  The point with the maximum slope was determined and selected as the 
optimum IAO for SHAPE.  The scanner was then configured to acquire SHAPE data at 
that IAO level. 
  
97 
 
 
Figure 3.19:  The dual grayscale (left) and pulse inversion subharmonic (right: in the 
ROI) imaging modes.  The PV and IVC are marked.  Note, that at the start of the IAO 
optimization function, the acoustic output corresponding to the subharmonic mode is set 
to 0 % (green arrow); due to no insonation, noise artifacts are seen in the subharmonic 
ROI. 
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Figure 3.20:  Flowchart of the incident acoustic output (IAO) optimization function. 
 
 
Data Acquisition:  As shown in Fig. 3.18, a synchronization signal from the Logiq 9 
scanner was connected to an oscilloscope set to acquire the PV pressures from the 
pressure catheter and the transducer control unit.  The synchronization signal enabled 
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simultaneous and synchronous RF and catheter data acquisition.  The oscilloscope 
transferred the pressure catheter data to a lab computer through LabVIEW. 
Under baseline conditions i.e., with normal PV pressures, the RF data and the 
pressure catheter data were acquired synchronously with 4, 8 and 16 transmit cycles at 
the optimum IAO level, at an IAO level below the optimum IAO level and then at an 
IAO level above the optimum IAO level (thus, three consecutive IAO levels were used).  
Each acquisition was a 5-second run and acquisitions at each IAO level were repeated in 
triplicate.  The order of data acquisition was randomly varied after acquiring 3 data sets at 
a given configuration.  Then, the Sonazoid infusion was stopped and PH states were 
established (by administering Gelfoam in the PV).  Data were again acquired in the portal 
hypertension states after Sonazoid infusion as mentioned above (in the same order as 
during baseline conditions).  The data were transferred to a computer for offline analyses 
in Matlab. 
 
Data Processing:  Since, the data from each acquisition were saved as a DICOM file, the 
subharmonic data were extracted using a proprietary software „GE Raw RF data 
extraction facility‟ (GE Global Research, Niskayuna NY).  This RF data were DC 
filtered.  The subharmonic data for SHAPE from the ROI shown in Fig. 3.19 were 
extracted using a filter centered at 1.25 MHz with 0.25 MHz bandwidth (167).  The mean 
subharmonic signal amplitude was then calculated from all the frames in the acquired 
DICOM file.  This process was repeated for all acquired data. 
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Statistical Analyses:  The hypothesis was that SHAPE‟s performance would be best at the 
optimum IAO level identified by the automatic IAO optimization program and at 4 
transmit cycles.  The subharmonic signal amplitudes and PV pressures before and after 
inducing PH were compared using paired t-tests.  Linear correlation analyses were 
performed to identify the relationship between change in the PV pressures and change in 
the subharmonic signal amplitude, and between absolute PV pressures and absolute 
subharmonic signal amplitudes.  P-values below 0.05 were considered significant. 
 
A summary of data acquisition parameters for the PH study (study 2) is provided 
in Table 3.6. 
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Table 3.6:  Data acquisition parameters for PH study (study 2) 
Scanner; Probe: Logiq 9; 4C 
Scanning mode: Standard / Pulse inversion subharmonic 
ftransmit; freceive: 2.5 MHz; 1.25 MHz 
Contrast agent; Administration: Sonazoid; 1.5 μl/kg/min via forelimb vein catheter 
(18 Gauge) 
Synchronous pressure monitoring: 5F solid state catheter tip manometer  
A. To determine the most-sensitive IAO for SHAPE 
IAO: Varied from 0 to 100 % i.e., 0 to 3.34 MPa
pk-pk
 
Transmit Cycles:  4, 8 and 16 transmit cycles  
B. To determine the efficacy of IAO optimization technique for SHAPE 
IAO: Most-sensitive IAO and one level above and 
below the most-sensitive IAO 
Transmit Cycles:  4, 8 and 16 transmit cycles  
Induced PH: 5 canines: Increased resistance: Gelfoam 
Acquisitions: 5 second runs (n = 3 per combination of IAO 
levels and transmit cycles) 
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The overall experimental approach, summarizing the in vivo PH SHAPE studies, 
is shown in Fig. 3.21 (analogous to Fig. 3.9 for in vivo cardiac SHAPE studies) 
 
 
 
Figure 3.21:  Summary of experimental approach for in vivo PH SHAPE studies 
 
 
Additionally, Appendix 6 is included to provide very specific details about the 
experimental setup and operating procedures for these SHAPE experiments with Logiq 9 
scanner. 
 
Also, Appendix 7 provides a list of all the canines used for the in vivo PH studies. 
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In this chapter the materials used and methods espoused for dynamic in vitro 
SHAPE studies, in vivo cardiac SHAPE studies and in vivo PH studies were explained.  A 
detailed list of all the statistics used for specific sections is provided as Appendix 8.  The 
next chapter presents the results of the experiments described in this chapter along with 
the discussions in light of relevant published literature.  Conclusions and future 
recommendations are presented in Chapter 5. 
 
A list of key personnel associated with this project for future reference is provided 
in Appendix 9.  A complete list of software used throughout this project is provided in 
Appendix 10.  A list of grants which supported the work towards this thesis is provided in 
Appendix 11. 
  
104 
 
4.  RESULTS AND DISCUSSIONS 
 
This chapter includes the results corresponding to each sub-section in the 
Methods of Chapter 3 along with discussions and summary.  A general discussion is also 
provided towards the end of the chapter.  Specific result-statements that evaluate the 
hypotheses of Specific Aims 1-3 are underlined.  All values are mean ± standard 
deviation unless explicitly stated. 
 
4.1  Dynamic In Vitro Studies 
4.1.1  Acoustic Output Measurements for Sonix RP scanner with the PA4-2 Array 
There were 17 encoded IAO levels on the Sonix RP scanner ranging from -32 dB 
to 0 dB in steps of 2 dB.  IAO levels below –8 dB were too low, even to form a grayscale 
B-mode image of the lumen of the flow phantom used in the experimental setup.  
Consequently only IAO levels ranging from -8 dB to 0 dB were used in the in vitro and in 
vivo studies.  The corresponding range of IAOs was 76 to 897 kPa peak to peak.  In order 
to present the results consistently for different scanners, the IAO levels will be 
represented as percentage values for plotting such that, -8 dB, -6 dB, -4 dB, -2 dB and 0 
dB correspond to 39 %, 50 %, 63 %, 79 % and 100 %, respectively.  This approach is 
also adopted because it was not feasible to know the exact IAO levels (in kPa) at the site 
of microbubbles in vitro and in vivo, due to differences in attenuation offered to the 
ultrasound beam on a case-by-case basis, aggravated by changes in tissue compositions 
and scanning depth. 
  
105 
 
4.1.2  Identifying Most Sensitive IAO Level for Dynamic In Vitro SHAPE 
Fig. 4.1 shows the change in the subharmonic signal amplitude at different IAO as 
the ambient pressure cycled between 0 mmHg and 120 mmHg.  As seen in Fig. 4.1A, the 
change in subharmonic signal amplitude gradually increased as the IAO was varied from 
-39 % to 100 %.  The maximum range was seen for the incident acoustic pressure of 79 
%.  Fig. 4.1B is a boxplot of the changes in the subharmonic signal amplitude for each 
pulse contour in the 3 acquisitions at every IAO level.  Video 1 in Ref. (167) 
demonstrates the change in the range of subharmonic amplitude as the IAO is varied from 
39 % to 100 %.  A between group comparison (for different IAO levels) revealed 
significant differences in the changes observed in the received subharmonic signals (F4,51 
= 558.903; p < 0.001). 
 
 
 
Figure 4.1:  Variation in subharmonic signal amplitude as a function of IAO levels.  (A) 
The change in subharmonic signal amplitude was analyzed as IAO levels were varied 
after 4 seconds (dash-dot line indicates maximum range).  (B) Boxplot of subharmonic 
signal amplitude changes analyzed over several pressure contours as a function of IAO 
levels.  
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The range of the subharmonic signal at 79 % IAO level (8.148 dB) was 
significantly greater (p < 0.001) than the range at 39 % (4.014 dB), 50 % (4.338 dB) and 
100 % (7.376 dB) (Table 4.1).  No significant difference was observed between the range 
of the subharmonic signal at an IAO level of 63 % and 79 % (mean difference 0.327 dB; 
95 % Confidence Interval -0.020 to 0.675 dB; p = 0.08).  This indicates that at IAO levels 
corresponding to 63 % and 79 %, the subharmonic response from the microbubbles was 
in the growth stage (required for pressure tracking).  Since the range of the subharmonic 
signal at 79 % was greater (8.148 dB) than that at 63 % (7.821 dB), 79 % was the IAO 
selected for ambient pressure tracking (Table 4.1). 
 
 
Table 4.1:  Variation in subharmonic signal amplitude as a function of IAO levels.  The 
range of extracted and processed time varying subharmonic signal at different incident 
acoustic output levels as the in vitro ambient pressures cycled between 0 mmHg and 120 
mmHg. 
 
IAO (%)  
Range of subharmonic signals (dB; n>10) 
 Mean Standard Deviation 95% Confidence Interval 
   Lower Bound Upper Bound 
39 4.0 0.1 3.9 4.1 
50 4.3 0.4 4.1 4.6 
63 7.8 0.3 7.6 8.0 
79 8.1 0.2 8.0 8.3 
100 7.4 0.3 7.2 7.6 
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4.1.3  Ability of SHAPE to Estimate Ambient Pressures 
Fig. 4.2A shows different components in the spectrum after the microbubbles 
were insonated with an IAO setting of 79 % (using the PA4-2).  The fundamental and the 
second harmonic component show maximum deviations of 1.6 and 1.9 dB, respectively, 
whereas the subharmonic component shows a full-scale deflection of 8.5 dB.  Based on 
this observation, it can be concluded that subharmonic response from the microbubbles 
alone may be used to track ambient pressures.  Fig. 4.2B depicts the subharmonic signal 
amplitude variation with ambient pressure, while Fig. 4.2C demonstrates that the 
subharmonic response from the microbubbles may be calibrated to yield ambient pressure 
values as discussed below.  Fig. 4.2B shows that the subharmonic signal varies inversely 
(or exhibits an out-of-phase relationship) with the ambient pressure as documented 
previously in the literature (3, 23, 135, 136).  As shown in Fig. 4.2C, the subharmonic 
signal amplitude significantly predicted ambient pressure values using regression 
analysis, with standardized coefficient  = -0.960, t (13330) = -398.206, p < 0.001.  The 
standardized coefficient reported here indicates the change in the number of standard 
deviations that will occur in the reported pressure values as a result of one standard 
deviation change in the subharmonic amplitude (168).  A significant t-value indicates that 
the subharmonic amplitude is significantly contributing to the linear model in predicting 
the ambient pressure values.  Moreover, the unstandardized coefficient representing the 
gradient of the regression line was -10.881 mmHg/dB (95% Confidence Interval: -10.935 
mmHg/dB to -10.828 mmHg/dB).  The subharmonic signal amplitude also explained a 
significant proportion of variance in the ambient pressure signal, r
2
 = 0.922, F (1, 13330) 
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= 1.58e5, p < 0.001, indicating that 92 % of the change in the subharmonic amplitude 
was due to the ambient pressure variation. 
In Fig. 4.2D a time trace of 20 seconds obtained from SHAPE using the 
abovementioned regression analysis is shown along with the reference pressure signal 
(standard error of the estimate: 7.890 mmHg).  (Based on these results Hypothesis 1, 
which was to evaluate if standard error between catheter pressures and SHAPE results 
would be below 10 mmHg with an r
2
 > 0.75 for continuous runs of at least 4 seconds, 
was accepted).  Figs. 4.2E and 4.2F illustrate the agreement between DC-suppressed 
normalized power spectrum of the pressure catheter data and the subharmonic signal 
respectively (for the 20 second trace of Fig. 4.2D).  From these spectra it is possible to 
determine different components of the pressure signal such as the heart rate by 
determining the frequency corresponding to the peak spectral amplitude.  As the heart 
rate can be obtained noninvasively, this data can be used for verification of the SHAPE 
estimates before tracking cardiac pressures.  Note, video 2 in Ref. (167) demonstrates 
active SHAPE for 20 seconds (the pressure catheter signal i.e., the reference standard is 
also shown). 
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Figure 4.2:  In vitro SHAPE results.  (A) Time varying subharmonic, fundamental and 
second harmonic components extracted after processing the RF data.  (B) The 
subharmonic component variation with time is plotted with the reference pressure signal 
from the catheter.  (C) Linear regression analyses was performed to determine the 
relationship between the ambient pressure signal and the subharmonic signal amplitude 
and the resulting pressure signal (from SHAPE) was plotted with the pressure catheter 
signal (D). The DC suppressed normalized power spectrum for the pressure catheter data 
(E) and the SHAPE data (F) are also shown.  
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4.1.4  Confirmation of Variation of Subharmonic Signals as a Function of Ambient 
Pressures 
Fig. 4.3 shows the SHAPE results after removing the 8 cm tissue mimicking 
material (tissue mimicking phantom attenuation: 0.5 dB/cm/MHz) and insonating with 
IAO level of 79 %.  With the removal of the attenuation from the beam, the IAO level of 
79 % elicited the subharmonic signals from the microbubbles in the saturation stage in 
which the subharmonic signals are not sensitive to ambient pressures.  This resulted in 
the distorted pressure waveform obtained with the SHAPE technique as seen in Fig. 4.3.  
These results corroborate findings of the previous section that growth stage subharmonic 
emissions are best suited for SHAPE. 
 
 
 
Figure 4.3:  In vitro SHAPE with IAO levels that resulted in likely bubble destruction.  
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4.1.5  Developing “Best” Processing Technique for SHAPE 
4.1.5.1  Comparing Processing Techniques 
Both the median filtering approach and the wavelet based approach eliminated 
noise (noise seen in Fig. 3.2D) from the subharmonic signals delineating the underlying 
subharmonic signals, which are modulated by ambient pressures (Figs. 4.4 and 4.5).  The 
wavelet-stage decompositions in Fig. 4.5 also revealed high frequency noise as was 
expected due to multiple scattering, etc.  Moreover, again the subharmonic amplitude 
variations observed in this study along with the ambient pressure fluctuations confirm the 
inverse relationship between the ambient pressure and the subharmonic amplitude that 
was seen in previous data sets and also documented in the literature (e.g., (3)).  The 
RMSEs obtained from the linear regression analysis of the subharmonic data for 
determining the ambient pressure values using the median and wavelet filters are shown 
in Fig. 4.6 as a function of the extraction techniques and the filter order. 
The repeated measures design involving the median filter revealed a significant 
main effect of the extraction technique F(1,4) = 16.01, p = 0.016, of the filter order F(1,4) 
= 58.17, p = 0.002 and of the interaction effect between the extraction technique and the 
filter order F(1,4) = 58.46, p = 0.002 on the RMSEs obtained after regression analyses.  
On average, the least RMSEs (8.89 ± 0.27 mmHg) were noted for the extraction 
technique that utilized a 0.2 MHz bandwidth about the subharmonic frequency.  This 
suggest that utilizing a bandwidth to extract the subharmonic amplitude accounts for the 
peak shifts that were noted (cf., Fig. 3.3A) and that were not accounted for in the control 
situation i.e., by extracting the amplitude at the exact theoretical subharmonic frequency.  
This best approach (least RMSEs) was similar to the technique in section 4.1.3  
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Figure 4.4:  Processing of the subharmonic data using median filtering.  Processing of 
the extracted average subharmonic signal in a 0.2 MHz bandwidth (center frequency 1.25 
MHz) with a median filter (solid) of order 50 (A), 100 (B), 250 (C), 325 (D) and 500 (E) 
along with the pressure catheter data (dashed). 
  
113 
 
 
Figure 4.5:  Processing of the subharmonic data using wavelet technique.  An 8-stage 
sub-band decomposition of the extracted average subharmonic signal in a 0.2 MHz 
bandwidth (center frequency 1.25 MHz) into the scaling stage (left) and the wavelet stage 
(right).  Note the high frequency noise components being filtered out at each successive 
scaling stage.  The eight scaling stage (at the bottom) represented frequencies in a band of 
0 to 6.51 Hz (spanning a clinical range of 0 to 390 beats per minute) and was used for 
linear least squares regression analysis. 
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Figure 4.6:  Comparing RMSEs obtained with different processing techniques.  
Comparison of the root mean square errors between the pressure catheter data and the 
pressure estimated using SHAPE technique for median-filter processing (A) and wavelet 
based filtering (B) (BW: bandwidth). 
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For the extraction technique utilizing a bandwidth to extract the subharmonic 
amplitude, the RMSEs were the least for the filter order of 500 (8.16 ± 0.26 mmHg) 
which were less than the RMSEs obtained with a filter order of 50 (9.82 ± 0.30 mmHg, p 
= 0.003), of order 100 (9.42 ± 0.30 mmHg, p = 0.013), of order 250 (8.72 ± 0.28 mmHg, 
p = 0.179), and of order 325 (8.38 ± 0.26 mmHg, p = 0.575); albeit the two later were not 
statistically significant.  This suggests that there may exist a threshold order for median 
processing of the subharmonic signals and increasing the order of the filter above this 
level may not necessarily improve the derived pressure estimates.  This filter order will 
be a function of the PRF and may be changed based on the PRF used to acquire the data.  
A maximum PRF will yield optimal temporal resolution; however, the PRF that can be 
used in vivo is primarily limited by the depth of scanning. 
For the wavelet based approach, the repeated measures design indicated no 
significant difference between the RMSEs obtained using the different extraction 
techniques (p = 1) – the overall error produced by the wavelet based approach was 13.08 
± 0.13 mmHg as compared to an error of 8.98 mmHg ± 0.27 mmHg with the median 
filtering approach.  The wavelet based filtering technique reported higher RMSEs 
probably due to the associated down-sampling while stepping through the hierarchical 
filter bank leading to an increasing frequency resolution but decreasing the time 
resolution.  Thus, the pressure contours obtained with the wavelet based approach may be 
limited in applications like estimating wave reflections, determining the cardiac index, 
etc. (65, 66), where temporal resolution requirement is relatively high. 
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4.1.5.2  SHAPE with “Best” Processing Technique 
Based on achieving the smallest RMSE, a median filtering approach with a filter 
order of 500 in conjunction with the extraction technique utilizing a mean signal in a 0.2 
MHz bandwidth about the subharmonic center frequency of 1.25 MHz was selected for 
processing.  The temporally varying subharmonic signals thus obtained significantly 
predicted the ambient pressure values (r
2
 = 0.90; p < 0.001; Fig. 4.7).  The overall 
RMSEs and the mean absolute errors were 8.16 ± 0.26 mmHg and 6.70 ± 0.17 mmHg, 
respectively.  (These results confirm the acceptance of Hypothesis 1). 
 
 
 
Figure 4.7:  Comparing SHAPE results with catheter pressures.  Ambient pressure values 
obtained using the catheter (dashed) and SHAPE (solid) data after least squares linear 
regression analysis of the extracted average subharmonic data in a 0.5 MHz bandwidth 
about 1.25 MHz, median-filtered with an order of 500.  
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The minimal errors obtained with this extraction and processing technique are 
presumably due to a compromise between utilizing the exact position of the subharmonic 
frequency i.e., at 1.25 MHz (because slight shifts in the observed subharmonic peaks 
were noted) and utilizing a much broader bandwidth of 0.5 MHz where the extracted 
amplitude may suffer from other ambient noise.  While Fig. 4.7 represents a compelling 
result for the SHAPE technique, the pressures obtained using SHAPE did not capture the 
peak pressures.  One reason for this could be the use of the best fit line for obtaining 
ambient pressures from the subharmonic amplitudes, because the best fit line tries to 
minimize the RMSE and consequently, may have compromised the peak end-points for a 
better pressure contour fit (an r
2
 value of 0.90 still implies that only 10 % of the variance 
was not accounted for by the model).  Another reason may be the ultrasound data 
acquisition PRF of 3.3 kHz, whereas for the pressure catheter the acquisition rate was 50 
kHz.  Thus, the ultrasound data may potentially have missed the peak pressures, which 
were captured by the pressure catheter. 
 
4.1.6  Discussion Based on In Vitro Experiments 
Currently different techniques are being developed (and tested) for subharmonic 
imaging (e.g., (124, 141, 170, 171), however the effort in developing and testing 
appropriate processing techniques to utilize the subharmonic emissions for ambient 
pressure estimation is lagging.  Since the SHAPE approach may reduce/eliminate the 
number of catheterizations (and consequently the associated costs and complications) 
currently required for in vivo clinical ambient pressure estimation (4, 5), developing a 
robust processing technique for SHAPE is required before the clinical applications can be 
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investigated.  Therefore, the goal of this study was to develop a signal processing 
technique to extract and process subharmonic signals from the Sonix RP scanner that 
may be used for ambient pressure estimation.  As the subharmonic emissions and the 
pressure modulated subharmonic amplitudes from UCAs are dependent on IAO (given 
that the other transmit parameters were fixed) (1, 3, 109) the SHAPE approach also 
requires a technique to determine the most sensitive IAO.  This approach was presented 
in section 4.1.2. 
Sonazoid microbubbles in the in vitro studies study showed a sensitivity of -
10.881 mmHg/dB (section 4.1.3) and -10.655 mmHg/dB (section 4.1.5).  This similarity 
is because out of the different extraction and processing techniques considered in section 
4.1.5 for SHAPE, the best processing technique  turned out to be the approach previously 
espoused (section 4.1.3: extracting the subharmonic signal in a 0.2 MHz bandwidth about 
the theoretical subharmonic frequency and then median filtering the signal to reduce 
high-frequency noise); nonetheless these results corroborate the findings.  The negative 
sign of the sensitivity indicates that the subharmonic signals were 180
°
 out-of-phase with 
ambient pressure variations.  The use of subharmonic microbubble emissions for pressure 
estimation have previously shown a sensitivity of -13.985 mmHg/dB in vitro (144), -
6.759 mmHg/dB in simulation studies (135)  and approximately -4.444 mmHg/dB in vivo 
(23) (in an invasive proof-of-concept study with single element transducers).  This 
difference of sensitivity in the experimental setup adopted here is attributed to the flow 
component as the contrast agent concentration may vary spatially and temporally (as in 
the clinical environment).  The time dependent behavior of subharmonic signals from 
Optison has been described with an in-phase and out-of-phase relationship with ambient 
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pressures (138).  However, this setup did not include flow and the transient in-phase 
relationship was attributed to the gaseous exchanges due to diffusion.  Interestingly, some 
other studies have reported that shell encapsulated microbubbles engineered with 
“optimized” initial surface tension may exhibit an in-phase relationship (2.12 mmHg/dB) 
between the ambient pressure and the corresponding modulated subharmonic amplitudes 
(137) and that this relationship may be exploited for subharmonic imaging (141).  
However, with Sonazoid such in-phase relationship between ambient pressures and 
pressure modulated subharmonics has not been observed.  In theory, the threshold IAO 
required for subharmonic generation is the least when the microbubbles are insonated at 
twice their resonant frequency (109).  However, recent simulation studies have shown 
that the maximum subharmonic generation may also occur for insonation frequencies less 
than twice the resonant frequency (172).  For the studies conducted in this work, an 
insonation frequency of 2.5 MHz with Sonazoid (resonance frequency is 4.4 MHz) was 
used because the resulting subharmonic emissions were utilized for SHAPE and the 
ambient pressure sensitivity of Sonazoid subharmonic emissions was found to be the best 
when insonated at 2.5 MHz (144). 
Currently, there is no accurate theoretical explanation governing the decrease in 
subharmonic emissions from microbubbles as the ambient pressure increases.  This effect 
was first documented empirically (3) and other independent studies have also reported the 
same (e.g., (134, 136)).  A simulation study using excitation frequencies of 2.06 MHz and 
2.46 MHz for Levovist and Sonazoid, respectively, also demonstrated a decrease in the 
subharmonic signal amplitude as the ambient pressures increased (135).  It may be 
surmised that the volume pulsations of the bubbles give rise to the scattered signal when 
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insonated by IAO and as the amplitude of these pulsations increase (when the IAO is in 
the growth stage), nonlinear effects dominate giving rise to a strong subharmonic signal. 
At this stage, an increase in the ambient pressures will then, perhaps, dampen the 
nonlinear oscillations thus causing a reduction in the subharmonic signal amplitude.  
Finally, when the incident acoustic pressure is very high, the bubbles oscillate violently 
before collapsing and thus the sensitivity to ambient pressure is lost (cf., section 4.1.4, 
Fig. 4.3).  A more recent simulation study using a range of excitation frequencies again 
emulating Levovist and Sonazoid, showed that the subharmonic signal amplitude may 
vary differently if the excitation frequencies are varied (172) i.e., the subharmonic 
response increases as the excitation frequency increases by 40 % to 60 % above the 
bubbles‟ natural resonance frequency, and then, the subharmonic response decreases for 
increases in excitation frequency above a rise of 60 % beyond the bubbles‟ natural 
resonance frequency.  Additionally, using single free-bubble (free: un-encapsulated) 
simulations the authors postulated that the emanated subharmonic response may be a 
function of the ratio of excitation frequency to the bubbles‟ natural resonance frequency, 
the latter being affected by changes in ambient pressure (172).  These results with single-
free bubble simulation models (without considering gas diffusion) indicate that the 
properties of a single and then an aggregate population of shell encapsulated 
microbubble(s) will have to be more thoroughly modeled before a complete 
understanding of the theory of subharmonic amplitude decrease due to an increase in 
ambient pressure can be established.  Alternately in another study it was shown that the 
shift of subharmonic optimum driving frequency (i.e., in the frequency eliciting 
maximum subharmonic response) was maximum when the microbubbles were insonated 
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with an “optimized” IAO (142).  The authors further postulate that this may even explain 
a reduction in the subharmonic amplitude as the ambient pressure is increased if the 
microbubbles are insonated with that same value of “optimized” IAO (142).  However 
these results should be interpreted with caution given that the results were obtained using 
simulations alone, and the microbubble and population of microbubbles considered (i.e., 
SonoVue microbubbles) do not represent the properties (like shell parameters, etc.) of 
Sonazoid microbubbles. 
 
4.1.7  Summary Based on In Vitro Experiments 
A practical and accurate technique to determine ambient pressure values in 
dynamic flow environments using subharmonic emissions from UCAs (i.e., SHAPE) and 
a commercial ultrasound unit has been developed (sections 4.1.1-4.1.4).  Subharmonic 
amplitudes from microbubble emissions were extracted from the RF data and processed 
using different techniques.  A median filter with an order of 500 showed the least RMSEs 
relative to pressure catheter data after regression analysis for the subharmonic signals 
extracted as the average amplitude in a 0.2 MHz bandwidth about the theoretical 
subharmonic frequency (section 4.1.5).  This processing technique may be implemented 
for real-time SHAPE applications in the future. 
The standard error between catheter pressures and SHAPE results ranged from 7.9 
to 8.2 mmHg (i.e., was below 10 mmHg) with an r
2
 ≥ 0.9 for repeatable (n > 5) 
continuous runs of at least 4 second segments.  Thus, Hypothesis 1 was accepted.  These 
results indicate the viability of translating the SHAPE technique for in vivo noninvasive 
pressure measuring applications, given that no other technique utilizing UCAs to estimate 
ambient pressures produced errors below 10 mmHg.  
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4.2  Cardiac SHAPE Studies 
4.2.1  Determination of Optimum IAO Levels for Cardiac SHAPE Studies 
The determination of optimum IAO levels i.e., the IAO level eliciting growth 
phase subharmonic emissions is crucial before the SHAPE technique may be used to 
estimate ambient pressures.  Thus, a separate section with detailed explanation is 
provided here before the results of SHAPE in predicting LV and RV pressures are shown.  
Also, since this step was repeated for all the cases (for LV data from 2 canines, then from 
LV data from 4 canines and for RV data from 5 canines), a representative data set was 
chosen such that it portrayed, both the occurrence of saturation and possibly bubble 
destruction, and also the un-occurrence of saturation at 100 % IAO levels.  The case 
selected here is for data from the aorta and the RV of a canine. 
The data set of subharmonic amplitudes obtained from the aorta and the RV of a 
single canine is shown in Fig. 4.8.  Fig. 4.8A depicts the subharmonic data acquired from 
the aorta, specifically with the subharmonic amplitudes corresponding to the peak 
systolic and minimum diastolic pressures and Fig. 4.8B shows the data acquired from the 
RV.  From the aortic data (Fig. 4.8A), it can be seen that the subharmonic signals are 
either in the occurrence stage or the growth phase, because the subharmonic amplitudes 
did not achieve a steady state value (characteristic of the saturation phase) even with 100 
% IAO.  Statistically, this was confirmed by results obtained from the ANOVA, which 
showed significant main effect of the IAO level (F (4, 23) = 50.7, and F (4, 28) = 27.8, p 
< 0.001) with subharmonic amplitudes at both 79 % and 100 % greater than at other IAO 
levels (indicating that saturation was not reached).  Thus, based on higher subharmonic 
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signal amplitude in the growth phase, the 100 % IAO level was selected (over 79 % IAO 
level) based on the aortic data from this canine. 
On the other hand, the RV data exhibited subharmonic signals in all three phases 
– occurrence (up to 50 % IAO level), growth (up to 79 % IAO level) and then saturation 
followed by bubble destruction (marked by a decreased in subharmonic amplitude at 100 
% IAO) (Fig. 4.8B).  Statistically, this was confirmed by results obtained from ANOVA, 
which showed significant main effect of the IAO level (F (4, 31) = 129.2 and F (4, 36) = 
98.5, p < 0.001).  The post-hoc analyses revealed that subharmonic amplitudes at 100 % 
were less than at 79 % IAO level (p < 0.001) indicating saturation at 79 % IAO level and 
possibly bubble destruction at 100 % IAO level.  Thus, 63 % IAO level was selected for 
the RV data from this canine. 
Similarly, data from all other canines were analyzed with ANOVA revealing the 
optimum IAO levels to be used for SHAPE from the aorta and the LV or the RV and 
these are presented in the respective sections. 
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Figure 4.8:  Selection of optimum IAO level for in vivo cardiac SHAPE.  Sample 
subharmonic signal amplitudes from the aorta and RV of one canine.  The mean 
subharmonic amplitudes corresponding to the peak systolic (squares) and minimum 
diastolic (circles) pressures in the aorta (A) and the RV (B).  The distinct phases of 
subharmonic emissions from microbubbles identified using ANOVA and post-hoc 
comparisons are indicated.  
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4.2.2  Feasibility of Noninvasive In Vivo SHAPE 
The results of ANOVA and post-hoc comparisons revealed that the most sensitive 
IAO pressures eliciting growth stage subharmonics in the 2 canines were 50 % and 100 
% IAO levels.  The depth of placement of the PW Doppler gate was between 5 to 7 cm 
(cf., Fig. 3.5).  This difference in the IAO setting for the 2 canines suggests that this 
process of selecting the most sensitive IAO level will be required as the attenuation 
between cases (canines) will vary. 
The SHAPE results in the LV of both the canines are shown in Figs. 4.9 and 4.10. 
 
 
 
Figure 4.9:  SHAPE results for LV pressures obtained from canine 1.  (A) The pressure 
catheter signal and the SHAPE estimates.  The amplitude spectrum of the pressure 
catheter data (B) and the SHAPE data (C) are depicted with the peak frequency in the 
range of 0.5 to 6.0 Hz (spanning the heart rate from 30 beats per minute to 360 beats per 
minute).  
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Figure 4.10:  SHAPE results for LV pressures obtained from canine 2.  (A) The pressure 
catheter signal and the SHAPE estimates.  The amplitude spectrum of the pressure 
catheter data (B) and the SHAPE data (C) are depicted with the peak frequency in the 
range of 0.5 to 6.0 Hz (spanning the heart rate from 30 beats per minute to 360 beats per 
minute). 
 
 
The subharmonic signal amplitude significantly predicted LV pressure 
values/waveform in both the canines (p < 0.001).  The subharmonic signal amplitude also 
explained a significant proportion of variance in the left ventricle pressure profiles of the 
2 canines, (r
2
 = 0.821 and r
2
 = 0.794; p < 0.001).  (Based on these results Hypothesis 2, 
that evaluated if the SHAPE data correlated with catheter pressures with an r
2
 value 
greater than 0.75, was accepted).  The standard errors of the estimate were 10.607 and 
12.452 mmHg in the canines.  The LVPSP and LVDmin were extracted from the SHAPE 
data and compared to the data obtained from the reference standard (Table 4.2).  The 
maximum error in this comparison was 2.84 mmHg. 
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Table 4.2:  Comparing SHAPE and catheter pressures after regression analyses.  
Comparison of the peak systolic pressures and the minimum diastolic pressures obtained 
using the SHAPE approach and the reference pressure catheter in the 2 canines. 
 
 Canine 1  Canine 2 
Pressure Phases 
SHAPE 
(mmHg) 
Catheter 
(mmHg) 
 
SHAPE 
(mmHg) 
Catheter 
(mmHg) 
LVPSP 77.6 ± 3.4 77.8 ± 1.0  68.9 ± 1.3 68.5 ± 0.1 
LVDmin 8.8 ± 2.2 8.2 ± 0.9  18.6 ± 0.5 15.8 ± 0.1 
 
 
The heart rate calculated using the peak amplitude in the normalized amplitude 
spectrum of the SHAPE data matched the true heart rate obtained using the power 
spectrum of the reference standard data (i.e., the pressure catheter waveform; 1.67 vs. 
1.68 Hz for canine 1 and 1.83 Hz vs. 1.83 Hz for canine 2; Figs. 4.9 and 4.10).  The peak 
signal frequency will indicate the heart rate as each pressure cycle corresponds to 
myocardial contraction followed by LV relaxation.  This heart rate match between the 
SHAPE data and the true heart-rate (that can be obtained noninvasively) may be used as 
an additional verification criterion before confirming the “optimum” IAO for LV 
pressure monitoring. 
The dynamic in vitro experiments were conducted at an ambient temperature of 
25° C whereas the temperatures in the canines would be relatively higher (about 38° to 
39° C).  There are differences between bubble behaviors in vitro at 25° C and in vivo at 
38° to 39° C (173).  However, the fact that under both circumstances SHAPE works 
demonstrates that this is not an important effect for this particular application.  Also the 
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bubble concentration may vary somewhat in vitro, but will vary more in vivo due to 
mechanisms like phagocytosis.  These transient variations in the bubble concentration 
result in noise in the un-filtered subharmonic signal and this problem was addressed by 
the use of median filtering to eliminate these resulting transient noise signals.  Also, in 
vivo to compensate for this concentration gradient, a continuous infusion at a steady rate 
was maintained.  Thus, these results demonstrate the feasibility of conducting other in 
vivo SHAPE studies.  Also, the pressure contours obtained using the subharmonic data 
are reproducible and this permits evaluation of parameters based on pressure contours 
like ventricular relaxation, cardiac output and wave reflection (65, 66).  Note, that these 
experiments were done with a commercial scanner and UCA.  Further validation and 
refinement of this technique are required for clinical application i.e., to estimate cardiac 
pressures using the subharmonic data alone, and then compare the values with the 
pressure catheter – this is addressed in the following sections. 
 
4.2.3  Efficacy of SHAPE for Clinically Relevant LV Pressures 
4.2.3.1  Optimum IAO levels for SHAPE 
A representative data set explaining the criteria governing the selection of 
optimum IAO levels for SHAPE was shown in section 4.2.1.  Consequently the optimum 
IAO levels obtained based on the aortic and the LV data from the canines used to 
evaluate the efficacy of SHAPE for clinically relevant LV pressures is provided in Table 
4.3.  The aortic data from canines 3 and 4 were not obtained because a sub-hypothesis to 
investigate the effect of using a mean calibration factor based on data from other canines 
was investigated in these canines.  
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Table 4.3:  Optimum IAO levels obtained from the aortic and the LV data 
  Optimum IAO Levels 
  For Aortic Data  For LV Data 
Canines 
 
(%) 
(as indicated on 
scanner) 
 
(%) 
(as indicated on 
scanner) 
1  100 0 dB  50 -6 dB 
2  39 -8 dB  79 -2 dB 
3  N/A
*
 N/A
*
  100 0 dB 
4  N/A
*
 N/A
*
  100 0 dB 
*
 N/A:  Not applicable 
 
 
4.2.3.2  Calculation of Calibration Factor (mmHg/dB) in the Aorta 
The systemic pulse pressures and the subharmonic amplitudes corresponding to 
the peak systolic and minimum diastolic pressures are given in Table 4.4.  The standard 
deviations were derived from about 5 to 7 pressure contours per 5 second acquisition and, 
since data were acquired from three runs, this corresponded to about 15 to 21 values for 
each canine.  The resulting calibration factors for each canine are also shown in Table 
4.4.  Note, that these values were quite similar.  For the two other canines, the mean 
calibration factor obtained from canines 1 and 2 was used i.e., a value of -4.9245 
mmHg/dB. 
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Table 4.4:  Calibration factor calculations from the aorta for LV pressure estimation.  
Subharmonic signal amplitudes at optimum IAO setting are indicated.  Systemic pulse 
values are calculated as the difference between the systolic and diastolic values.  The 
calibration factor values are calculated by dividing the systemic pulse pressures by the 
systemic pulse subharmonic amplitudes. 
 
Specific Aortic Pressure Phases 
Catheter 
(mmHg) 
Subharmonic 
Amplitude (dB) 
Calibration Factor 
(mmHg/dB) 
Canine 1: Peak Systolic 67.0 ± 0.4 45.3 ± 0.3  
Minimum Diastolic 44.3 ± 0.2 49.9 ± 0.4  
Systemic Pulse 22.7 ± 0.3 -4.6 ± 0.5 -4.93 
Canine 2: Peak Systolic 81.1 ± 0.6 49.8 ± 0.7  
Minimum Diastolic 57.0 ± 0.5 54.7 ± 0.5  
Systemic Pulse 24.1 ± 0.7 -4.9 ± 0.8 -4.92 
 
 
4.2.3.3  Obtaining LV Pressure Profiles in Canines 
Fig. 4.11 shows the subharmonic signal variation and SHAPE in the LV 
compared to the measured pressure, along with the SHAPE generated LV pressure profile 
from a single canine.  Specifically, Fig. 4.11A shows that the subharmonic signals varied 
inversely with respect to the LV pressures.  Fig 4.11B is obtained when the subharmonic 
data from the LV, the calibration factor from the aorta and the peak systolic aortic 
pressures were combined. 
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Figure 4.11:  SHAPE results in the LV.  (A) The subharmonic and the pressure signals 
are shown – note the inverse relationship which is in agreement with documented 
literature (3, 23, 135, 136).  (B) LV pressure waveform obtained using the pressure 
catheter and the corresponding SHAPE results.  
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4.2.3.4  Comparison of SHAPE LV Pressures with Catheter Pressures 
For two canines where the calibration factor were obtained from the aorta, the LV 
pressure estimates were calculated and compared with the pressure catheter (Table 4.5).  
Overall the errors between the SHAPE approach and the pressure catheter ranged from 
0.19 to 2.5 mmHg.  For two other canines, the mean calibration factor from the first two 
canines was used to estimate the LV pressures (Table 4.6).  For these canines, relatively 
higher errors between the SHAPE approach and the pressure catheter were reported 
ranging from 0.64 to 8.98 mmHg. 
None of the differences between the SHAPE and the reference standard for all the 
estimates of LV pressures were significant (Table 4.7; p > 0.17).  The mean absolute 
errors for M-LVDP, LVDmin, LVEDP and LVPSP were 1.58 ± 1.01 mmHg, 1.35 ± 0.92 
mmHg, 4.90 ± 3.26 mmHg and 1.75 ± 0.98 mmHg, respectively.  Heart rate obtained 
from the frequency domain representation of SHAPE data and pressure catheter data was 
also in good agreement with maximum absolute error of 4.39 beats per minute (Tables 
4.5 and 4.6).  These results, based on estimates from all four canines, indicate that 
SHAPE is able to noninvasively track in vivo pressures in the LV, if the pulse pressures 
in the aorta are known. 
The percentage errors when the calibration factors were obtained from respective 
canines ranged from 1 % to 15 %, but the maximum percentage error i.e., 15 % 
corresponded to a pressure value error of 1.4 mmHg.  Such errors are sufficiently small to 
explore clinical applications of SHAPE.  
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Table 4.5:  LV pressure measurements with aortic calibration factors. 
 Canine 1  Canine 2 
 SHAPE Catheter Error  SHAPE Catheter Error 
 mmHg mmHg mmHg %  mmHg mmHg mmHg % 
M-LVDP
*
 20.1 17.6 2.5 14  14.2 13.4 0.8 6 
LVDmin
†
 15.9 15.7 0.2 1  7.5 8.9 -1.4 -15 
LVEDP
‡
 22.1 19.7 2.3 12  19.1 16.9 2.2 13 
LVPSP
§
 70.2 68.8 1.4 2  83.8 82.1 1.7 2 
Heart Rate 
(per min.) 
109.8 109.9 N/A N/A  105.5 109.9 N/A N/A 
*
mean LV diastolic pressure, 
†
 minimum LV diastolic pressure, 
‡
LV end diastolic 
pressure, 
§
LV peak systolic pressure 
 
 
Table 4.6:  LV pressure measurements without aortic calibration factors. 
(abbreviations same as (Table 4.5) 
 
 Canine 3  Canine 4 
 SHAPE Catheter Error  SHAPE Catheter Error 
 mmHg mmHg mmHg %  mmHg mmHg mmHg % 
M-LVDP
*
 13.6 14.2 -0.6 -4  15.4 13.0 2.4 19 
LVDmin
†
 5.8 7.2 -1.4 -20  12.0 9.6 2.4 26 
LVEDP
‡
 12.1 18.1 -6.1 -33  22.0 13.0 9.0 69 
LVPSP
§
 82.7 79.6 3.1 4  83.8 84.6 -0.7 1 
Heart Rate 
(per min.) 
100.0 100.7 N/A N/A  94.8 91.5 N/A N/A 
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Table 4.7:  Paired comparisons of SHAPE in LV and the manometer pressures for all 
canines. 
 
 
Difference (mmHg) 
(SHAPE – manometer 
pressure) 
 
95% Confidence 
Interval of the 
Difference (mmHg) 
 
Significance 
(2-tailed) 
 Mean 
Standard 
deviation 
Standard 
error of 
mean 
 Lower Upper   
M-LVDP
*
 1.3 1.5 0.7  -1.1 3.6  0.18 
LVDmin
†
 -0.0 1.8 0.9  -2.9 2.8  0.97 
LVEDP
‡
 1.9 6.2 3.1  -7.9 11.7  0.59 
LVPSP
§
 1.4 1.6 0.8  -1.2 3.9  0.18 
 
 
4.2.3.5  Discussion for Cardiac SHAPE - LV 
In this study, two hypotheses were tested.  First, it was hypothesized that the 
subharmonic emissions from microbubbles can be utilized to quantify in vivo LV 
pressures noninvasively.  The resultant errors in the pressures recorded by SHAPE with 
respect to the reference catheter measurements did not exceed 2.50 mmHg when the 
calibration factor from the aorta of the individual canine was used in the pressure 
derivation stage (cf., Table 4.5).  Additionally, there were no statistically significant 
difference between the pressures recorded by the SHAPE approach and the pressure 
catheter (p > 0.17; cf., Table 4.7).  Second, it was hypothesized that a mean calibration 
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factor may be used across all subjects.  As seen from results in Table 4.6, the errors 
increased up to 8.98 mmHg under this hypothesis (cf., Table 4.6).  This suggests that the 
addition of aortic measurements to obtain calibration factor from each individual subject 
allows LV pressure estimates to be obtained with less error.  Thus, the results obtained 
from SHAPE are in good agreement with the reference standard (maximum mean 
absolute error: 2.40 ± 2.22 mmHg) based on data from four canines across all pressure 
estimates. 
 
 
4.2.4  Efficacy of SHAPE for Clinically Relevant RV Pressures 
4.2.4.1  Optimum IAO levels for SHAPE 
A representative data set explaining the criteria governing the selection of 
optimum IAO levels for SHAPE was shown in section 4.2.1.  Consequently the optimum 
IAO levels obtained based on the aortic and the RV data from the canines used to 
evaluate the efficacy of SHAPE for clinically relevant RV pressures is provided in Table 
4.8. 
 
  
136 
 
Table 4.8:  Optimum IAO levels obtained from the aortic and the RV data. 
  Optimum IAO Levels 
  For Aortic Data  For RV Data 
Canines 
 
(%) 
(as indicated on 
scanner) 
 
(%) 
(as indicated on 
scanner) 
1  79 -2 dB  79 -2 dB 
2  63 -4 dB  63 -4 dB 
3  63 -4 dB  63 -4 dB 
4  63 -4 dB  50 -6 dB 
5  100 0 dB  63 -4 dB 
 
 
4.2.4.2  Calculation of Calibration Factor (mmHg/dB) in the Aorta 
The systemic pulse pressures and the subharmonic amplitudes corresponding to 
the peak systolic and minimum diastolic pressures are given in Table 4.9.  The resulting 
calibration factors for each canine are also shown in Table 4.9.  The mean peak systolic 
and minimum diastolic pressures in the aorta were 86.9 ± 20.1 mmHg and 57.5 ± 14.2 
mmHg, respectively.  The corresponding mean subharmonic amplitudes were 51.5 ± 6.1 
dB and 61.6 ± 7.0 dB with higher subharmonic amplitudes associated with lower ambient 
pressures (minimum diastolic) and lower subharmonic amplitudes associated with higher 
ambient pressures (peak systolic), as is reported in the literature (e.g., (3)). 
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Table 4.9:  Calibration factor calculations from the aorta for RV pressure estimation.  
Subharmonic signal amplitudes at optimum IAO setting are indicated.  Systemic pulse 
values are calculated as the difference between the systolic and diastolic values.  The 
calibration factor values are calculated by dividing the systemic pulse pressures by the 
systemic pulse subharmonic amplitudes. 
 
Specific Aortic Pressure 
Phases 
Catheter 
(mmHg) 
Subharmonic 
Amplitude (dB) 
Calibration Factor 
(mmHg/dB) 
Canine 1: Peak Systolic 74.8 ± 1.2 53.0 ± 1.1  
Minimum Diastolic 49.6 ± 0.4 65.5 ± 1.3  
Systemic Pulse 25.2 ± 1.0 -12.5 ± 1.0 -2.0 
Canine 2: Peak Systolic 81.0 ± 1.1 48.6±0.2  
Minimum Diastolic 59.9 ± 1.0 54.1 ± 0.3  
Systemic Pulse 21.1 ± 0.3 -5.5 ± 0.1 -3.8 
Canine 3: Peak Systolic 76.7 ± 1.8 61.6 ± 2.4  
Minimum Diastolic 45.3 ± 3.0 71.6 ± 1.9  
Systemic Pulse 31.4 ± 3.5 -10.0 ± 3.1 -3.1 
Canine 4: Peak Systolic 79.3 ± 0.6 47.6 ± 0.9  
Minimum Diastolic 51.7 ± 0.8 59.3 ± 1.3  
Systemic Pulse 27.6 ± 1.0 -11.7 ± 1.6 -2.4 
Canine 5: Peak Systolic 122.8 ± 0.8 46.9 ± 1.7  
Minimum Diastolic 81.0 ±1.0 57.3 ± 1.1  
Systemic Pulse 41.8 ± 1.3 -10.4 ± 2.0 -4.0 
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4.2.4.3  Obtaining RV Pressure Profiles in Canines 
Fig. 4.12 shows the subharmonic signal variation and SHAPE in the RV 
compared to the measured pressure, along with the SHAPE generated RV pressure 
profile from a single canine.  Specifically, Fig. 4.12A shows that the subharmonic signals 
varied inversely with respect to the RV pressures.  Fig 4.12B is obtained when the 
subharmonic data from the RV, the calibration factor from the aorta and the RA pressures 
were combined. 
 
 
 
Figure 4.12:  SHAPE results in the RV.  (A) The subharmonic and the pressure signals 
are shown – note the inverse relationship which is in agreement with documented 
literature (3, 23, 135, 136).  (B) RV pressure waveform obtained using the pressure 
catheter and the corresponding SHAPE results.  
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4.2.4.4  Comparison of SHAPE RV Pressures with Catheter Pressures 
Table 4.10 lists the RVSP and RVDmin obtained using the SHAPE pressure 
contours and using the pressure catheter data.  For the 5 canines the mean RVSP and 
RVDmin pressures obtained using the pressure catheter were 22.4 ± 4.6 mmHg and 4.7 ± 
1.1 mmHg, respectively and obtained using the SHAPE pressures were 24.7 ± 4.8 mmHg 
and 5.5 ± 1.7 mmHg, respectively.  The absolute errors in RVSP and RVDmin 
measurements ranged from 0.0 to 3.4 mmHg and from 0.1 to 1.8 mmHg.  Table 4.10 also 
lists the RV relaxation rate (peak isovolumic –dp/dt) with a mean value of -132.7 ± 39.8 
mmHg/s obtained with the pressure catheter data and a mean value of -135.7 ± 38.7 
mmHg/s obtained with the SHAPE data; here the maximum error relative to the catheter 
pressure data was 5.9 mmHg/s. 
Finally, the results of paired comparisons for RVSP, RVDmin, and RV relaxation 
rate obtained with the pressure catheter data and the SHAPE data are presented in Table 
4.11.  Although the RVSP measurements showed a significant difference (p = 0.02) 
between the pressure catheter data and SHAPE data, the absolute difference was less than 
4 mmHg (mean 2.3 ± 1.3 mmHg; Table 4.11).  The differences in RVDmin, and RV 
relaxation rates were small and not statistically significant (absolute mean differences 0.8 
± 0.7 mmHg and 2.9 ± 3.1 mmHg/s, respectively). 
The percentage errors ranged from 1 % to 28 %, but the maximum percentage 
error i.e., 28 % corresponded to a pressure value error of 1.8 mmHg.  Such errors are 
sufficiently small to explore clinical applications of SHAPE. 
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Table 4.10:  RV pressure measurements with aortic calibration factors.  RV relaxation 
corresponds to the late peak –dp/dt.  Errors are indicated as catheter values – SHAPE 
values. 
 
 Catheter SHAPE Error 
   Absolute % 
Canine 1: RVSP (mmHg) 22.2 ± 1.1 24.5 ± 1.1 -2.3 10.4 
RVDmin Pressure (mmHg) 4.5 ± 1.0 5.4 ± 0.9 -0.9 20.0 
RV relaxation (mmHg/s) -154.1 -155.2 1.2 0.8 
Canine 2: RVSP (mmHg) 21.3 ± 0.6 21.3 ± 1.0 0.0 0.0 
RVDmin Pressure (mmHg) 4.2 ± 1.0 5.0 ± 0.7 -0.8 19.0 
RV relaxation (mmHg/s) -162.5 -161.0 -1.5 0.9 
Canine 3: RVSP (mmHg) 20.2 ± 0.9 23.6 ± 0.6 -3.4 16.8 
RVDmin Pressure (mmHg) 5.0 ± 0.1 5.3 ± 1.2 -0.3 6.0 
RV relaxation (mmHg/s) -113.1 -118.6 5.5 4.9 
Canine 4: RVSP (mmHg) 18.1 ± 0.3 21.2 ± 0.6 -3.1 17.1 
RVDmin Pressure (mmHg) 3.5 ± 0.2 3.6 ± 1.2 -0.1 2.9 
RV relaxation (mmHg/s) -71.5 -75.4 3.9 5.5 
Canine 5: RVSP (mmHg) 30.2 ± 3.6 32.8 ± 2.8 -2.6 8.6 
RVDmin Pressure (mmHg) 6.4 ± 0.9 8.2 ± 1.8 -1.8 28.1 
RV relaxation (mmHg/s) -162.2 -168.1 5.9 3.6 
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Table 4.11:  Paired comparisons of SHAPE in RV and the manometer pressures for all 
canines. 
 
 
Catheter Pressure – 
SHAPE Pressures 
 
95 % Confidence 
Interval of the 
Difference 
  
 Mean 
Standard 
Deviation 
 Lower Upper  
Significance 
(2-tailed) 
RVSP (mmHg) -2.3 1.3  -3.9 -0.6  0.02 
RVDmin (mmHg) -0.8 0.7  -1.6 0.0  0.06 
RV relaxation 
(mmHg/s) 
2.9 3.1  -0.9 6.9  0.10 
 
 
4.2.4.5  Discussion for Cardiac SHAPE - RV 
The SHAPE technique recorded errors ranging from 0.0 and 3.4 mmHg in 
measuring RVSPs and provided reproducible RV pressure waveforms for contour based 
analysis.  Also, impairment in RV relaxation (calculated using RV filling pressure 
difference) is marked by a reduced RV driving force (64).  Thus, measuring the RV 
filling pressures may identify RV diastolic dysfunction.  In this regard, the SHAPE 
measurements yielded errors on the order of 0.1 to 1.8 mmHg in estimating RV diastolic 
pressures.  These errors are sufficiently small to explore clinical applications of SHAPE.  
Finally, note that the calibration factor varied by as much as a factor of 2, encompassing a 
range from -2 mmHg/dB to -4 mmHg/dB; underscoring the need to obtain individual 
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calibration factors for each case – this observation matches and supports the conclusion 
derived from the LV data set regarding the need to obtain individual calibration factors. 
 
4.2.5  Discussion Based on In Vivo Cardiac SHAPE Studies 
The IAO level required to elicit a subharmonic response sensitive to in vivo 
pressures will vary on a case-by-case basis based on attenuation of the incident beam and 
the scanning depth.  Therefore, IAO levels on the scanner were varied and the IAO level 
showing maximum stable subharmonic range was selected for pressure monitoring.  The 
data from the aorta, the LV and the RV obtained from all canines show an inverse 
relationship between the subharmonic signals and the ambient pressure values.  A 
calibration factor from the aorta increases the accuracy of pressures obtained with the 
SHAPE approach.  The calibration factor was successfully obtained for a wide range of 
systemic pulse pressures i.e., from 21.1 mmHg to 41.8 mmHg. 
As already noted, the SHAPE technique is dependent on incident acoustic 
pressures.  In this study, discrete increments (of 2 dB) for the IAO (fixed by the 
ultrasound scanner) were used.  Thus, if the most “sensitive” IAO for SHAPE falls within 
the range of the increment then the SHAPE pressure sensing will not be “optimum”, 
thereby contributing to the errors attained in the LV and RV pressure estimates here. 
Most importantly, the results in these pilot studies for the LV and the RV pressure 
measurements were obtained from only four and five canines, respectively.  This small 
sample size may obscure any statistically significant difference between SHAPE 
estimates and the manometer pressures.  Also, the hemodynamics in the canines were not 
altered.  However, as evident in Figs. 4.11 and 4.12, relative changes occur in the 
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subharmonic amplitude of the signal in response to changes in the ambient pressures, and 
thus real-time pressure tracking is feasible (to monitor instantaneous changes as well). 
 
4.2.6  Summary Based on In Vivo Cardiac SHAPE Studies 
The cardiac studies performed in this work, represent the first ever application of 
in vivo noninvasive cardiac pressure estimation.  The correlation between the SHAPE 
data and pressure catheter values showed values for r
2
 > 0.79.  Thus Hypothesis 2, that 
SHAPE data would correlate with catheter pressures with an r
2
 > 0.75, was accepted.  
The percentage errors for LV pressures, when the calibration factors were obtained from 
respective canines, ranged from 1 % to 15 %, but notice that the maximum percentage 
error i.e., 15 % corresponded to a pressure value of 1.4 mmHg.  The percentage errors for 
RV pressures, when the calibration factors were obtained from respective canines, ranged 
from 0 % to 28 %, but the maximum percentage error i.e., 28 % corresponded to a 
pressure value of only 1.8 mmHg.  Such errors are sufficiently small to explore clinical 
applications of SHAPE – thus, while Hypothesis 3 should strictly be rejected (because in 
few cases the percent errors exceeded 10 %), the practical implications of using SHAPE 
to estimate cardiac pressures can neither be neglected nor be ignored.  The favorable 
results of these pilot studies, showing errors in LV and RV systolic and diastolic 
pressures below 3.5 mmHg using the SHAPE technique as compared to the pressure 
catheter, are promising.  Subharmonic emissions from UCAs have the potential to track 
LV and RV pressures noninvasively.  These results warrant further studies and validation 
in clinical populations.  As UCA are already approved in the United States for LV 
opacification, the supplementary pressure values obtained using SHAPE may provide a 
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quantitative parameter for the diagnosis of a myriad of cardiac pathologies.  Moreover, 
these pressures can be obtained with the same contrast administration dosage as the 
subharmonic signal amplitude reduction was negligible even when the concentration of 
the bubbles was varied by a factor of 3 (3). 
 
 
4.3  PH SHAPE Studies 
4.3.1  Verification of PH Models In Canines 
4.3.1.1  PH Induction in Canines 
The baseline IVC pressures obtained from the canines were 5.7 ± 1.2 mmHg 
(range: 4.4 to 6.7 mmHg) whereas the baseline PV pressures from the canines were 10.1 
± 2.7 mmHg (range: 7.1 to 15.8 mmHg).  For the canines in the Gelfoam group, the 
number of Gelfoam sheets administered to reach the PH endpoint ranged from 1/3
rd
 to 4 
sheets and the time taken to attain the PH endpoint varied from 2 to 15 minutes (Table 
4.12).  There was no correlation between the quantity of Gelfoam used and time taken to 
induce PH (r = 0.22) or the change in PV pressures (r = 0.05).  For 10 out of 13 canines, 
PH endpoint was reached (Table 4.12).  For 3 other canines the data acquisition was 
hampered as explained in Table 4.12. 
For the canines in the A-V shunt group, Table 4.13 summarizes the details about 
the acquired PH status.  In 2 canines (Table 4.13: canines 1-2) when an increased flow 
volume was obtained from the femoral artery alone, the pulsatility index increased, but 
the defined PH endpoint was not reached.  For the 3 other canines (Table 4.13: canines 4-
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6) PV flow volume (in addition to the A-V shunt) was augmented by pressure saline 
infusion into portal circulation via 3-way stopcock connection; in these cases the PH 
endpoint was reached after 20 minutes. 
 
 
Table 4.12:  PH induction in canines using the Gelfoam technique (low-flow model) 
Canine Sheets 
of Gelfoam 
used 
Time to induce 
PH (minutes)
*
 
 Canine Sheets 
of Gelfoam 
used 
Time to induce 
PH (minutes)
*
 
1 8 N/A
†
  8 2 6 
2 4 8  9 1/3 5 
3 3 4  10 1/2 5 
4 2 2  11 1 15 
5 2 6  12 N/A
§
 N/A
§
 
6
‡
 N/A
‡
 N/A
‡
  13 1/2 10 
7 1 8     
*
This denotes the time taken after Gelfoam injection(s) to reach the PH endpoint 
 
†
No increase in PV pressures seen and the experiment was terminated (60 minutes after 
the Gelfoam injections) 
 
‡
The pressure sensor was physically damaged and thus data from this canine were not 
considered 
 
§
Acute embolization was observed on ultrasound images and the experiment was 
terminated 
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Table 4.13:  PH induction in canines using the A-V shunt technique (high-flow model) 
Canine Flow to the PV obtained from Time to induce PH (minutes)
*
 
1 Femoral artery N/A
†
 
2 Femoral artery N/A
†,‡
 
3 Femoral artery N/A
§
 
4 Femoral artery plus saline bag flushed with a 
pressure cuff 
20 
5 Same as for canine 4 20 
6 Same as for canine 4 20 
*
This denotes the time taken after starting the flow from the 3-way stopcock in the PV to 
reach the PH endpoint 
†
No increase in PV pressures were seen; data were still acquired for the post-PH phase 
‡
The pressure signal showed high pulsatility 
§
No rise in PV pressure was observed after 45 minutes and the experiment was 
terminated; no data were collected for the post-PH phase 
 
 
4.3.1.2  Inferior Vena Cava (IVC) and PV Data 
Fig. 4.13 shows the pressure data obtained from the IVC, and from the PV before 
and after PH.  Fig. 4.13A shows the pressure trace from the IVC, while Figs. 4.13B and 
4.13C depict sample PV pressures under baseline and PH conditions from canines in the 
Gelfoam and the A-V shunt group, respectively.  Note that the PH pressure trace in Fig. 
4.13C representing the A-V shunt group shows more pulsatility as compared to the 
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baseline pressures and pressures illustrated in Fig. 4.13B, as predicted.  The pressures, 
pulsatility indices and diameters obtained from the IVC and the PV from all the canines 
are summarized in Table 4.14.  From the A-V shunt group, the data from canines where 
the high flow volume was augmented using an additional pressure saline infusion with 
the help of a pressure cuff are also presented separately, as the PH endpoint was only 
reached in these canines (cf., Table 4.13; Table 4.14). 
 
 
 
Figure 4.13:  IVC and PV pressure waveforms.  (A) Pressure trace obtained from the 
IVC of a canine. (B) Pressure traces obtained from the PV under baseline and PH states 
in a canine from the Gelfoam group. (C) Pressure traces obtained from the PV under 
baseline and PH states in a canine from the A-V shunt group. Note, the high pulsatility 
seen in the PV pressures after PH in the A-V shunt group relative to pressures in (B) and 
baseline pressures in (C).  
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Table 4.14:  Parameters obtained from the canines before and after inducing PH from the 
PV and from the IVC 
 
Experimental condition: location Pressures 
(mmHg) 
Pulsatility  
Index 
Diameter 
(mm) 
Baseline: IVC 5.7 ± 1.2 1.6 ± 0.3 11.4 ± 3.3 
Baseline: PV 10.1 ± 2.7 0.6 ± 0.3 9.3 ± 1.7 
Gelfoam induced PH: PV 26.5 ± 7.5 0.3 ± 0.2 9.6 ± 1.6 
A-V shunt induced PH: PV 19.1 ± 6.5 0.8 ± 0.4 9.7 ± 1.6 
A-V shunt induced PH
*
: PV 23.2 ± 4.3 0.6 ± 0.1 9.8 ± 1.5 
a
Only canines where the flow from femoral artery and saline bag were used 
 
 
For all the canines where the PV data were acquired before and after PH, the PV 
pressures, the pulsatility index and diameter values are depicted in Figs 4.14, 4.15 and 
4.16, respectively.  For the Gelfoam group note the increasing trend of PV pressures and 
decreasing trend of the pulsatility index after PH induction.  For the canines in the A-V 
shunt group an increasing trend of PV pressures was only seen when the saline was also 
used to increase the PV flow volume, whereas an overall increasing trend was observed 
for the pulsatility index values after induced PH.  For both groups no appreciable changes 
in the diameters were seen (Table 4.14). 
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Figure 4.14:  PV pressures before and after inducing PH.  (A) and (B) illustrate PV 
pressures (for individual canines) and boxplot of the PV pressures before and after 
inducing PH using Gelfoam, respectively.  (C) and (D) illustrate the data for the A-V 
shunt model.  For panel (C) the unfilled markers indicate 2 canines where changes in PV 
pressures were not seen.  For the boxplot, the vertical span of the box represents the 
interquartile range, the horizontal line within the box represents the median value, the 
whiskers represent the range, and minor and major outliers are indicated with circles and 
asterisks. 
 
 
 
Figure 4.15:  Pulsatility index values before and after inducing PH.  (A) and (B) 
illustrate PV pressures (for individual canines) and boxplot of the PV pressures before 
and after inducing PH using Gelfoam, respectively.  (C) and (D) illustrate the data for the 
A-V shunt model.  For panel (C) the unfilled markers indicate 2 canines where changes in 
PV pressures were not seen. (Boxplot description similar to Fig. 4.14). 
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Figure 4.16:  Diameter values before and after inducing PH.  (A) and (B) illustrate PV 
pressures (for individual canines) and boxplot of the PV pressures before and after 
inducing PH using Gelfoam, respectively.  (C) and (D) illustrate the data for the A-V 
shunt model.  For panel (C) the unfilled markers indicate 2 canines where changes in PV 
pressures were not seen. (Boxplot description similar to Fig. 4.14). 
 
 
4.3.1.3  Statistical Analyses for Comparing Parameters Before and After Inducing PH 
For the Gelfoam PH model, there was a statistically significant difference (p < 
0.001) between PV pressures in the before and after situation implying that PH was 
successfully induced (Table 4.15).  Also the pulsatility index was significantly lower (p = 
0.012) after PH suggesting a low and damped flow relative to the baseline conditions 
(Table 4.15).  There was no statistically significant difference (p = 0.89) between the 
diameter of the PV at baseline conditions and after PH. 
For the A-V shunt model, when all the canines in this group were considered the 
difference in pressures after inducing PH approached significance (p = 0.067); this 
difference reached significance (p = 0.010) for the sub-group of canines where the 
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pressure saline infusion were also used to increase the PV flow volume (Table 4.15).  
Interestingly, the results for the pulsatility index were inverse.  There was a statistically 
significant difference (p = 0.031) between the pulsatility index before and after PH when 
all the canines were considered, but this difference was not statistically significant (P = 
0.109) when the sub-group of canines with the pressure saline infusion were considered 
(Table 4.15).  There was no statistically significant difference (P > 0.36) between the 
diameters before and after inducing PH (Table 4.15). 
 
 
Table 4.15:  Comparing baseline and PH parameters in the PV 
Parameter PH model Paired samples test results 
  Mean Difference 95 % Confidence 
Interval of Difference 
p-value 
   Lower Upper  
Pressure (mmHg) Gelfoam 16.5 ± 7.6 11.5 21.6 < 0.001 
 A-V shunt 7.8 ± 7.6 0.9 16.6 0.067 
 A-V shunt
*
 12.8 ± 2.2 7.4 18.3 0.010 
Pulsatility Index Gelfoam -0.3 ± 0.4 -0.6 -0.1 0.012 
 A-V shunt 0.4 ± 0.3 0.1 0.7 0.031 
 A-V shunt
*
 0.3 ± 0.2 -0.2 0.8 0.109 
Diameter (mm) Gelfoam -0.1 ± 1.6 -1.8 1.6 0.886 
 A-V shunt -0.4 ± 1.7 -2.5 1.7 0.638 
 A-V shunt
*
 -1.1 ± 1.7 -5.4 3.1 0.368 
*
Only canines where the flow from femoral artery and saline bag were used  
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4.3.1.4  Discussion 
Portal hypertension could be caused by increased resistance to PV flow or by 
increase in PV flow volume or a combination of these (43, 73-75).  Thus, the robustness 
of the SHAPE technique to evaluate PH was to be investigated under both conditions.  
Consequently, two acute PH models were developed i.e., the Gelfoam model to represent 
increased resistance scenario (low-flow) and the A-V shunt model to represent the 
increased flow volume.  The PH endpoint was defined as an increase in PV pressures of 
at least 5 mmHg above the baseline values. The baseline IVC pressures were 5.7 ± 1.2 
mmHg (Table 4.14), which agree with mean values of 5.6 to 6.6 mmHg and the range of 
2.7 mmHg to 10 mmHg reported in the literature (169).  Baseline PV pressures in the 
canines were 10.1 ± 2.7 mmHg (Table 4.14) that are consistent with literature reported 
mean values ranging from 7 to 11 mmHg (152, 156, 158, 160, 165). 
For the Gelfoam model, the PH endpoint was reached in 10 out of 11 canines 
(success rate: 91 %), although in 2 other canines experimental conditions, not associated 
with the PH model, hampered data acquisition.  Thus, Gelfoam administered into the PV 
increased the resistance to PV flow and induced PH within 2 to 15 minutes.  However, 
there was no correlation between the quantity of Gelfoam used and induced PH or the 
time taken to induce PH, suggesting that inter-canine response varied considerably, 
probably due to variability in PV anatomy and liver sizes. 
For the A-V shunt group, in 3 canines when the flow from femoral artery was 
integrated with the PV flow, no rise in PV pressures were seen.  The A-V shunt failed to 
induce PH in all 3 cases.  For the remaining 3 canines in the A-V shunt group the flow 
from the femoral artery was augmented with pressure saline infusion and then PH was 
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successfully induced.  These results imply that when the flow from the femoral artery 
was coupled to the PV the compliance in the PV may be sufficient to compensate for the 
increased flow volume and thereby, resulted in high pulsatility index (by 0.4 or 40 % 
higher relative to baseline values; cf. Table 4.15). 
The canine PH models have traditionally aimed to elucidate the mechanism of PH 
development (75, 152, 157, 158, 160) (which is still not well understood (15)) and in all 
of these studies chronic PH is generally induced to evaluate the associated physiologic 
changes.  For the SHAPE application to identify induced PH, a relatively straightforward 
and acute low-flow and high-flow PH models were required, wherein the rise in PV 
pressures occurred within 30 minutes after acquiring baseline data and ultrasound 
scanning after contrast administration was feasible. 
There are various canine PH models that have been proposed in literature (75, 
152, 157, 158, 160).  A whole liver compression PH model using a polypropylene mesh 
resulted in death of one canine and, thus, this model was excluded from consideration 
(160).  That approach also involved wrapping the whole liver with mesh or gauze and, 
thus, was not applicable for evaluation of our ultrasound technique, due to possible 
scattering of the ultrasound beam by the mesh or gauze.  Another approach proposed in 
the literature was the use of portal and splenic vein stenoses to study the relationship 
between hypersplenism and hemodynamics in PH (152).  But the constriction of portal 
and splenic veins would affect the amount of ultrasound contrast reaching the PV and 
thus this model had limited applicability for the SHAPE PH study.  In another study, 
authors used anti-E. coli serum to induce portal fibrosis and tracked PH related changes 
over 2 weeks (159), but this 2 week time-frame to observe PH changes was not suitable 
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for this work because the baseline PV pressures were obtained after a mid-line abdominal 
incision to access the PV and then increases in PV pressures needed to be induced acutely 
for testing the efficacy of SHAPE technique to detect the increase in PV pressures.  An 
approach to use microspheres for inducing PH has been shown to be successful in 
canines, but the cost associated with these microspheres is relatively high (156).  Another 
approach to develop a multiple portosystemic shunt model using dimethylnitrosamine to 
study the PH induced portosystemic shunts was also discussed but the time taken to 
induce these shunts varies between 8 to 14 weeks and can also be as high as 56 weeks 
and thus not practical for the SHAPE PH study (155).  The natural occurrences of canine 
A-V shunts between the hepatic artery and PV resulting in vascular abnormalities have 
been reported in the literature (174-176), but none were noted in the canines that were 
used in the SHAPE PH experiments. 
Since Gelfoam was previously used in canines with no reported side effects (162, 
163), is known for its hemostatic properties, is inexpensive and is readily available in a 
hospital or animal laboratory setting, it was used to induce low-flow PH.  The success 
rate in inducing PH was 91 %.  However, for chronic PH models the applicability of this 
Gelfoam PH model is limited, mainly due to recanalization (177).  Thus, the choice of the 
Gelfoam model is application specific.  Similarly, it is known that a hyperkinetic 
syndrome (due to initial increase in resistance to PV flow) ultimately results in increased 
PV flow and contributes to PH (75).  The A-V shunt model was used in the SHAPE PH 
study because physiologically the hyperkinetic syndrome and the resulting increase in PV 
flow volume may require considerable time (in weeks) for development after increasing 
resistance to PV flow.  The A-V shunt model used in this study simulated the high-flow 
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condition but did not contribute to rise in PV pressures until the flow from a saline 
infusion was supplemented.  This suggests that A-V shunt alone may not be sufficient to 
produce a high-flow PH model acutely.  This is consistent with findings of a previous 
study (178) which showed that modest distal vein hypertension may be expected due to 
an A-V shunt as the high pressure at the arterial end may be dissipated before affecting 
pressures in a distal vein. 
Overall the performance of both models (mainly the Gelfoam model) was 
acceptable to investigate the efficacy of SHAPE for identifying PH. 
 
4.3.2  Efficacy of SHAPE to Investigate PH (Study 1) 
4.3.2.1  Induced PH in Canines 
For the canines (14 canines) used in this study, the baseline mean PV pressure 
was 9.4 ± 2.1 mmHg (Table 4.16).  For one canine from the Gelfoam group (8 canines), 
technical difficulty associated with the pressure catheter impeded data acquisition and 
thus, the data from this canine were not included in the analyses.  From the remaining 7 
canines where PH was induced using Gelfoam, one canine did not respond to treatment 
(determined from the pressure catheter readings), thus post PH data was not acquired for 
this canine.  Post-PH data for the remaining 6 canines in the Gelfoam group are shown in 
Table 4.16.  From the group of 6 canines where PH was induced using A-V shunt, one 
canine did not respond to the treatment (no rise in PV pressures).  No PH data were 
acquired from this canine and thus, PV data from the remaining 5 canines are shown in 
Table 4.16.  As stated above, two canines (one from the Gelfoam group and one from the 
A-V shunt group) only provided baseline data.  Instead, data from these 2 dogs were 
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subsequently used to test the efficacy of the SHAPE technique in predicting PV pressures 
along with the cross-validation approach in other canines. 
 
 
Table 4.16:  PV pressures from canines used in PH Study 1 
 
Minimum 
Pressure 
(mmHg) 
Mean 
Pressure 
(mmHg) 
Maximum 
Pressure 
(mmHg) 
Baseline conditions (13 canines)
*
 5.6 9.4 ± 2.1 16.0 
Gelfoam induced PH (6 canines)
†
 9.3 26.9 ± 8.3 36.7 
A-V shunt induced PH (5 canines)
†
 8.8 19.1 ± 6.5 28.1 
*
For one canine technical difficulty associated with the pressure catheter impeded data 
acquisition; thus baseline data have been reported for 13 canines 
 
†
A single canine did not respond to treatment in each case resulting in data acquisition 
post portal hypertension (PH) from 6 canines in the Gelfoam group and 5 canines in the 
A-V shunt group 
 
 
4.3.2.2  Subharmonic Amplitude as a Function of Number of Transmit Cycles and IAO 
Levels 
Fig. 4.17 shows a boxplot of the subharmonic signal amplitudes (SHMIP) obtained 
from the PVs.  Note the relatively low subharmonic signal amplitude obtained with 2 
transmit cycles and with 10 % IAO.  A factorial repeated measures ANOVA used to 
compare the subharmonic signal amplitudes (both SHMIP and SHAll_Frames) obtained from 
the PV (for baseline conditions) based on number of transmit cycles and incident acoustic 
157 
 
output revealed a significant main effect of the number of transmit cycles (F(1.10, 14.27) 
= 130.66; p < 0.001) and of the IAOs (F(1.15, 14.90) = 325.88; p < 0.001).  There was 
also a significant interaction effect between the number of transmit cycles and the IAO 
levels F(1.35, 17.55) = 78.15 (p < 0.001), indicating that the IAO levels had different 
effects on the subharmonic amplitude depending on the number of transmit cycles.  Post 
hoc tests using Bonferroni adjustment for multiple comparisons showed that the 
subharmonic amplitude obtained with 2 transmit cycles was significantly less than the 
subharmonic amplitude with 3 (by 11.5 dB; 95 % Confidence Interval: 8.8 dB to 14.1 dB; 
p < 0.001) and with 4 (by 11.1 dB; 95 % Confidence Interval: 8.4 dB to 13.8 dB; p < 
0.001) transmit cycles.  However, there was no statistically significant difference between 
the subharmonic amplitudes obtained with 3 and 4 transmit cycles (p = 0.498).  Thus, 2 
transmit cycles may have lacked the ability to elicit a sufficient subharmonic response 
given the IAO levels considered in this study.  Post hoc tests, again using Bonferroni 
adjustment for multiple comparisons, also showed that the subharmonic amplitude 
obtained with 10 % IAO was significantly less than the subharmonic amplitudes obtained 
with 20 % (by 7.7 dB; 95 % Confidence Interval: 6.4 dB to 8.9 dB; p < 0.001) and 40 % 
(by 11.3 dB; 95 % Confidence Interval: 9.7 dB to 13.0 dB; p < 0.001) IAOs.  Hence, 10 
% IAO at 2, 3, and 4 transmit cycles may not have sufficient acoustic pressure amplitude 
to elicit a subharmonic response detectable by the 4C probe used in this study.  Fig. 4.18 
depicts subharmonic MIP images as a function of IAO levels and the number of transmit 
cycles obtained from one canine, before PH was induced.  As seen in Fig. 4.18, the 
subharmonic signal amplitude was relatively low for 2 transmit cycles (Fig. 4.18A-C), 
with 3 transmit cycles the subharmonic signal amplitude gradually increased with an 
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increase in IAO from 10 % to 40 % (Fig. 4.18D-F), then the subharmonic signal 
amplitude dropped for 10 % IAO and 4 transmit cycles (Fig. 4.18G), and finally the 
subharmonic signal amplitude increased for 20 % and 40 % IAO levels with 4 transmit 
cycles (Fig. 6H-I).  Based on similar observations with data from other canines and the 
statistical analyses, it was concluded that the subharmonic signal at 10 % IAO and with 2 
transmit cycles did not elicit the subharmonic signal in the growth-stage required for 
SHAPE application.  Thus, only data obtained with 20 % and 40 % IAO level with 3 and 
4 transmit cycles were considered for further analyses. 
 
 
 
Figure 4.17:  Boxplot of the subharmonic signal amplitudes obtained at 10 %, 20 % and 
40 % incident acoustic output (IAO) levels with 2, 3 and 4 transmit cycles.  Minor and 
major outliers are indicated with circles and asterisks, respectively.  Note, that the 
subharmonic signal amplitudes obtained with 10 % IAO and with 2 cycles are relatively 
low as compared to the amplitudes obtained with 20 % and 40 % IAO, for 3 and 4 
transmit cycles.  
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Figure 4.18:  MIP subharmonic images of the data obtained from ROI at 10 % (A, D, G), 
20 %, (B, E, H) and 40 % (C, F, I) IAO with 2 (A-C), 3 (D-F), and 4 (G-I) transmit 
cycles.  Note, that subharmonic signal amplitude increases with an increase in IAO 
levels; but is relatively low for 2 transmit cycles. 
 
 
4.3.2.3 Comparison of 3 and 4 Transmit Cycles for SHAPE Based PH Tracking 
Fig. 4.19 (3 cycle pulses) and Fig. 4.20 (4 cycles pulses) illustrate the relationship 
between the mean change in PV pressures (PH pressures – baseline PV pressures) and the 
mean change in the subharmonic signal amplitude (at PH state – at baseline conditions).  
Data obtained using the MIP image alone (SHMIP; panels A and B) and obtained as an 
average of subharmonic signals from all the frames (SHAll_Frames; panels C and D) at 20 % 
(panels A and C) and at 40 % (panels B and D) IAO levels are shown in Figs. 4.19 and 
4.20.  As depicted in Fig. 4.19, for both models of PH when 3 transmit cycles were used, 
there was a reasonably good correlation (ranging from -0.62 to -0.81, n = 6 for the 
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Gelfoam model and from -0.52 to -0.73, n = 5 for the A-V shunt model) between the 
change in subharmonic signal amplitude and change in PV pressures, with increased 
changes in PV pressures associated with increased changes in subharmonic signal.  
However, as shown in Fig. 4.20, when 4 transmit cycles were used, a relatively stronger 
correlation (ranging from -0.88 to -0.94, n = 6 for the Gelfoam model and from -0.82 to -
0.83, n = 5 for the A-V shunt model) was observed. 
 
 
 
Figure 4.19:  Mean changes in the PV pressures are plotted with mean changes in 
subharmonic signal amplitudes acquired with 3 transmit cycles along with the best-fit line 
and the correlation coefficient is indicated for both the Gelfoam and A-V shunt PH 
models.  (A) and (C) represent data acquired at 20 % IAO levels for subharmonic signal 
analyzed from the MIP image (SHMIP) and as the mean value from all the frames 
(SHAll_Frames), respectively.  (B) and (D) represent the corresponding data acquired at 40 
% IAO. 
  
161 
 
 
Figure 4.20:  Mean changes in the PV pressures are plotted with mean changes in 
subharmonic signal amplitudes acquired with 4 transmit cycles along with the best-fit line 
and the correlation coefficient is indicated for both the Gelfoam and A-V shunt PH 
models.  (A) and (C) represent data acquired at 20 % IAO levels for subharmonic signal 
analyzed from the MIP image (SHMIP) and as the mean value from all the frames 
(SHAll_Frames), respectively.  (B) and (D) represent the corresponding data acquired at 40 
% IAO. 
 
 
Table 4.17 presents the correlation coefficients observed with 3 and 4 transmit 
cycles at 20 % and 40 % IAO levels, when the data from both the PH models were 
combined (as a more robust indicator of SHAPE‟s performance).  As seen in Table 4.17, 
significant and higher correlation coefficients were observed for 4 transmit cycles (p-
values ranging from 0.01 to 0.02) as compared to 3 transmit cycles (p-values ranging 
from 0.07 to 0.1).  This suggests that the use of 4 transmit cycles is preferred over 3 
transmit cycles for SHAPE applications.  (And based on these results Hypothesis 5, that 
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was formulated to determine if significant correlations between changes in PV pressures 
and the subharmonic amplitude existed, was accepted). 
 
 
Table 4.17:  Pearson‟s correlation coefficient (r) between the change in subharmonic 
signal and change in PV pressures.  Data from the Gelfoam and A-V shunt models were 
combined (n = 11). 
 
 
4.3.2.4  Comparison of 20 % and 40 % IAO Levels with 4 Transmit Cycles for SHAPE 
Based PH Tracking 
There was no statistically significant difference (p > 0.4) between the correlation 
coefficients obtained with 20 % and 40 % IAO levels for 4 transmit cycles (cf. Table 
4.17).  This suggests that at both these IAO levels the subharmonic emissions may be in 
the growth-phase and thus sensitive to ambient PV pressure changes.  Additionally there 
was a strong significant correlation between the mean values of absolute subharmonic 
amplitudes and mean values of absolute PV pressures as documented in Table 4.18 and 
Fig. 4.21.  This confirms that at both 20 % and 40 % IAO levels the subharmonic signal 
Transmit Cycles IAO (%)  From SHMIP  From SHAll_Frames 
   r p-value  r p-value 
3 20  -0.53 0.094  -0.54 0.090 
3 40  -0.56 0.071  -0.52 0.103 
4 20  -0.72 0.013  -0.70 0.017 
4 40  -0.70 0.016  -0.73 0.011 
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was in the ambient pressure sensitive phase.  This result was consistent with evaluation of 
subharmonic MIP images (cf. Fig. 4.18).  As shown in Fig. 4.21A, the subharmonic 
signal amplitudes extracted from ROIPV of all the frames (SHAll_Frames) were lower than 
the subharmonic signal amplitudes extracted from the MIP image (SHMIP) (mostly due to 
some Sonazoid concentration fluctuations likely to happen in vivo).  The gradients of the 
best-fit lines representing the sensitivity of Sonazoid microbubbles to ambient PV 
pressures ranged from -1.44 mmHg/dB to -1.69 mmHg/dB (Figs. 4.21A and 4.21C).  
Interestingly, the gradients for 20 % (Fig. 4.21A) and 40 % (Fig. 4.21C) IAOs were 
nearly independent of the technique used in analyzing the extracted subharmonic signals 
(either SHMIP or SHAll_Frames).  Also the gradient was lower for 20 % IAO as compared to 
40 % IAO, indicating that the ambient pressure sensitivity was relatively more at 20 % 
IAO, with saturation most likely to occur above 40 % IAO.  Figs. 4.21B and 4.21D show 
boxplots of subharmonic signals obtained before and after inducing PH, at 20 % and 40 
% IAO levels with 4 transmit cycles, respectively.  Note, that at baseline conditions (pre-
PH) the spread in the subharmonic amplitudes is much less than the spread after PH 
(Figs. 4.21B and 4.21D), primarily because the PV pressures after induced PH also varied 
considerably between canines (see Table 4.16).  A paired t-test comparing these 
subharmonic amplitudes revealed that there was a statistically significant difference 
between the subharmonic signal amplitudes obtained under baseline and under PH 
conditions at 20 % and 40 % IAOs (Table 4.19).  Thus, subharmonic signal amplitudes 
may predict the PV pressures.  (Based on this result Hypothesis 4, that investigated if the 
SHAPE results would be able to identify induce PH, was accepted). 
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Table 4.18:  Pearson‟s correlation coefficient (r) between absolute subharmonic signal 
amplitudes and absolute PV pressures when data from the Gelfoam and A-V shunt 
models were combined for 4 transmit cycles (n = 22). 
 
 
 
Figure 4.21:  Absolute PV pressures are plotted with absolute subharmonic signal 
amplitudes acquired with 4 transmit cycles (note, these are mean values obtained from 
each canine).  (A-B) and (C-D) represent data acquired at 20 % and 40 % IAO levels, 
respectively.  The subharmonic amplitudes obtained from SHMIP and from SHAll_Frames)are 
shown separately in each panel.  The best-fit line along with its gradient is indicated in 
(A) and (C).  Boxplots in (B) and (D) indicate the interquartile range (vertical span of the 
box), the median value (horizontal line within the box), the range (whiskers) and minor 
outliers (circles) for the subharmonic signal amplitudes.  Note that the SHAll_Frames is 
relatively less than the SHMIP (as expected).  
IAO (%)  From SHMIP  From SHAll_Frames 
  r p-value  r p-value 
20  -0.74 < 0.001  -0.71 < 0.001 
40  -0.79 < 0.001  -0.73 < 0.001 
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Table 4.19:  Paired t-test results when comparing subharmonic signal amplitudes 
obtained at baseline and PH conditions, with 4 transmit cycles (n = 11) 
 
 
In order to test the viability of using subharmonic signal amplitudes to predict PV 
pressures, the subharmonic signal amplitudes obtained in 2 canines, where data were only 
obtained under baseline conditions were first analyzed.  The subharmonic signal 
amplitudes were combined with the equation of the best fit line (shown in Figs. 4.21A 
and 4.21C) to predict the baseline PV pressures; the values were compared to the catheter 
pressures.  These results are presented in Table 4.20 which demonstrate that the 
subharmonic signals analyzed from all the frames (SHAll_Frames) have relatively less error 
(error range: 0.2 to 1.9 mmHg) as compared to subharmonic signals analyzed only from 
the MIP image (SHMIP; error range: 1.8 to 6.9 mmHg) in predicting PV pressures.  This 
suggests that the subharmonic signal amplitude analyzed from all the frames (SHAll_Frames) 
is a more robust indicator (in comparison to SHMIP) of PV pressures and should be the 
most appropriate means to predict PV pressures; albeit based on analyses in 2 canines. 
IAO (%)  From SHMIP  From SHAll_Frames 
 Mean 
Difference 
(dB) 
95 % 
Confidence 
Interval of 
Difference 
(dB) 
p-
value 
 Mean 
Difference 
(dB) 
95 % 
Confidence 
Interval of 
Difference 
(dB) 
p-
value 
20  5.0 2.1-7.8 0.003  4.7 2.0-7.4 0.003 
40  4.6 2.0-7.2 0.003  4.4 1.3-7.4 0.01 
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Table 4.20:  Predicting PV pressures and comparing with true pressures (true pressures 
were obtained with the Millar catheter) 
 
 
Next, the results of the cross-validation study are summarized in Table 4.21 for 
the baseline and PH data compared together and also, independently.  None of the 
differences between the pressures obtained using the catheter, and using the cross-
validation approach and the SHAPE data were statistically significant (p > 0.05; Table 
4.21).  Finally, the results of the binary classification and the resulting sensitivity, 
specificity and accuracy of predicting PH are presented in Table 4.22. 
  
IAO (%) 
 From SHMIP  From SHAll_Frames 
 
Calculated 
Pressure 
(mmHg) 
True Pressure 
(mmHg) 
 
Calculated 
Pressure 
(mmHg) 
True Pressure 
(mmHg) 
Canine 1 
20  10.1 8.0  8.2 8.0 
40  9.8 8.0  8.5 8.0 
Canine 2 
20  2.6 7.8  9.7 7.8 
40  0.9 7.8  9.0 7.8 
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Table 4.21:  Comparing errors between manometer pressures and SHAPE results using 
cross-validation approach 
 
  
IAO (%)  From SHMIP 
SHAPE vs. catheter pressures 
 From SHAll_Frames 
SHAPE vs. catheter pressures 
 Mean 
Difference 
(mmHg) 
95 % 
Confidence 
Interval of 
Difference 
(mmHg) 
p-
value 
 Mean 
Difference 
(mmHg) 
95 % 
Confidence 
Interval of 
Difference 
(mmHg) 
p-
value 
a) For all data 
20  0.0 -3.0 to 3.0 0.982  -0.1 -3.4 to 3.1 0.924 
40  0.1 -2.7 to 2.9 0.951  -0.1 -3.3 to 3.1 0.952 
b) For baseline data only (before PH) 
20  3.5 -0.1 to 7.0 0.053  3.5 -0.9 to 7.9 0.110 
40  3.2 -0.3 to 6.8 0.070  3.6 -0.9 to 8.2 0.103 
c) For PH data only 
20  -3.5 -8.0 to 0.9 0.109  -3.8 -8.0 to 0.4 0.072 
40  -3.1 -7.0 to 0.9 0.113  -3.8 -7.9 to 0.2 0.062 
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Table 4.22:  Sensitivity, specificity and accuracy for detecting moderate through severe 
PH.  A cut-off threshold for PV pressures of 16 mmHg (13 instances with PV pressures 
below 16 mmHg and 9 instances with PV pressures above 16 mmHg). 
 
 
4.3.2.5  Discussion based on PH Study 1 
The goal of this study was to analyze if subharmonic emissions from Sonazoid 
microbubbles (i.e., SHAPE) were useful in predicting PV pressures in canines.  Results 
showed that SHAPE performance in tracking PH was best with 4 transmit cycles for 20 
% and 40 % IAO levels; the changes in PV pressures correlated with the changes in the 
subharmonic signal amplitudes for both cases, when the two PH models were evaluated 
separately (r ranging from -0.82 to -0.94; Fig. 4.20) and when evaluated together (r 
ranging from -0.70 to -0.73; Table 4.17).  The subharmonic signal amplitude decreased 
with an increase in ambient pressure, which is consistent with previously published 
reports (e.g.,  (3)) and with previous results obtained in this work.  Based on this result, 
the relationship between the absolute PV pressures and absolute subharmonic signal 
amplitudes were evaluated for data combined from both PH models and obtained with 4 
transmit cycles.  The correlation coefficient in this case ranged from -0.71 to -0.79 (Table 
4.18) and a statistically significant difference was seen between the subharmonic signal 
IAO 
(%) 
 With SHAPE using SHMIP  With SHAPE using SHAll_Frames 
 Sensitivity 
(%) 
Specificity  
(%) 
Accuracy 
(%) 
 Sensitivity 
(%) 
Specificity 
(%)  
Accuracy 
(%) 
20  67 69 68  78 69 73 
40  78 85 82  78 77 77 
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amplitudes obtained before and after inducing PH (Table 4.19).  Finally, the relationship 
between absolute subharmonic signal amplitudes and PV pressures were used to track PV 
pressures in 2 other canines.  The errors were lower when the SHAll_Frames were used as 
against the use of SHMIP (0.2 to 1.9 mmHg vs. 1.8 to 6.9 mmHg) for 2 canines (Table 
4.20); similar to the errors reported in the cardiac SHAPE study conducted in canines 
(range: 0.0 to 3.5 mmHg; (179, 180)).  Results from the cross-validation study indicate 
that the robustness of approximating the PV pressures using SHAPE (Table 4.21).  The 
sensitivity, specificity and accuracy values for identifying clinically relevant PH (in 
canines) ranged from 67 to 85 % (Table 4.22).  Thus, PV pressure monitoring using 
SHAPE appears to be feasible for testing clinical applications. 
A major limitation of this study involves the use of fixed IAO levels (10 %, 20 % 
and 40 %) for eliciting subharmonic emissions for SHAPE.  This is reflected in the values 
presented in Table 4.22.  For clinical applications, the optimization of IAO will be 
required on a case-by-case basis depending on body habitus, PV location and 
visualization, and other practical factors.  Specifically, in a variable clinical population 
differences due to the attenuation, reverberation and aberration in the abdominal wall 
may make the promising results obtained in canines difficult to reproduce or the results 
could be better with the optimal IAO levels.  However, these results do warrant a 
preliminary investigation in a clinical population to evaluate the usefulness of SHAPE in 
identifying PH. 
A real-time display of the subharmonic signal amplitude as a function of IAO will 
allow the selection of optimum IAO levels (eliciting subharmonic emissions in the 
growth stage) for clinical SHAPE applications as well as future animal investigations – 
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this was the purpose for implementing incident acoustic output optimization program (as 
discussed in section 3.2.3.6) for which the results are presented in section 4.3.3.  Further, 
the inability to operate in grayscale imaging mode during RF data acquisition may be 
addressed by the use of newly available dual and simultaneous B-mode and subharmonic 
imaging mode ((130, 181)). 
For the purpose of subharmonic imaging, it was shown that relatively low 
threshold values (0.02 - 0.15 MPa; ≤ levels corresponding to 10 % incident acoustic 
output considered in this study) are required to elicit subharmonic emissions from 
microbubbles closest to their buckling state (137).  This buckling state is characterized by 
zero (minimal) initial surface tension and, thus, specific bubbles engineered with zero 
initial surface tension may be useful to extract this relationship for subharmonic imaging 
(137).  Alternately, a different approach was proposed in another study where low 
ambient pressure modulations in the microbubbles‟ vicinity may be established, that 
possibly drive the microbubbles to their buckling state by altering the surface tension 
values and consequently lead to emission of a relatively higher subharmonic signal at 
relatively lower IAO (141).  These studies indicate that the subharmonic emissions may 
be tailored for subharmonic imaging, but in vivo applications were not implemented (137, 
141).  Besides, in the study presented here the subharmonic emissions at 10 % IAO were 
too low to be separated from the ambient noise level. Thus, the in vivo application of 
using even lower IAO values to elicit a stronger subharmonic signal in vivo remains 
technically challenging. 
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4.3.3  Efficacy of SHAPE to Investigate PH (Study 2) 
4.3.3.1  Induced PH in Canines 
The baseline PV pressures were 11.9 ± 3.9 mmHg.  For one canine, the surgical 
procedure to induce PH resulted in acute embolization and thus, data from this canine 
were not considered in the analyses.  For the remaining 4 canines there was a statistically 
significant difference of 15.93 ± 6.15 mmHg between the PV pressures before and after 
inducing PH (95 % Confidence Interval: 6.15 to 25.71 mmHg; p = 0.014; Table 4.23). 
 
 
Table 4.23:  PV pressures from canines used in PH Study 2 
 
Minimum 
Pressure 
(mmHg) 
Mean 
Pressure 
(mmHg) 
Maximum 
Pressure 
(mmHg) 
Baseline conditions 8.4 11.9 ± 3.9 15.8 
Induced PH 17.2 27.8 ± 7.1 32.2 
 
 
4.3.3.2  Analyses of IAO Optimization Function 
Fig. 4.22 represents the output of the IAO optimization function.  The optimum 
IAO selected for the case shown in Fig. 3.19 was 20 % (0.56 MPa peak to peak) (Fig. 
4.22).  Fig. 4.23 illustrates the subharmonic ROI signal at 5 % (0.18 MPa peak to peak; 
beginning of the growth phase; Fig. 4.23A), 20 % (0.56 MPa peak to peak; at the center 
of the growth phase; Fig. 4.23B), 60 % (1.19 MPa peak to peak; the end of the growth 
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phase; Fig. 4.23C) and 100 % (3.34 MPa peak to peak; saturation of the subharmonic 
signal; Fig. 4.23D) IAO levels.  The occurrence, growth and saturation phases were also 
seen in the output obtained from the IAO optimization program for the other canines and 
the optimum IAO levels computed by the automatic IAO optimization were 6 %, 28 %, 
40 % and 32 % (range: 0.2 to 0.9 MPa), respectively. 
 
 
 
Figure 4.22:  Output of the IAO optimization function.  The abscissa corresponds to log 
transformation of the IAO indicated on the scanner in percentage.  The fitting function 
compensates for motion artifacts during IAO optimization, mostly observed due to 
respiration.  The optimum IAO was calculated as the IAO level with the maximum slope.  
In this case, the optimum IAO (arrow) was 20 % which corresponds to 1.30 on the 
abscissa.  
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Figure 4.23:  Representation of the subharmonic signal at varying IAO levels (green 
arrows) used in the optimization function.  (A) At 5 % IAO level the subharmonic signal 
begins to appear and resides at the beginning of the growth phase.  (B) At 20 % IAO 
level the subharmonic signal resides in the linear portion of growth phase (ambient 
pressure sensitive phase).  (C) At 60 % IAO level the subharmonic saturation begins, 
possible with the occurrence of bubble destruction.  (D) At 100 % IAO level the 
subharmonic signal is not that different from (C) indicating saturation. 
 
 
4.3.3.3  SHAPE’s Performance for PV pressures and PH Tracking 
The correlation coefficient relating the change in PV pressures to the change in 
subharmonic signal amplitude, before and after inducing PH, and the absolute values of 
PV pressures and subharmonic signal amplitudes are presented in Table 4.24.  For 2 
canines the subharmonic data were not acquired in the post PH stage at IAO levels that 
were higher than the optimized IAO levels due to timing constraints. 
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Table 4.24:  Pearson‟s correlation coefficient between subharmonic signals and PV 
pressures.  Correlation coefficient relating change in subharmonic signal amplitude to 
change in PV pressures (rchange) and relating absolute subharmonic signal amplitude to 
absolute PV pressures (rabsolute) are presented. 
 
IAO Level  Number of 
transmit cycles 
 
Correlation coefficient 
   n rchange p-value  n rabsolute p-value 
Optimized 4  4 -.76 0.24  8 -.89 < 0.01 
 8  4 .30 0.70  8 -.54 0.16 
 16  4 .10 0.90  8 -.59 0.12 
Below optimized 4  4 .04 0.95  8 -.72 0.04 
 8  4 .15 0.85  8 -.29 0.49 
 16  4 .31 0.69  8 -.65 0.08 
Above optimized 4  2 N/A
*
 N/A
*
  4 -.73 0.27 
 8  2 N/A
*
 N/A
*
  4 -.61 0.39 
 16  2 N/A
*
 N/A
*
  4 -.18 0.82 
*
N/A:  not applicable as the number of data points was insufficient, because data from 2 
canines were not acquired at higher acoustic IAO level 
 
 
Fig. 4.24A-C represent the data obtained with 4, 8 and 16 transmit cycles at the 
optimized IAO level.  The best correlation (r = -0.76) for changes in PV pressures and the 
subharmonic signal amplitude was obtained at the optimized IAO level with 4 transmit 
cycles (Table 4.24 and Fig. 4.24A-C).  These results imply that the optimized IAO level 
selected by the IAO optimization algorithm worked and 4 transmit cycles (out of 2, 3, 4, 
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8, and 16 transmit cycles; 2 and 3 transmit cycles were compared to 4 transmit cycles in 
sections 4.3.2.2 and 4.3.2.3) is best suited for SHAPE application.  Also the data acquired 
with optimized IAO and 4 transmit cycles shows that the increases in PV pressures were 
associated with a greater reduction in subharmonic signal amplitude consistent with 
previously published reports (e.g., (3)) and other results presented in thesis. 
 
 
 
Figure 4.24:  (A), (B) and (C) depict the relationship between change in PV pressures 
and change in subharmonic signal amplitude at optimized IAO levels with 4, 8 and 16 
transmit cycles – the best fit line is shown (dashed) with correlation coefficient.  Note the 
best correlation was obtained with 4 transmit cycles and optimized IAO level (A).  (D) 
The relationship between absolute PV pressures and subharmonic signal amplitude is 
shown with the best fit line (dashed) and the correlation coefficient is indicated. 
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For other combinations of transmit parameters the correlations between changes 
in subharmonic signal amplitude and changes in PV pressures were low i.e., ranged from 
0.04 to 0.31 (Table 4.24).  Table 4.24 also presents the correlation coefficient between 
absolute values of the subharmonic signal amplitudes and PV pressures.  Again, the best 
and significant correlation coefficient (r = -0.89, p < 0.01) was obtained when the 
subharmonic signals were acquired with optimized IAO level and 4 transmit cycles (Fig. 
6D). (Based on this result Hypothesis 6, that evaluated if the SHAPE data correlated with 
catheter pressures, was accepted.) For the other sets of transmit parameters, the absolute 
correlation between subharmonic signal amplitudes and PV pressures ranged from -0.18 
to -0.65, with the exception of 4 transmit cycles where correlations of -0.72 and -0.73 at 
IAO below and above the optimized IAO were observed, respectively (Table 4.24).  
These correlation coefficients of -0.72 and -0.73 may stem from the fact that the 
subharmonic signals were in the growth phase of subharmonic emissions even above and 
below the optimum IAO; but these correlations were still less than -0.89 observed at 
optimum IAO and were not statistically significant.  Also the correlation of -0.73 was 
obtained with 4 data points only.  The results obtained here also agree with results 
obtained previously where the sensitivity of Sonazoid microbubbles to ambient pressures 
was maintained throughout the growth phase of subharmonic emissions, but peaked at 
optimum insonification (144).  The decrease in axial resolution and/or using relatively 
longer duration pulses by using higher transmit cycles (8 and 16) may have resulted in 
the relatively lower observed correlation coefficient for the changes in PV pressures and 
subharmonic signal amplitudes, and the absolute PV pressures and subharmonic signal 
amplitudes with 8 and 16 transmit cycle pulses. 
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The data in Table 4.25 represent the results of paired comparisons for 
subharmonic signal amplitudes before and after inducing PH.  A statistically significant 
difference between subharmonic signal amplitudes, before and after inducing PH, was 
only noted for data acquired with 4 transmit cycles and at optimized IAO level.  Thus, 
based on data presented in Tables 4.24 and 4.25, and Fig. 4.24, the hypothesis that 
SHAPE‟s performance would be best at optimum IAO level identified by the IAO 
optimization program and at 4 transmit cycles was accepted.  These results further 
demonstrate the need to optimize IAO levels for SHAPE applications. 
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Table 4.25:  Paired t-test results when comparing subharmonic signal amplitudes 
obtained at baseline and PH conditions 
 
IAO level Number of 
transmit cycles 
 Results of paired differences test 
  n Mean Difference 
(dB) 
95 % 
Confidence 
Interval (dB) 
p-
value 
    Lower Upper  
Optimized 4  4 -8.35 ± 2.45 -12.26 -4.44 < 0.01 
 8  4 -3.99 ± 6.19 -13.85 5.86 0.29 
 16  4 -3.61 ± 4.48 -10.74 3.51 0.21 
Below 
optimized 
4  4 -4.51 ± 3.81 -10.57 -1.55 0.10 
8  4 -1.67 ± 6.01 -11.23 7.89 0.62 
16  4 -5.02 ± 4.42 -12.04 -2.01 0.11 
Above 
optimized 
4  2
*
 -7.57 ± 5.57 N/A
†
 N/A
†
 0.31 
8  2
*
 -6.85 ± 7.12 N/A
†
 N/A
†
 0.40 
16  2
*
 -2.52 ± 5.01 N/A
†
 N/A
†
 0.61 
*
Should be interpreted with caution as data from 2 canines at higher IAO level were not 
acquired due to timing constraints (data provided here for reference); 
†
N/A:  not applicable  
179 
 
4.3.3.4  Discussion based on PH Study 2 
As seen in Fig. 4.22, the subharmonic signal documents a sigmoidal relationship 
with IAO as documented previously (3, 114, 133, 144); the initial occurrence stage, the 
growth stage and the gradual saturation at acoustic output above 60 % (1.19 MPa) are 
seen.  The fitting function shown in Fig. 4.22 compensates for motion artifacts, mainly 
due to respiration, during the data collection phase for determining the optimum IAO 
levels. 
This study builds on previous in vitro and in vivo SHAPE applications (3, 133, 
144, 167, 179, 180, 182) and solves the problem of determining optimum IAO levels to 
insonate the UCAs for SHAPE applications; the feasibility and reliability of this approach 
to track PV pressures was demonstrated.  A small sample size used in this study remains 
a limitation along with the acute embolization that was developed in one out of the five 
canines due to the surgical procedure for introducing the pressure catheter in the PV.  
Since ultrasound scanning and data acquisition were performed by placing the transducer 
through the open abdominal cavity created to gain access to the PV, the backscattered 
signals had less attenuation relative to an intact abdomen – this difference in attenuation 
varies on a case by case basis depending on inter-subject variability. 
 
4.3.4  Discussion Based on PH SHAPE Studies 
For PH evaluation using SHAPE, 2 different studies were performed.  In PH 
Study 1, the efficacy of SHAPE to detect PV pressure rises was studied.  Since, the 
results of PH Study 1 were promising with respect to the utility of the SHAPE technique 
to identify PH, in PH Study 2 the goal was to develop a technique to identify optimum 
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IAO for SHAPE.  This is an important step because the attenuation in clinical cases will 
vary on a case-by-case basis; without this IAO optimization algorithm the IAO level may 
have to be selected arbitrarily or data at all IAO levels may have to be captured – this last 
possibility is computationally expensive and more importantly limits real-time capability. 
Similar to the Sonix RP scanner used for cardiac studies, the Logiq 9 scanner used 
in PH studies also showed discreet IAO levels.  Thus, if the „most-sensitive‟ IAO level 
for SHAPE falls between two consecutive discrete levels, then SHAPE‟s performance 
may not be optimum.  Another practical problem before translating this technique into 
clinical applications arises from the fact that the subharmonic response depends on both 
the insonification IAO levels and ambient pressures.  By displaying in real-time the 
subharmonic emissions as a function of acoustic pressure, the optimal IAO level can be 
identified.  However, the associated subharmonic amplitude is still arbitrary due to 
variable attenuation and unknown ambient pressure.  In other words, the same 
subharmonic amplitude measured in different subjects at an optimal IAO level (eliciting 
ambient pressure sensitive subharmonic emissions) may correspond to different ambient 
pressures.  One approach to circumvent this problem may require obtaining the 
subharmonic gradient between the PV and the hepatic vein, which is analogous to the 
HVPG measurements used clinically (183, 184). 
Another factor in the PH studies was the mid-line abdominal incision created for 
accessing the main PV to obtain reference PV pressures; but absolute PV pressures 
cannot be obtained by another approach i.e., without accessing the PV. 
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4.3.5  Summary Based on PH SHAPE Studies 
In conclusion, two acute PH models were developed.  A low-flow PH model 
using Gelfoam was repeatable and successful in increasing PV pressures within 15 
minutes by 16.5 mmHg on average.  A high-flow PH model using A-V shunt (between 
the femoral artery and the PV vein) was not successful in increasing PV pressures.  
However, if the flow from the femoral artery was supplemented by additional saline 
infusion, mean increases in PV pressures of 12.8 mmHg were noted. 
The efficacy of SHAPE to determine PV pressures and monitor changes in PV 
pressures in the canine PH models considered here has been proven.  For “optimum” 
insonification, the changes in subharmonic signal amplitude correlated significantly (p < 
0.05) with changes in PV pressures; correlation coefficient ranged from -0.82 to -0.94 
and from -0.70 to -0.73 for PH models considered separately or together, respectively  
Thus, Hypothesis 5 was accepted.  The subharmonic signal amplitudes correlated with 
absolute PV pressures (r: -0.71 to -0.79). 
There was a statistically significant difference between subharmonic amplitudes 
before and after inducing PH (p ≤ 0.01).  PV pressures estimated using SHAPE did not 
reveal significant differences (p > 0.05) with respect to the pressures obtained using the 
Millar pressure catheter.  Thus, Hypothesis 4 was accepted. 
A novel automated IAO optimization program was developed to determine 
optimum IAO levels to insonate the UCAs for SHAPE applications.  The approach was 
validated to track PV pressures in canines using SHAPE.  The results demonstrated that 
SHAPE functions best when 4 transmit cycles were used to insonate the UCAs at the 
optimum IAO determined by the IAO optimization program.  SHAPE performance was 
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sub-optimal when IAO levels below- or above- the optimum IAO levels were used.  
Thus, the need to identify the optimum IAO level for SHAPE applications stands 
justified.  Also, the correlation coefficient between subharmonic amplitude (SHAPE data) 
and the PV pressures before and after inducing PH was -0.89 (i.e., an r
2 
= 0.79).  Thus 
Hypothesis 6 was accepted. 
Above all, the current standard of direct hepatic venous catheterization should be 
substituted by a noninvasive, accurate and reliable method to estimate HVPG or PV 
pressures (15).  Such a method would allow screening, diagnosis, monitoring and 
prognosis of chronic liver diseases or cirrhosis and would limit the number of 
endoscopies performed (especially for screening populations or patients without clinical 
signs of PH).  The work presented here documents that the SHAPE technique may be 
used to track PV pressures and thus, may be useful as a screening tool for PV pressure 
monitoring.  In the future, SHAPE may be a viable clinical tool for measuring PV 
pressures and monitoring treatment in symptomatic or critically ill cirrhotic patients, and 
identifying nascent PH in asymptomatic patients as well. 
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4.4  General Discussion Based on SHAPE Studies 
4.4.1  Cross Platform Compatibility 
In this thesis Sonazoid, which is not yet approved for human use by the USA 
FDA was selected as the UCA for ambient pressure estimation in vitro and in vivo.  
However, another preliminary study showed that subharmonic emissions from Definity 
(clinically approved to opacify the left ventricle for improved delineation of the left 
ventricular endocardial border) may also be used for in vivo pressure estimation (185); 
thus the SHAPE technique is not solely limited to the use of Sonazoid.  Also, the fact that 
SHAPE technique worked with scanners from two different manufacturers confirms the 
reliability of pressure estimation using SHAPE and that the workings of SHAPE are not 
specific to a given combination of UCA and any particular ultrasound scanner. 
 
4.4.2  Specific Aims and Hypotheses 
All specific aims were accomplished.  All hypotheses were accepted except 
Hypothesis 3 which was framed to investigate if “the SHAPE results in the LV and RV 
will be in agreement with catheter pressures and show a maximum error of less than 10 
%”.  The SHAPE results in the LV and RV were in agreement with the catheter pressures 
– this was confirmed because the clinically relevant LV and RV pressures did not differ 
significantly with respect to the values recorded by the pressure catheter which was the 
reference standard.  However, the percent error overall was as high as 28 %, but this 28 
% corresponds to an absolute pressure error of 1.8 mmHg.  This suggests that the percent 
criteria may not have been an appropriate choice to frame the hypothesis, incipiently.  
But the errors obtained with SHAPE in the LV and RV were all within 3.5 mmHg after 
184 
 
using a calibration factor (mmHg/dB) from the aorta data – i.e., the errors were within the 
5 mmHg error criteria recommended for noninvasive blood pressure measurement 
techniques (22).  This suggests that SHAPE technique may now be evaluated in a clinical 
setting – at least in a pilot study. 
4.4.3  Sensitivity of Sonazoid and other UCAs for SHAPE 
The table below (Table 4.26) lists the sensitivity of Sonazoid microbubbles to 
changes in ambient pressure expressed as mmHg/dB based on literature and the results 
presented in this thesis. 
 
Table 4.26:  Sensitivity of Sonazoid to ambient pressure changes 
*
Sensitivity  
 in mmHg/dB 
Experiment Description 
-6.6 (135) Simulation studies 
-14.0 (144) Static tank experiments with single element transducers 
-10.6 to -10.9 
(167, 182) 
In vitro flow phantom studies with a commercial ultrasound scanner
†
 
-4.4 (23) In vivo (from aorta) with single element transducers 
-4.9 (180) In vivo (cardiac LV studies) with a commercial ultrasound scanner
†
 
-2.0 to-4.0 (179) In vivo (cardiac RV studies) with a commercial ultrasound scanner
†
 
-1.4 to -1.7 In vivo PH studies with a commercial ultrasound scanner
‡
 
*
References are indicated in brackets where applicable; 
†
Sonix RP scanner; 
‡
Logiq 9 
scanner  
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A general trend appears from Table 4.26.  The studies report a decrease in 
subharmonic signal amplitude with an increase in ambient pressure (marked by a 
negative sign).  The simulation studies that were done at about the same transmit 
frequency (2.46 MHz) to the one used in this study (2.5 MHz), suggests that the behavior 
of the Sonazoid microbubbles in vitro and in vivo may not have been adequately captured 
in those simulation studies.  In vitro sensitivity values were much less (indicating that the 
change in subharmonic signal was relatively less) than in vivo sensitivity values.  A 
possible explanation for this may be the constantly changing environment that the 
microbubbles were exposed to in vivo as compared to in vitro – the interactions with 
other blood constituents may influence the bubble towards nonlinear oscillatory mode 
which is required for subharmonic emissions.  When examining the subset of in vivo 
experiments, the variability in sensitivity may be due to a combination of features, 
including, but not limited to, differences in the transfer function of the input/output 
systems on the scanner, the difference between the experimental setup i.e., PH studies 
were performed with an open abdominal cavity (relatively less attenuation as compared 
to an intact abdomen or the cardiac SHAPE studies), etc. 
In contrast to these findings, studies with phospholipid-shell microbubbles 
engineered with optimized initial surface tension have reported a sensitivity of 2.12 
mmHg/dB (137).  Also, in the studies mentioned in Table 4.26, the IAO level was chosen 
with maximum probability of the subharmonic emissions to reside in the growth phase 
(out of occurrence phase, growth phase and saturation phase) where the subharmonic 
emissions show a dependency on ambient pressures.  In two separate in vitro studies 
(137, 140) using in-house manufactured microbubbles and also SonoVue, it was shown 
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that subharmonic emissions may be characterized by five stages, namely, occurrence, 
growth, stabilization, regrowth and saturation.  Comparing the IAO levels considered in 
the studies in this thesis with the levels used in vitro (137, 140), it may be surmised that 
the subharmonic emissions in this study may correspond to the regrowth phase.  
However, major differences exist between these two referenced studies and the studies in 
this thesis.  The microbubbles used here were different (Sonazoid) and the cardiac and 
PH SHAPE studies were conducted in vivo, whereas the two other studies (137, 140) 
were based on behavior of the microbubbles in vitro where an idealized setup permits 
known peak negative acoustic pressures on the microbubbles and control over ambient 
pressures.  In vivo, conditions depart markedly from this idealized in vitro setup; in the 
cardiac and PH studies only ambient noise was observed at IAO levels corresponding to 
the occurrence stage in Ref. (3), whereas a reasonable subharmonic at IAO levels 
corresponding to the growth stage in Ref. (3).  Also, explicit analysis with Sonazoid 
microbubbles (which were used in this study) in vitro using a test setup mentioned 
elsewhere (144) revealed only the occurrence, growth and saturation phases as described 
previously (3).  This may indicate that the 5 stages of subharmonic emissions may be a 
characteristic of the in-house manufactured microbubbles (as in (137)), or of SonoVue 
microbubbles which are different in composition with respect to Sonazoid microbubbles 
used in this study – also there have been no observations (to the best of our knowledge) 
reported on these 5 stages of subharmonic emissions from microbubbles in vivo, whereas 
implications of the 3 stages of subharmonic emissions have been seen and utilized for in 
vivo ambient pressure estimation here. 
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4.4.4  Algorithm for Future SHAPE Applications 
Towards the work put forward for this thesis, an approach to use SHAPE for 
pressure estimation was developed in vitro and then tested in vivo under two different 
conditions – cardiac SHAPE studies involving dynamic pressure variations and PH 
SHAPE studies involving static pressures (less amplitude of pressure excursions as 
compared to those encountered in the LV or the RV).  A technique to identify optimum 
IAO level for SHAPE was validated. 
In Fig. 4.25, based on the results and discussions of the SHAPE studies, an “on-
demand” approach is proposed to identify the optimum IAO level for SHAPE based on 
the application – pressures that do not oscillate rapidly (like those encountered in the PV) 
or pressures that do oscillate rapidly (like those encountered in the heart). 
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5.  CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
5.1  Conclusions and Contributions to Science 
The overall goal of this thesis was to develop and evaluate the efficacy of SHAPE 
for investigating in vivo pressures noninvasively.  The immediate clinical applications of 
noninvasive pressure estimation were recognized in monitoring central cardiac pressures 
and pressures in blood vessels feeding vital organs like liver, etc. where invasive pressure 
measurements are the clinical standard (4, 5).  Consequently the in vivo efficacy of 
SHAPE to evaluate pressures noninvasively in the heart and in the PV (to investigate PH) 
was to be determined.  All prior studies (before the start of this thesis work) were mostly 
performed in vitro and/or with idealized equipment setup; too remote from the situations 
encountered clinically.  This led to the entire project being divided into 3 specific aims. 
In specific aim 1, the ability of SHAPE to estimate dynamic pressures including a 
circulating flow component through a flow-phantom was investigated.  Also, an attempt 
to compare different processing techniques to process the received UCA signals was 
undertaken.  These experiments were performed using a commercially available 
ultrasound scanner and UCA to readily adopt the technique for in vivo evaluations.  A 
signal processing technique was developed and the results showed that the standard error 
between catheter pressures (used as reference pressures) and SHAPE results were below 
10 mmHg – this estimate with commercially available equipment was better than other 
reported techniques of measuring ambient pressures using UCAs that showed errors 
above 10 mmHg (even with idealized in vitro setup, e.g., isolating single bubble, etc.) 
(17-21).  The results of this work were published (167, 182). 
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In specific aim 2, the feasibility of noninvasive SHAPE was investigated and then 
the accuracy of SHAPE in obtaining clinically relevant LV and RV pressures was 
studied.  The feasibility of noninvasive SHAPE using commercially available ultrasound 
scanner and UCA was demonstrated, and this was the first noninvasive in vivo SHAPE 
study to be documented.  Also the LV and the RV pressure estimates using SHAPE and 
the pressure catheter were within 3.5 mmHg for both, systolic and diastolic pressures.  
The robust results of these pilot studies are promising and should pave the way for 
validation in clinical populations, given that if these errors are translatable to the clinical 
population they would drastically reduce the number of cardiac catheterizations 
performed to obtain central cardiac pressures.  These results were published (179, 180). 
In specific aim 3, the ability of SHAPE to detect and identify induced PH in 
canines was tested.  A secondary outcome of this study was the development of two acute 
models of PH and the results thus, obtained are “in press” (186).  The results obtained 
through SHAPE demonstrated that the subharmonic emissions from microbubbles have 
the potential to discriminate PH cases.  This is clinically beneficial given that symptoms 
associated with PH manifest only after severe liver dysfunction develop and are often 
associated with relatively high mortality – since the clinical standard is invasive 
measurements and the liver can compensate for mild PH, asymptomatic patients are at 
greater risk from PH. Thus this noninvasive technique developed here may, ultimately, be 
useful for PH screening.  The SHAPE results obtained from PH studies are “in press” 
(187). 
Also, given that UCA studies are cheaper than other imaging counterparts like 
nuclear medicine, MRI, CT or fluoroscopy, the SHAPE technique will provide functional 
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status of the organ (in addition to the anatomic imaging) and thus, may potentially be a 
cost-saver.  Overall this thesis germinated from a potential idea of measuring in vivo 
pressures noninvasively using UCAs (3, 23) and led to the development of a processing 
technique and approach to quantify in vivo pressures noninvasively, albeit in canines.  
Thus, this thesis shall serve as a link between past in vitro tank studies and future clinical 
studies – probably, justifying the editors‟ choice of acknowledging the manuscripts 
resulting from this thesis as “Innovative Methodology”, “Concepts on the verge of 
translation”, and reviewers‟ classifying the studies as “professionally conducted”.  In that 
regard, recently, preliminary findings of a similar approach to identify PH in a clinical 
population were presented and the results revealed a correlation of 0.81 between the 
HVPG and the subharmonic gradient, when based on data from 27 patients and, this 
correlation improved to 0.86 when the study included data from 37 patients (183, 184).  
These preliminary results in a very limited patient population corroborate the findings of 
the results presented in this thesis.  The complete results of the patient study will be 
published in the future. 
Above all, the SHAPE approach has been refined and validated in vivo using 
commercial equipment which is expected to offer a safer and more cost effective 
alternative to current invasive pressure measurement techniques. 
In total, the work presented in this thesis has resulted in 6 peer reviewed first-
author publications (or in press articles), 2 first–author published conference proceedings 
and several conference presentations at the Annual Conventions of the AIUM, the IEEE 
International Ultrasonic Symposia and the Annual Scientific Meetings of the 
Radiological Society of North America.  A complete list of abstracts, conference 
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proceedings and publications while specifically working towards this project is presented 
in Appendix 12. 
5.2  Future Recommendations 
For all the work presented in this thesis, data was processed off-line.  Thus, the 
extraction and processing techniques developed for SHAPE should be ported on 
commercial ultrasound scanners and the real-time pressure estimation should be 
evaluated.  Also the approach presented in Fig. 4.25 requires in vivo validation. 
In the canine cardiac studies, the need to obtain a calibration factor from the 
systemic pulse pressures was realized.  The calibration factor was calculated based on the 
pressure catheter data present in the aorta.  The efficacy of using cuff-
sphygmomanometer values for calculating the calibration factor remain to be 
investigated.  Also hemodynamic alterations should be introduced to study the effect of 
increase or decrease in pulse rate, vasodilation, vasoconstriction, etc. on SHAPE results. 
Currently work is also underway in the lab to develop the SHAPE technique for 
investigating interstitial fluid pressure in tumors to monitor treatment response following 
neoadjuvant chemotherapy. 
Finally, pilot studies for cardiac SHAPE and a larger clinical study to evaluate the 
usefulness of screening asymptomatic or symptomatic patients to identify nascent PH 
should follow.  The application of SHAPE may be extended for any other in vivo pressure 
measuring applications where noninvasive techniques are not available. 
Lastly the use of subharmonic emissions from microbubbles to detect ambient 
pressures has been shown – the technique may be useful for ambient pressure measuring 
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applications away from the field of biomedical engineering as well; in that sense the 
project has potential applications → ∞! 
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Appendix 1:  Detailed List of Equipment and Materials Used 
 
 
 
I.  Ultrasound scanners and UCA 
1.  Sonix RP scanner (S/N: SX 1.0-0606.0389) and PA4-2 transducer (S/N: TRA 1.0-
SP00.194): Ultrasonix (Richmond, British Columbia, Canada).  Software version:3.2.2. 
 
2.  GE Logiq 9 (System ID:  L988822): GE Healthcare (Milwaukee, WI, USA). 
 
3.  UCA – Sonazoid: GE Healthcare (Oslo, Norway). 
 
II.  For measuring acoustic output of the transducers 
1.  Hydrophone: Used to determine the acoustic output in MPa at a transmit frequency of 
2.5 MHz for both, the PA4-2 transducer and the 4C transducer: 
0.2 mm needle hydrophone: Precision Acoustics (UK); sensitivity: 57.1 mV/MPa. 
 
2.  X-Y-Z Positioning System: Newport Corporation (Irvine, CA) – This positioning 
system is used to determine the focal point of the transducer by finding the point of 
maximum acoustic pressure. 
 
 
III.  For closed loop flow system (for dynamic in vitro SHAPE studies) 
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1.  Acrylic Chamber (volume: 4071.5 cm
3
): Constructed In-House – This chamber was 
used as a reservoir for the isotonic diluent with reconstituted Sonazoid microbubbles. 
 
2.  Magnetic Stirrer (Model 4657; S/N: 805970823021) and Stirring Bars (Kit # 4772-
15): Cole Parmer Instrument Company (Vernon Hills, IL) – These were used to ensure 
uniform concentration of the Sonazoid microbubbles in the acrylic chamber as the 
isotonic diluent circulated through the closed-loop flow system. 
 
3.  Isotonic Diluent: Val Tech Diagnostics (Pittsburgh, PA) – This was used for in vitro 
experiments. 
 
4.  Blood Pump (Model: Sarns S10K II): Sarns Inc. (Ann Arbor, MI) – The pump was 
used to induce pulsatile flow and control pressures in the closed-loop flow system. 
 
5.  Flexible polyvinyl chloride tubes (inner diameter: 8 mm): In-House – The tubes were 
used to complete the closed-loop flow system. 
 
6.  Doppler Flow Phantom and Tissue Mimicking Phantom (15 x 9.5 x 8 cm
3
): ATS 
Laboratories, Inc. (Bridgeport, CT) – The lumen within the Doppler flow phantom was 
used to simulate a blood vessel within the closed-loop flow system and the tissue 
mimicking phantom was used to alter the depth of scanning. 
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7.  Acoustic Gel: MediChoice (Distributed by Owens & Minor, Richmond, VA) – For 
acoustic coupling between the tissue mimicking phantom / Doppler flow phantom and the 
ultrasound transducer. 
 
IV.  For pressure recording (both, in vitro and in vivo) 
1.  Oscilloscope (S/N: 9350-8088): LeCroy Corporation (Chestnut Ridge, NY) – The 
oscilloscope was used to observe and record the pressure catheter data. 
 
2.  Pressure Catheter System: This was used to measure ambient pressures around the 
microbubbles. 
2.a.  Solid State Pressure Catheter: SPR 350 (S/Ns 415521 & 485859) and SPR 350S 
(S/N: 492105; „S‟ after 350 denotes straight tip otherwise the catheter has a curved tip): 
Millar Instruments, Inc. (Houston, TX).  The SPR 350 catheter (S/N: 415521) has a 
broken sensor and is not functional (at the time of this writing). 
2.b.  Pressure Catheter Transducer Control Unit (Model: TCB 500, S/N: 2119): Millar 
Instruments, Inc. (Houston, TX).  The control unit provides the bias voltages to the 
pressure catheter and was also used for calibrating the pressure catheter sensor. 
 
3.  Standard BNC cables (50 Ω): For connection between the pressure catheter transducer 
control unit and the oscilloscope. 
 
V.  For synchronization between the ultrasound scanners and the oscilloscope 
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1.  Sonix RP scanner and oscilloscope: Synchronization signal from the Sonix RP scanner 
to the oscilloscope was obtained with a standard BNC cable (50 Ω). 
 
2.  GE Logiq 9 scanner and oscilloscope: Synchronization signal from the Logiq 9 
scanner to the oscilloscope was obtained with a high impedance probe (PP005; 1 MΩ) 
from LeCroy Corporation (Chestnut Ridge, NY). 
 
VI.  In vivo experiments (items 2 through 4 were from the Office of Animal 
Resources, Thomas Jefferson University) 
1.  Sterile Surgi-Tip Transducer Covers: Civco Medical Solutions (Kaolna, IA) – These 
were used to maintain a sterile ultrasound scanning environment. 
 
2.  Anesthesia Equipment: To maintain anesthesia during experiments. 
2.a.  Anesthesia Ventilator (Model 2000) from Hallowell EMC (Pittsfield, MA) 
2.b.  Anesthesia Unit (Quatiflex VMC) from Matrx Medical Inc. (Orchard Park, NY) 
 
3.  Canine Monitoring Equipment: 
3.a.  Capnomac Ultima from Datex Ohmeda (Finland) – This was used to monitor 
canines‟ anesthesia, respiration and ventilation. 
3.b.  Vet/OX Plus 4700 from Sensor Devices Inc. (Lancaster, PA) – This was used to 
monitor canines‟ electrocardiogram, temperature and respiration, and for pulse-oximetry. 
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4.  Heat Therapy Pump (Model: TP 400) from Gaymar Industries, Inc. (Orchard Park, 
NY) – This was connected to a warming blanket to maintain canines‟ body temperature. 
 
VII.  Computers used (for usernames and passwords contact Dr. Flemming Forsberg) 
1.  Computer 1: PCSO229 (Thomas Jefferson University): 
Microsoft Windows XP Professional Ver. 2002 SP3 
(3.6 GHz, 1 GB RAM, MAC: 001143B30159) 
Used for running LabVIEW to interface with the oscilloscope 
 
2.  Computer 2: PCSP800 (Thomas Jefferson University): 
(2.83 GHz, 3.25 GB RAM, MAC: 0026B97FEE05) 
Used for processing and also, for interfacing with the GE Logiq 9 Scanner 
 
3.  Computer 3: PCSL663 (Thomas Jefferson University Hospital): 
Microsoft Windows XP Professional Ver. 2002 SP3 
(3.0 GHz, 4 GB RAM, MAC: 0017A41F0B7B) 
Used for processing and publishing 
 
4.  Computer 4: Personal Laptop 
MAC OS X Ver. 10.5.8 
(2.4 GHz, 2 GB RAM) 
Used for processing and publishing 
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Appendix 2:  Use of Vertebrate Animals in the Experiments 
 
 
 
Genus and Species:  Canis Familiaris 
 
Strain:  Mongrel 
 
Sex:  Both male and female 
 
Age:  Between 6 months and 1 year 
 
Number:  11 (for cardiac SHAPE; this being a pilot study for noninvasive SHAPE, no 
power analysis was performed) 
 
Number:  22 (to develop SHAPE processing technique and to evaluate the feasibility and 
application of SHAPE to identify portal hypertension in canines; with 3 repetitions in 
each canine, the data obtained will have sufficient power (i.e., > 0.8) to detect the 
relationship of decrease in the subharmonic signals with an increase in PV pressures if a 
large effect (r > 0.5) genuinely exists (44)) 
 
Justification:  Techniques for utilizing microbubbles to estimate ambient pressures have 
persisted over the last 4 decades (2, 3, 17-21, 23).  However, none of these techniques 
have been translated to clinical use due to idealized in vitro experimental setups (like the 
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use of single element transducers, isolation of single bubble for pressure estimation, etc.) 
or due to large errors associated with the proposed techniques.  The proof-of-concept for 
SHAPE technique in vitro (3, 134-138) and in vivo has been provided (23), but again the 
experimental setup with single element transducers lacking imaging capability and/or 
open-thoracic cavity (in vivo studies) for obtaining subharmonic data preclude clinical 
use. 
The overall purpose of this thesis was to investigate the application of SHAPE for 
cardiac and hepatic applications and provide a tool for clinical applications.  The initial 
studies for developing SHAPE algorithm using commercially available ultrasound 
scanners and UCAs were performed in vitro using standard water-bath technique and 
flow phantoms.  However, before clinical testing the efficacy and accuracy of this 
technique must be investigated in vivo.  Canines were selected for these studies, because 
smaller animals, such as rabbits, have blood vessels too small to catheterize and because 
some species, such as swine, may have marked pulmonary hypertension during contrast 
microbubble experiments (45).  The initial proof-of-concept in vivo study was also 
performed in canines.  Also the team at Thomas Jefferson University has had extensive 
experience in UCA studies in canines. 
 
Veterinary care:  The canines were obtained from Marshall BioResources (North Rose, 
NY).  The canines were vaccinated at Marshall BioResources for bordetella, 
parainfluenza, adenovirus, leptospirosis, distemper, parvovirus and rabies; and these 
vaccinations were updated as needed while the canines resided at Thomas Jefferson 
University.  Before arrival at Thomas Jefferson University, the canines were dewormed 
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with pyrantel pamoate anthelmintic (Med-Pharmex, Inc., Pomona, CA) and ivermectin 
(Merck, Whitehouse Station, NJ).  When the canines arrived at Thomas Jefferson 
University, their general appearance was recorded as well as a detailed physical 
examination was performed including temperature, pulse rate and respiratory rate 
recordings.  The canines were then kept in the AAALAC (Association for Assessment 
and Accreditation of Laboratory Animal Care International) accredited facilities of 
Thomas Jefferson University and were cared for and monitored using practices that 
comply with the principles for the utilization and care of vertebrate animals used in 
testing, research and training (188).  The canines were housed in large and appropriately 
ventilated animal pens, and acclimated for at least 72 hours before they were allowed to 
be used in the research study.  Since at Thomas Jefferson University the canines were 
housed inside at all times, parasite infections were not an issue.  While Thomas Jefferson 
University requires treatment for all parasite infections and other illnesses as per the 
veterinarian‟s instructions, the canines in this project did not have any problems and thus 
no treatments were issued.  They were fed a mix of canned science diet dog food and a 
laboratory canine diet produced by Purina Mills (Gray Summit, MO). 
 
Experimental procedures alleviating animal discomfort:  An intravenous injection of 
Propofol (Abbott Laboratories, Chicago, IL; dose 7 mg/kg) was used for initial sedation.  
The animals were intubated and anesthesia maintained with 0.5 to 2 % of Isoflurane (Iso-
thesia; Abbott Laboratories, Chicago, IL) via an endotracheal tube throughout the 
experiment.  For this purpose, a calibrated anesthesia ventilator (Model 2000, Hallowell 
EMC, Pittsfield, MA) was used with the anesthesia unit (Quatiflex VMC, Matrx Medical 
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Inc., Orchard Park, NY).  Throughout the experiment the canines‟ anesthesia, respiration 
and ventilation were monitored (Capnomac Ultima, Datex Ohmeda, Finland) by certified 
veterinary technicians.  During the course of the experiments, the canines were placed on 
a warming blanket connected to a heated water pump (TP 400, Gaymar Industries, Inc., 
Orchard Park, NY) to maintain body temperature.  The canines‟ electrocardiogram, 
temperature and respiration along with pulse-oximeter data were also monitored (Vet/OX 
Plus 4700, Sensors Devices, Inc., Lancaster, PA).  All procedures were performed when 
the canines were fully anesthetized (Stage 3, Plane 2) (189). 
 
Euthanasia:  The canines were sacrificed by intravenous injection of Beuthanasia (0.25 
mg/kg).  These experiments were conducted in accordance with guidelines provided by 
the Institutional Animal Care and Use Committee of Thomas Jefferson University.  These 
guidelines are consistent with the recommendations of the Panel on Euthanasia of the 
American Veterinary Medical Association (190). 
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Appendix 3:  Detailed Operating Procedures 
 
 
 
I.  Pressure catheter setup 
1.  Soak the pressure catheter tip in sterile water or sterile saline for 30 minutes before the 
experiment(s) for stabilization. 
2.  Connect the Millar transducer control unit to one of the channels on the oscilloscope. 
3.  The verification of the pressure control unit performance is performed as follows: 
 Turn on the power switch on the transducer control unit 
 Set the knob on transducer control unit to „Standby‟ position and center the trace 
on the oscilloscope monitor 
 Verify the conversion factor from mV to mmHg by setting the transducer control 
unit to 20 mmHg, and noting a DC offset of 40 mV on the oscilloscope 
 Again verify the conversion factor from mV to mmHg by setting the transducer 
control unit knob to 100 mmHg, and noting a DC offset of 200 mV on the 
oscilloscope 
(Note, that if the observed DC offset for 20 and 100 mmHg are different from the values 
mentioned above, then check the BNC cable used to connect the transducer control unit 
to the oscilloscope; if the problem persist then contact Millar Instruments) 
4.  Adjust the oscilloscope „Volts/div‟ setting to cover the range of pressures that may be 
present during the experiment – this is required because only the visible portion of the 
trace will be captured by LabVIEW.  Thus if the trace is partially clipped on the monitor, 
then, the digitized data output of LabVIEW will also be clipped. 
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5.  Connect the pressure catheter to the transducer control unit (either directly or using an 
extension cable) and switch the knob on the transducer control unit to „Transducer‟. 
6.  Shield the pressure catheter tip from the ambient light and then adjust the „Transducer 
Balance Control‟ on the transducer control unit so that the trace remains centered on the 
oscilloscope display at the same position as in Step 3 (baseline position).  Once the trace 
is returned to its baseline position, „Lock‟ the transducer balance control. 
7.  Troubleshooting tips for the pressure catheter: 
 A continuous drift seen in the signal on the oscilloscope implies the presence of 
some bias voltage.  In order to remove this bias voltage insert a conducting wire 
(example, a solder wire) near the pressure catheter tip and ground it (to 
oscilloscope outer panel/phantom outer covering/transducer control unit housing).  
This step removes any static charge that may be picked up by the catheter. 
 If the above step does not work, then remove the catheter and use a water jet 
(from a syringe) to clean the tip.  Note, that the pressure sensor located at the tip 
is extremely fragile and thus delicate handling is required. 
 For additional details regarding troubleshooting, cleaning the pressure catheter 
and for sterilization of the pressure catheter before in vivo experiments refer to the 
„Millar Mikro-Tip catheter pressure transducer Animal use Only Instructions for 
Use‟ manual in the lab.  Alternately, the technical sales and support engineer 
Blayne P. Fleck (bfleck@millarmail.com; (832) 667-7165) at Millar Instruments 
may be contacted. 
 
II.  Experimental setup: 
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1.  Take known quantity of isotonic diluent in an acrylic water bath.  Typically for the 
flow phantom experiments 750 ml of isotonic diluent was used. 
2.  Place the acrylic water bath on the magnetic stirrer and insert a magnetic stirring bar 
in the acrylic water bath. 
3.  Obtain a close loop flow system between the acrylic water bath and the Doppler flow 
phantom using flexible PVC (polyvinyl chloride) tubes and the roller pump. 
4.  After the pressure catheter has been setup as explained in this Appendix – Part I 
(Appendix – 3I), insert it carefully (because the pressure sensor tip is fragile) through the 
PVC tubes till the pressure catheter tip resides in the selected lumen within the Doppler 
flow phantom. 
5.  Turn the roller pump „RPM‟ setting to the desired level to initiate the flow and obtain 
the desired level of pressure in the flow phantom.  Let the pump run for up to 3 to 4 
minutes to remove the resident air cavities in the lumen of the flow phantom and the 
tubes. 
 
III.  LabVIEW setup  (Note, that this setup was first developed by Flemming Forsberg 
and William T. Shi) 
1.  Start LabVIEW on the lab computer (Computer 1: Appendix 1(VII)). 
2.  Select 'Basic Waveform' from –  
(C:\Documents and Settings\fxf105\My Documents\William\LabViewBill) 
3.  Enter a filename. 
4.  Select the channel source (this should be same as the channel where the output of the 
transducer control unit is connected). 
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5.  Click „Run‟ - to start capturing and click into file name field and save by clicking the 
'tick' symbol. 
6.  The text files gets saved in - (C:\Documents and Settings\fxf105\My Documents\Ray). 
 
IV.  Synchronization Settings for Triggering the Oscilloscope Capture with Sonix 
RP scanner and Data Acquisition: 
1.  Connect „Ext‟ on the oscilloscope to the „Print‟ button on the Sonix RP located on the 
“Back Panel Control System Board”. 
2.  Set the „Sync Output (1)‟ to „1‟ on the Sonix RP software (this option appears on the 
left hand side panel when the unit is operated in „Research‟ mode). 
3.  The settings on the oscilloscope should be as follows: 
 Trigger Setup:  „Edge‟ trigger, with trigger on „Ext‟ with coupling set to „DC‟, 
slope set to „Pos‟ and external setting selected as „DC 50 Ω‟ 
 Time-Base Setup:  Time per division set to „0.5 sec‟ (to collect data 
corresponding to 5 seconds), with recording set to 50000 samples at 10 kS/sec for 
5 seconds.  Sampling is set to „Single Shot‟, sequence set to “Off” and the „Peak 
Detect‟ option selected.  Recording setting should be set to „Record up to 50K 
samples‟.  Obviously select the channel (either 1 or 2) depending on the channel 
where the output of the transducer control unit is connected. 
 The update mode should be set to „Normal‟ 
4.  Verification of the synchronization may be performed as follows: 
 While the „Freeze‟ button is engaged, the pressure trace on the oscilloscope 
display should not update (and the Sonix RP scanner should not be scanning). 
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 When the „Freeze‟ button is dis-engaged, the pressure trace on the oscilloscope 
should update every 5 seconds (and the Sonix RP scanner should be scanning). 
5.  The data acquisition steps are detailed below: 
 User releases (or disengages) the „Freeze‟ on the Ultrasonix Unit and waits for 5 
seconds 
 After 5 seconds, engage the „Freeze‟ button on the Ultrasonix Unit 
 Simultaneously, the „Run‟ command on LabView should be clicked to collect the 
digitized pressure data visible on the oscilloscope monitor.  Note, that if the 
ultrasound data is captured for more than 5 seconds, then there may be a second 
trigger signal from the Sonix RP sent to the oscilloscope which may refresh the 
data displayed on the oscilloscope monitor and consequently the pressure data 
may not correspond to the acquired RF data.  Thus, care should be taken to 
capture the pressure data before a second update of pressure data initiates 
(corresponding to pressure data from 5 to 10 seconds). 
 Verify the text file is saved on the hard-drive at location specified in Appendix 3 
III-3 
6.  The data on the Sonix RP is stored „D:\PatientInfo‟ in the folder with the same name 
as the „patient name‟ entered before starting the scanning.  The RF data can be accessed 
using the Matlab code provided by Ultrasonix at: 
http://research.ultrasonix.com/ucp.php?mode=login (will require registration and login) – 
Program used was: „RPread.m‟. 
7.  For additional details on RF data capture options refer the Ultrasonix Research Forum 
(at: http://research.ultrasonix.com/ucp.php?mode=login).  
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Appendix 4:  Matlab Functions Developed for Processing 
 
 
For reading encoded data files captured using the Sonix RP unit, a proprietary 
function „RPead.m‟ was obtained from Kris Dickie and Corina Leung (Ultrasonix; 
available on the Research Users Forum: 
http://research.ultrasonix.com/ucp.php?mode=login) 
This function loads the encoded data in the Matlab workspace as a variable.  Then, the 
under mentioned functions and subroutines may be used.  „RPread.m‟ function is thus not 
presented here. 
 
I.  Inbuilt Matlab Functions Used 
fft & fftshift:  to obtain the Fast Fourier Transform (FFT) of the data 
squeeze:  to adjust the dimensions of the array 
uigetfile:  to open a file dialog box from Matlab; for pointing to the location on the hard-
drive where the data is stored 
xlswrite:  to write values into Microsoft Excel directly 
 
II.  Function:  To Extract Signal Within a Bandwidth of 1 to 1.5 MHz 
Input:  FFT of the vectors such that first column represents frequency values, the second 
column represents the FFT amplitude and the third column represents the number of 
vectors 
Output:  Array of FFT values with the size dependent on the number of vectors 
function [output]=shape101_averageauto(rfdata) 
228 
 
 
sz=size(rfdata); 
for i=1:sz(3) 
    data=rfdata(:,:,i); 
    loc=find(data(:,1)>1 & data(:,1)<1.5); 
    red_data=data(loc,:); 
    output(i)=mean(red_data(:,2)); 
end 
 
output=20*log10(output);    
 
III.  Function:  To Extract Signal Within a Bandwidth of 1.15 to 1.35 MHz 
Input:  FFT of the vectors such that first column represents frequency values, the second 
column represents the FFT amplitude and the third column represents the number of 
vectors 
Output:  Array of FFT values with the size dependent on the number of vectors 
function [output]=shape101_averageauto_red(rfdata) 
 
sz=size(rfdata); 
for i=1:sz(3) 
    data=rfdata(:,:,i); 
    loc=find(data(:,1)>1.15 & data(:,1)<1.35); 
    red_data=data(loc,:); 
    output(i)=mean(red_data(:,2)); 
end 
 
output=20*log10(output);    
 
IV.  Function:  To Extract Signal at 1.25 MHz after a Parabolic Fit Within a 
Bandwidth of 1.0 to 1.5 MHz 
Input:  FFT of the vectors such that first column represents frequency values, the second 
column represents the FFT amplitude and the third column represents the number of 
vectors 
Output:  Array of FFT values with the size dependent on the number of vectors 
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function [output]=shape101_parabolafit125(rfdata) 
 
sz=size(rfdata); 
for i=1:sz(3) 
    data=rfdata(:,:,i); 
    loc=find(data(:,1)>1 & data(:,1)<1.5); 
    red_data=data(loc,:); 
    pcoeff2=polyfit(red_data(:,1),red_data(:,2),2); 
    yfitted =polyval(pcoeff2,red_data(:,1)); 
    n=max(size(yfitted)); 
    E2=sqrt( sum(abs(yfitted-red_data(:,2) ).^2 )/n ); 
    output(i,1)=polyval(pcoeff2,1.25); 
    output(i,2)=E2; 
end 
parabolafiterror=output(:,2); 
output=20*log10(output(:,1)); 
output=output'; 
 
V.  Function:  To Extract Signal at 1.25 MHz 
Input:  FFT of the vectors such that first column represents frequency values, the second 
column represents the FFT amplitude and the third column represents the number of 
vectors 
Output:  Array of FFT values with the size dependent on the number of vectors 
function [output]=shape101_125(rfdata); 
 
sz=size(rfdata); 
for i=1:sz(3) 
    data=rfdata(:,:,i); 
    loc=find(data(:,1)==1.25); 
    output(i)=data(loc,2); 
end 
 
output=20*log10(output); 
 
VI.  Subroutine:  To Operate with Pressure Catheter Data (in batch mode) i.e., text 
files obtained from LabVIEW  
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Purpose:  To read all data from the text files, convert the catheter data (in mV) to pressure 
data (in mmHg) and then store the values in variables time_cat and pres_cat in an array 
format; each column in time_cat corresponds to the time points for the corresponding 
column in pres_cat with the number of columns depending on number of text files 
present. 
files1=dir('*.txt'); 
number_txt_files1=max(size(files1)); 
for i=1:(number_txt_files1) 
    txt_files(i)={files1(i).name}; 
end 
txt_files=txt_files'; 
  
for i=1:number_txt_files1 
    temp_info=importdata(char(txt_files(i))); 
    pres=(temp_info(:,2)*1000)/2; 
    loc1=find(temp_info(:,1)>0.5 & temp_info(:,1)<4.5); 
    time_cat(:,i)=temp_info(loc1,1); 
    pres_cat(:,i)=pres(loc1); 
    clearvars temp_info pres temp_info loc1 
end 
 
VII.  Subroutine:  To Operate with Data Captured with Sonix RP Scanner (in batch 
mode) 
Purpose:  To read all data from the „.drf‟ files, and for the given file obtain the 
subharmonic amplitude.  Note that the „fft_signal‟ utilizes the standard Matlab functions 
to obtain the FFT. 
files2=dir('*.drf'); 
number_drf_files2=max(size(files2)); 
for i=1:(number_drf_files2) 
    drf_files(i)={files2(i).name}; 
end 
drf_files=drf_files'; 
i =  %enter the file number to work with 
[image,header] = RPread(char(drf_files(i))); 
sampling_freq = header.sf/1000000; %in MHz 
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rfdata=image; 
sz=size(rfdata); 
for j=1:sz(3) 
    rfdata_fft(:,:,j)=fft_signal(rfdata(:,:,j)); 
end  
shape_average = shape101_averageauto(rfdata_fft); % OR any other function to extract 
the RF data (from functions I through IV listed above) 
s1=medfilt1(shape_average,order); %enter the order of the filter as required 
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Appendix 5:  Canines Used for Cardiac SHAPE Studies 
 
 
 
Table A5.1:  List of canines used for cardiac SHAPE studies 
Experiment Date Canine ID Weight (kg) 
12/10/2008 720763 24.0 
12/11/2008 729493 24.0 
12/15/2008 718815 25.0 
12/18/2008 712361 24.0 
07/20/2009 766119 23.0 
07/21/2009 762750 21.0 
09/15/2009 771333 22.6 
09/18/2009 763489 23.2 
01/31/2012 830241 20.0 
03/08/2012 826944 22.3 
03/13/2012 826235 22.0 
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Appendix 6:  Equipment Setup and Matlab Functions Specific to Logiq 9 Scanner 
 
 
 
I.  Synchronization Settings for Triggering the Oscilloscope Capture with GE Logiq 
9 Unit and Data Acquisition:  (this was used to acquire data before the optimized 
incident acoustic output control algorithm was implemented on the Logiq 9 scanner) 
 
1.  Obtain the password from GE personnel to operate the unit in the maintenance mode; 
the password is updated periodically so the latest password should be obtained to do the 
experiments.  Also be sure that the RF data capture „option keys‟ are current and have not 
expired; else contact GE to obtain the updated „option keys‟. 
2.  Before powering on the GE Log 9 unit, remove the side panel to access the Scan 
Control Board. 
3.  Insert the USB „Hasp‟ key in the USB slot and power on the unit. 
4.  Enter the maintenance password and then let the unit start-up. 
5.  Make a folder: „Projects„ and within it create a folder „mke07_shi‟. 
6.  Copy „vars.bat‟ file in this folder and extract „target‟ in this folder („target‟ contains 
the RF data capture software). 
7.  Copy files for the required frequency in the folder „target/RO/Probe‟. 
8.  Then, on the command prompt execute the following commands: 
 E: 
 cd Projects 
 cd mke07_shi 
234 
 
 vars.bat 
 echoloader/reg 
9.  Wait for the software to initiate. 
10.  If the unit shows streak like artifacts while scanning: 
 push the turn off button located on the top-left hand side of the keyboard 
 click on exit 
 at the command prompt – type „rackpower‟ – press „enter‟ 
 after about 10 seconds click „escape‟ on the keyboard 
 again execute „vars.bat‟ and „echoloader/reg‟ on the command prompt 
11.  Unplug the 4C probe and wait for the probe icon in the touch panel to be grayed out 
and then plug the probe back in. 
12.  Enter in the „Contrast‟ mode and the new settings will be in effect. 
13.  Verify that the „Investigational Device‟ notification appears on Logiq 9 monitor. 
14.  Confirm that the RF data capture button is available under „Utility-> Admin-> 
System Admin‟.  The „installed option keys‟ should be current and should not have 
expired.  If the keys have expired then contact GE and obtain the new software keys. 
15.  Under contrast select the desired option „Coded PI 1/2‟ or „Res‟ or „Pen‟, then select 
the RF capture button. 
16.  Adjust the depth and incident acoustic output as required. 
17.  Then place the sampling volume so that it lies in the area of interest. 
18.  Connect the „txsync‟ signal from the scan control board on the GE unit to the 
available channel (e.g., channel 2) on the oscilloscope using a high impedance cable.  If 
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at this point the unit shows streak like artifacts then follow directions indicated in Step 10 
in this section. 
19.  The settings on the oscilloscope should be as follows: 
 Trigger Setup:  „Smart-Qualified‟ trigger, with setup for „Smart‟ trigger 
configured by „State‟ to trigger on „channel as per step 18‟ only after that 
„channel‟ goes and stays above „0.18 V‟.  The „wait‟ should be set to „Off‟. 
 Time-Base Setup:  Time per division set to „0.5 sec‟ (to collect data 
corresponding to 5 seconds), with recording set to 50000 samples at 10 kS/sec for 
5 seconds.  Sampling is set to „Single Shot‟, sample clock set to „Internal‟ with 
the „Peak Detect‟ option selected.  Recording setting should be set to „Record up 
to 50K samples‟.  Obviously select the channel depending on the channel where 
the output of the transducer control unit is connected. 
 The update mode should be set to „Normal‟ 
20.  The data acquisition steps are detailed below: 
 User releases (or disengages) the „Freeze‟ on the GE Unit and waits for 5 seconds 
 After 5 seconds, engage the „Freeze‟ button on the GE Unit 
 Simultaneously, the „Run‟ command on LabView should be clicked to collect the 
digitized pressure data visible on the monitor.  Note, that if the ultrasound data is 
captured for more than 5 seconds, then there may be a second trigger signal from 
the GE Logiq 9 sent to the oscilloscope which may refresh the data displayed on 
the oscilloscope monitor and consequently the pressure data may not correspond 
to the acquired RF data.  Thus, care should be taken to capture the pressure data 
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before a second update of pressure data initiates (corresponding to pressure data 
from 5 to 10 seconds). 
21.  To save the file on the GE unit perform the following steps: 
 Move the mouse controller to top right slightly 
 Cine Option should appear on the display panel above the keyboard 
 Press – „Cine Capture on‟ – on the display unit 
 Press – „Run/Stop‟ – on the display unit 
 On the keyboard – Press „DICOM Store‟ 
22.  Verify the text file is saved on the hard-drive at location specified in Appendix 3 
III3. 
23.  The dicom data is stored under „E:\Image Buffer‟ in the form of „.dcm‟ files.  The RF 
data may be extracted in Matlab using the proprietary „extractRFFromDicom‟ software 
made available by GE. 
 
II.  Sample Output of the „GE Raw RF data extraction facility‟ Software:  (the 
example below is from a „.dcm‟ file acquired during an experiment, before the optimized 
incident acoustic output control algorithm was implemented on the Logiq 9 scanner) 
 
Microsoft Windows XP [Version 5.1.2600] 
(C) Copyright 1985-2001 Microsoft Corp. 
C:\Documents and Settings\jxd026.TJUH-MST\Desktop\Extract_RF_10262010> 
extractRFFromDicom Image29.dcm 
GE Raw RF data extraction facility V2.2. 
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Copyright GE 2010, all rights reserved. 
Processing .\\Image29.dcm... 
Data acquired with 4C probe on Logic.Musashi at 2009/11/25-10:26:04. 
Processing simplex movie type 2D with sampleType Tissue(8) 
Processing simplex movie type 2D with sampleType Complex(n*32) 
This data set contains raw RF data.  The data matrix is dimensioned as 
(377 samples X 4 firingsperzone X 1 zones X 1 packets X 27 vectors X 126 frames) 
Reading public image data...the public image data is dimensioned: 
  3 bytes/pixel x 480 rows x 640 columns x 1 frames 
Done 
Saving the 2D RF data and timestamps to .\Image29_2DRF.mat 
Saving the public image pixel data to .\Image29_2DImage.mat 
Done. 
 
Note, in the output, the data matrix contains 377 samples that correspond to a 
span of 2.9 cm in the axial direction which is the size of the region of interest seen in Fig. 
3.16B. 
 
III.  Subroutine:  To Operate with Data Captured on the Logiq 9 Scanner 
Note, functions „dc_filter.m‟ and „eq_filter.m‟ were obtained from Feng Lin (GE 
Global Research) for pre-processing the RF data obtained after using their proprietary 
software for extracting RF data from the acquired DICOM files (Appendix 6 II).  These 
functions are not presented here.  Also other functions and subroutines presented in 
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Appendix 4 are applicable here, once the data is present in the Matlab workspace as a 
variable.  Thus, these functions and subroutines are not repeated here; but a subroutine 
created to operate in batch mode and load all the workspaces obtained after extracting the 
data from „.dcm‟ files (output of Appendix 6 II) in Matlab is given below: 
 
Purpose:  To create an array with file names for batch mode processing; then the filter 
functions mentioned above i.e., „dc_filter.m‟ and „eq_filter.m‟ and processing functions 
mentioned in Appendix 4 were used. 
files=dir('*.mat'); 
sprintf('Determining number of workspaces # :  ...') 
number_ws_files=max(size(files)); 
for i=1:(number_ws_files) 
    ws_files(i)={files(i).name}; 
end 
ws_files=flipud(ws_files'); 
% ws_files=ws_files'; 
sprintf('The total number of ws files in the folder: %d',max(size(ws_files))) 
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Appendix 7:  Canines Used for PH SHAPE studies 
 
 
Table A7.1:  List of canines used for PH SHAPE studies before the optimized incident 
acoustic output control algorithm was implemented on the Logiq 9 scanner 
Experiment Date Canine ID Weight (kg) 
10/19/2009 773450 21.5 
10/27/2009 768774 22.7 
10/27/2009 772372 20.8 
10/30/2009 773026 22.0 
11/13/2009 773492 21.0 
11/17/2009 769593 23.0 
11/17/2009 774651 22.0 
11/19/2009 768138 21.0 
11/19/2009 774791 21.0 
11/25/2009 770621 22.0 
12/09/2009 774634 24.0 
12/11/2009 774839 25.0 
12/15/2009 772917 25.0 
12/15/2009 777510 24.0 
12/17/2009 779512 21.0 
12/17/2009 777277 22.0 
12/21/2009 7811193 22.0 
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Table A7.2:  List of canines used for PH SHAPE studies after the optimized incident 
acoustic output control algorithm was implemented on the Logiq 9 scanner 
Experiment Date Canine ID Weight (kg) 
10/19/2010 809781 20.8 
10/25/2010 809161 21.0 
01/13/2011 809322 22.0 
01/18/2011 808971 25.0 
01/20/2011 811696 23.0 
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Appendix 8:  List of Statistical Tests Used 
 
 
 
ANOVA:  ANOVA was used when mean values acquired with multiple settings were to 
be compared in contrast to the t-test used when values acquired with two settings were to 
be compared – ANOVA was used to maintain the probability of making type I error to 5 
% (i.e., a p-value of 0.05).  Multiple t-tests for such comparisons would increase the 
probability of type I error e.g., 2 t-tests on the same data set would increase the 
probability of type I error to 9.75 % (calculation: 1-0.95
2
). 
1.  One-Way:  In vitro and in vivo studies to identify the most sensitive IAO level. 
2.  Repeated:  In vitro studies to compare the extraction and filtering techniques for 
SHAPE. 
3.  Factorial Repeated:  In vivo PH studies to determine differences in subharmonic signal 
amplitude for the number of transmit cycles and the IAO levels 
 
Bonferroni Corrections: 
1.  Adopted for post-hoc multiple comparisons to control for Type-I error rate, by 
dividing the desired significance level by the number of comparisons performed. 
 
Linear Regression Analyses: 
1.  In vitro and in vivo studies to predict the ability of the processed subharmonic signal 
to estimate ambient pressure values. 
 
242 
 
Paired t-test:  Paired t-test was used for obtained from the same subject (in this case, 
canines) and when comparisons were required before and after some form of treatment 
(e.g., inducing PH) or when comparisons were required between two techniques (e.g., 
pressures obtained with SHAPE and with the pressure catheter) 
1.  In vivo studies to investigate if there were significant differences between the 
pressures obtained using the subharmonic data and the pressure catheter. 
2.  In vivo PH studies to investigate differences in pressures, pulsatility index and 
diameter of the PV before and after inducing PH. 
3.  In vivo PH studies to investigate difference between baseline and PH conditions for 
subharmonic signal amplitudes. 
 
Correlation Analyses: 
1.  In vivo PH studies to identify the relationship between change in the mean PV 
pressures and change in the subharmonic signal amplitude, and between absolute mean 
PV pressures and absolute subharmonic signal amplitudes. 
 
Correlation Comparisons using T-Test: 
1.  In vivo PH studies to compare correlation coefficients obtained with different transmit 
parameters. 
 
Cross-Validation Study: 
1.  In vivo PH Studies to investigate robustness of the predictive capability of the results 
of correlation analyses for identifying PH. 
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Appendix 9:  List of Key Personnel 
 
 
 
The work towards this thesis required communication between various 
manufacturers and between colleagues at Thomas Jefferson University.  Thus, a list of 
key personnel is compiled here for future reference.  This list is not exhaustive but it at 
least provides a first point-of-reference for communication (at the time of this writing); it 
is intended to provide a guidance if laboratory team members or Dr. Flemming Forsberg 
are not available.  Dr. Flemming Forsberg should be otherwise contacted for all practical 
purposes. 
 
I.  Thomas Jefferson University: 
a.  For scheduling and coordinating in vivo experiments: 
 Ji-Bin Liu: Ji-Bin.Liu@jefferson.edu 
 Joseph Altemus: Joseph.altemus@jefferson.edu 
b.  For scanning during in vivo experiments: 
 Daniel Merton: Daniel.A.Merton@jeffersonhospital.org 
 Maureen E McDonald: maureen.e.mcdonald@jefferson.edu 
c.  For ensuring catheter sterilization before in vivo experiments: 
 Crystal: (7th Floor, Thomson Building, Department of Ultrasound) 
 
II.  Millar Instruments, Inc. 
For technical information on Millar pressure catheters: 
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 Blayne P Fleck: bfleck@millarmail.com 
 
III.  GE Global Research 
For assistance in configuring the software implemented on the GE ultrasound scanner and 
for providing the utility function to extract acquired RF data from the DICOM files: 
 Kai E. Thomenius: thomeniu@ge.com 
 Feng Lin: linf@research.ge.com 
 Suhyun Park: tumbler77@gmail.com 
 Scott Dianis: dianis@ge.com (now with Philips: scott.dianis@philips.com) 
 Carl L. Chalek: chalekcl@ge.com 
 Kirk Wallace: wallacek@ge.com 
 
IV.  Ultrasonix 
For technical information and troubleshooting during data acquisition with the Sonix RP 
scanner and for the Matlab program to decode the acquired RF data: 
 Kris Dickie: Kris.Dickie@ultrasonix.com 
 Corina Leung: Corina.Leung@ultrasonix.com 
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Appendix 10:  List of Software Used 
 
 
 
Note, that specific software versions are not provided because the software were 
upgraded between 2008-2012. 
 
1.  Matlab (The Mathworks Inc., Natick, WA) 
License:  Thomas Jefferson University & Drexel University 
Purpose:  For programming and, acquiring and processing RF data 
 
2.  LabVIEW (National Instruments Corporation, Austin, TX) 
License:  Thomas Jefferson University 
Purpose: For capturing oscilloscope data (interface between oscilloscope and a lab 
computer) 
 
3.  IBM SPSS (IBM Corporation, Armonk, NY) 
License:  Drexel University 
Purpose:  For statistical analyses 
 
4.  G*Power (http://www.psycho.uni-duesseldorf.de/aap/projects/gpower/)  
Link last verified: May 31, 2012 
License:  Freely Available 
Purpose:  For power analyses 
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5.  Virtual Dub (http://www.virtualdub.org/index.html) 
Link last verified: May 31, 2012 
License:  GNU General Public License 
Purpose:  For creating animations and processing video files 
 
6.  Endnote (Thomas Reuters, New York, NY) 
License:  Drexel University 
Purpose:  For managing and publishing bibliographies 
 
7.  Microsoft Office (Microsoft Corporation, Redmond, WA) 
License:  Thomas Jefferson University & Drexel University 
Purpose:  For record keeping, publishing and presentations 
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Appendix 11:  Grants  
 
 
 
1.  The American Heart Association (Dallas, Texas):  Grant 0655441U 
2.  The National Institutes of Health (Bethesda, Maryland):  Grant R21 HL081892 
3.  The National Institutes of Health (Bethesda, Maryland):  Grant RC1 DK087365 
4.  The USA Army Medical Research and Material Command (Fort Detrick, Maryland):  
Grant W81XWH-08-1-0503 
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Appendix 12:  List of Professional Contributions 
 
A complete list of abstracts, conference proceedings and publications while working 
towards this project is presented. 
I.  Peer Reviewed Publications: 
1) Dave JK, Halldorsdottir VG, Eisenbrey JR, Raichlen JS, Liu JB, McDonald ME, 
Dickie K, Wang S, Leung C and Forsberg F. Subharmonic microbubble emissions for 
noninvasively tracking right ventricular pressures. Am J Physiol Heart Circ Physiol. 
2012 303:H126-32. 
 
2) Dave JK, Halldorsdottir VG, Eisenbrey JR and Forsberg F. On the processing of 
subharmonic signals from ultrasound contrast agents to determine ambient pressures. 
Ultrason Imaging. 2012 34:65-75. 
 
3) Dave JK, Halldorsdottir VG, Eisenbrey JR, Raichlen JS, Liu, JB, McDonald ME, 
Dickie K, Wang S, Leung C and Forsberg F. Noninvasive left ventricular pressure 
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Am Coll Cardiol. Img. 2012 5:87-92. 
 
4) Halldorsdottir VG, Dave JK, Leodore LM, Eisenbrey JR, Park S, Hall AL, 
Thomenius KE and Forsberg F. Subharmonic contrast microbubble signals for 
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Imaging. 2011 33: 153-64. 
 
5) Eisenbrey JR, Dave JK, Halldorsdottir VG, Merton DA, Machado P, Liu JB, 
Miller C, Gonzalez JM, Park S, Dianis S, Chalek CL, Thomenius KE, Brown DB, 
Navarro V and Forsberg F. Dual grayscale and subharmonic imaging on a modified 
commercial ultrasound scanner. Ultrasonics. 2011 51: 890-7. 
 
6) Dave JK, Halldorsdottir VG, Eisenbrey JR, Liu JB, McDonald ME, Dickie K, 
Leung C and Forsberg F. Noninvasive estimation of dynamic pressures in vitro and in 
vivo using the subharmonic response from microbubbles. IEEE Trans. Ultrason. 
Ferroelectr. Freq. Control. 2011 58: 2056-66. 
 
II.  Accepted Manuscripts (pending publication): 
1) Dave JK, Liu JB, Halldorsdottir VG, Eisenbrey JR, Merton DA, Machado P, Zhao 
H, Needleman L, Brown DB and Forsberg F. Acute portal hypertension models in 
canines: low- & high- flow approaches. Comp Med. (Jan 2012). 
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Forsberg F. Subharmonic aided pressure estimation in patients with suspected portal 
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Forsberg F. Noninvasive measurement of portal hypertension using subharmonic 
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 March 2012: The American Institute of Ultrasound in Medicine, Oral Presentation 
 J. Ultrasound Med. vol. 31 pp. S11, 2012 
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 March 2012: The American Institute of Ultrasound in Medicine, Oral Presentation 
 J. Ultrasound Med. vol. 31 pp. S44, 2012 
 
3) Dave JK*, Halldorsdottir VG, Eisenbrey JR, Merton DA, Liu JB, Zhou JH, Wang 
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 March 2012: The American Institute of Ultrasound in Medicine, Oral Presentation 
 J. Ultrasound Med. vol. 31 pp. S28, 2012 
 
4) Eisenbrey JR, Dave JK, Halldorsdottir VG, Merton DA, Gonzalez JM, Miller C, 
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enhanced ultrasound technique. 
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Appendix 13:  Ambigram for SHAPE 
 
 
 
Taking a cue from Dan Brown‟s fictional character Robert Langdon and from an 
adjunct professor John Langdon associated with Drexel University, in “some” “free” 
time, an attempt was made to develop an ambigram for SHAPE! 
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